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ABSTRACT
The chemokine receptor CXCR4 is a trans-membrane protein which has been 
implicated in many physiological and pathological processes including cancer, rheumatoid 
arthritis and most significantly HIV replication. CXCR4 plays a vital role in embryonic 
development but is not essential at the post-development stage; therefore, it has been 
identified as a potential therapeutic target.
Bis-macrocyclic drugs (e.g. AMDS 100) bind to aspartate residues on the CXCR4 
surface and inhibit HIV replication by blocking the interaction of gp!20/gp41 with the 
protein. The incorporation of transition metals (e.g. zinc(II) and copper(II)) into the 
macrocyclic cavity increases anti-viral potency. The addition of a bridging ethylene unit to 
the macrocyclic framework locks the complex into a single configuration, potentially 
optimising the interaction with the receptor.
A series of configurationally restricted macrocyclic compounds have been prepared 
utilising bis-aminal chemistry. Characterisation by X-ray crystallography and X-ray 
absorption spectroscopy has confirmed that the complexes possessing an ethylene bridge 
between adjacent nitrogen atoms are fixed in the trans-II configuration and that complexes 
containing an ethylene bridge between non-adjacent nitrogen atoms adopt the cis-V 
configuration. In addition, solution EXAFS has been used as a model to probe the binding 
of the complexes to aspartate residues on the receptor surface.
The zinc(II) trans-II and copper(II) cis-V complexes reported here are more potent 
against HIV replication than AMDS 100 (IC50 values against IIIB ; 0.00208 uM, 0.00491 uM 
and 0.018 uM respectively), confirming the importance of coordination interactions for 
potent binding to CXCR4 and also validating the strategy of configurationally fixing the 
macrocyclic unit for optimising receptor binding. It is believed that both thermodynamic 
and kinetic properties are important for effective binding to CXCR4.
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Chapter 1. INTRODUCTION
1.1 Chemokines & Chemokine Receptors
Chemokines are involved in the regulation of the immune system cell network and 
are primarily responsible for the migration of cells and directing leukocytes to sites of 
inflammation. They exert their biological effect by binding to and activating chemokine 
receptors. These receptors have been identified as potential therapeutic targets and one 
example of a chemokine receptor antagonist, Maraviroc, has recently been granted PDA 
approval as an anti-viral drug. The following section introduces chemokines and their 
receptors, particularly highlighting the CXCL12 and CXCR4 pair as they are relevant to 
this work.
1.1.1 Chemokines
Chemokines are a group of small (8-10 kDa) proteins which are divided into four 
sub-groups depending on the orientation of the first two conserved cysteine residues. 1 ' 2 The 
CXC and CC sub-groups comprise the majority of the chemokines, of which over 40 have 
been presently identified (Table I). 1 "3
Receptor Selective ligands Principal biological function
CC family
CCR1
CCR2
CCR3
CCR4
CCR5
CCR6
CCR7
CCR8
CCR9
CCR10
CCR11
DARC
CCL14
CCL2
CCL11 
CCL24
CCL17 
CCL22
CCL3 
CCL4
CCL20
CCL19 
CCL21
CCL1
CCL25
CCL27 
CCL28
CCL2 
CCL19
Many CC
Anti-viral response
Macrophage recruitment
Parasite response, Th2 recruitment
Skin homing, Th2 recruitment
Th2 and macrophage recruitment
Dendritic cell homing
Secondary lymphoid tissue homing of T, B and dendritic cells 
NK. cell recruitment
Th" recruitment
Intestinal homing, thymocyte migration
Skin homing of T cells
Macrophage recruitment
Does not signal-chemokine sink, malaria receptor
CXC family
CXCR1
CXCR2
CXCR3
CXCR4
CXCR5
CXCR6
CXCL8
CXCL1 
CXCL5 
CXCL7 
CXCL8
CXCL9 
CXCL10 
CXCL11
CXCL12
CXCL13
CXCL16
Neutrophil chemotaxis and deregulation
Neutrophil chemotaxis and deregulation
T cell responses
B cell responses, stem cell homing
B cell responses
Activated T cells
CX3C family
CX3CR1 CX3CL1 Inflammation
C family
XCR1 XCL1 XCL2 Inflammation
Table 1. Chemokine receptors and their major activity. DARC and CCR1 are 
included for completeness but are not as well characterised.3
Originally identified as immune cell traffickers, the actual role of chemokines in 
nature goes much further. They have been shown to be involved in embryonic 
development, hematopoiesis, growth regulation and angiogenesis.4"7 Given the crucial role 
chemokines play in nature, it is not difficult to imagine the consequences of a breakdown in
the regulation of the chemokine system. For example, chemokines have been proven to 
play an important* role in many disease states including multiple sclerosis, rheumatoid 
arthritis, asthma and diabetes. 8" 13
1.1.2 CXCL12
CXCL12 is a unique chemokine as it has a sole receptor, CXCR4, whereas all of the 
other chemokines found to date are promiscuous in their nature.5 It is a distant relative of 
the CXC chemokine family and was originally identified as a product from bone marrow 
stromal cells, hence its common alternative name, stromal-cell derived factor one (SDF- 
l). 14" 16 The structure of the 67 residue, highly basic protein has been determined by NMR
and is shown in Figure 1. 17
Figure 1. NMR structure of CXCL12 (A). Highlighting the extended loop and 3io helix 
(B), the 1st p-strand with a type III turn (C), the 2nd and 3rd p-strands with a type I 
turn (D) and the type I turn and c-terminal a-helix (E) (reproduced from Current
Medicinal Chemistry).3
The first and second P strands contain regions of positive charge on their surface, 
whereas the a-helix presents a negative surface charge. 17 These electrostatic properties are 
important in the receptor binding mechanism of CXCL12 to CXCR4. CXCL12 is produced 
by stromal cells in the bone marrow but is also expressed and secreted by other organs 
including the brain, liver, lung and lymph nodes. 18"22 CXCL12 gene knockout mice 
experience developmental defects of the immune, haematopoietic, circulatory, cardiac and 
central nervous systems at the embryonic stage and eventually die.23 "25
1.1.3 Chemokine Receptors
Chemokine receptors belong to the G-protein coupled receptor (GPCR) superfamily 
and are 340-370 amino acids in length.26 They are seven transmembrane serpentine 
receptors and are expressed on many different types of leukocytes and non-hematopoietic 
cells.27 Their role in nature is primarily involved in leukocyte chemotaxis and 
inflammation.28' 29 The identification of chemokine receptors as a class of GPCR was met 
with enthusiasm as most of the drugs currently on the market exploit this receptor type. The 
majority of chemokine receptors bind multiple ligands under a variety of conditions; 
however, CXCR4 has only one natural ligand, CXCL12.2
1.1.4 CXCR4
CXCR4 (Figure 2) is expressed on hematopoietic cells and, to a lesser extent, on 
vascular endothelial cells, neurons and astrocytes.30"33 The protein is important in 
embryonic and cardiac development and also hematopoiesis in the gastrointestinal tract.23 
In addition, the disruption of CXCR4 is embryologically lethal and results in serious 
developmental effects in the immune, circulatory and central nervous systems.24' 25 The
similarity of the defects between CXCL12 and CXCR4 knockouts reflects the monogamous 
relationship between the pair.
-COOH
Figure 2. Serpentine (A) and helical wheel (B) structure of CXCR4 (reproduced from
34the Journal of Biological Chemistry). 
1.1.5 Role of Chemokines & Chemokine Receptors in Disease
Over the last decade, there has been an increase in the understanding of the 
association between chemokine receptors and several human diseases. In addition to their 
role in inflammation, chemokine receptors have been found to be required by HIV for 
leukocyte infection.35"37 Furthermore, tumour metastasis can be influenced by the over- 
expression of chemokine receptors on tumour cells. 1 ' 20' 38"43
CXCR4 and its ligand CXCL12 have specifically been implicated in rheumatoid 
arthritis, inflammatory liver disease, several cancers and HIV.7' 13 ' 41> 43-49 The role of
CXCR4 in rheumatoid arthritis has been revealed due to the fact that receptor antagonists 
reduce the severity of arthritis in a collagen-induced mouse model.41 Most of the leukocytes 
obtained from the inflamed joints were found to express CXCR4, showing that CXCL12 
plays a central role in the pathogenesis of marine collagen-induced arthritis by attracting 
CXCR4(+) leukocytes to the site of inflammation. In addition, CXCR4 and CXCL12 have 
both been found in the synovium and articular cartilage of rheumatoid arthritis patients.50 
Levels of CXCL12 are found to be higher than normal in patients with inflammatory liver 
disease.51 Antagonising CXCR4 in a murine model of airway inflammation had not only a 
therapeutic effect, but also a protective effect against metacholine-induced airway hyper- 
responsiveness and inflammation in allergic mice.52
The literature highlighting the link between tumour growth, survival, metastasis and 
CXCR4/CXCL12 is ever increasing. For example, the over-expression of CXCR4 has been 
reported in numerous epithelial, mesenchymal and haemopoietic cancers.45' 53~59 The role of 
CXCL12 in breast cancer has been described.20' 60' 61 CXCR4(+) tumour cells migrate to 
sites rich in CXCL12 such as bone, liver and lung.45' 62 Furthermore, CXCR4 is highly 
expressed and has been implicated in lung, cervical, colorectal, prostate and pancreatic 
cancers.54' 58> 63~71 Samples of pancreatic cancer tissues constitutively express CXCL12 
which enables migration of cancer cells to other sites. In the presence of a CXCR4 
antagonist, cell migration was inhibited, suggesting potential for prevention of growth and 
spread of tumour.68 CXCR4/CXCL12 also play a role in certain brain tumours as CXCR4 
has been found to be over-expressed on malignant cells in comparison to normal neuronal 
cells. 72' 73
The expanding knowledge of the involvement of CXCR4 and CXCL12 in several 
diseases, in addition to successful receptor blocking results, suggests an immense 
therapeutic potential in targeting the CXCR4/CXCL12 axis.43' 44> 74'82 The majority of the 
literature has concentrated on the role of CXCR4 in HIV infection and this is discussed in 
detail in the following section.
1.2 Human Immunodeficiency Virus
HIV first appeared in 1981 and was identified in 1983 by Montagnier and co- 
workers. 83 Montagnier was rewarded with a share of the Nobel Prize for medicine in 2008 
for his work in this area. There are two known strains of the virus, HIV-1 and HIV-2. The 
virus contains a single stranded RNA genome, which is replicated through a double 
stranded DNA intermediate. The viral DNA becomes integrated into the genome of the host 
cell and viral genes are transcribed only when they have been integrated into the host cell. 
The HIV replication cycle is shown in Figure 3.84
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Figure 3. HIV replication (reproduced from Nature Medicine).84
The cycle can be summarised in five major steps: binding, reverse transcription, 
integration, transcription and translation. Each stage in the cycle can be targeted for 
treatment and over twenty anti-viral drugs have been approved over the past two decades 
(Table 2).85'87
Product Generic name Manufacturer Year approved
Nucleoside/nucleotide reverse transcriptase inhibitors
Retrovir
Videx
Zerit
Epivir
Combivir
Ziagen
Trizivir
Viread
Emtriva
Epzicom
Truvada
Zidovudine (AZT)
Didanosine (ddl)
Stavudine (d4T)
Lamivudine (3TC)
Lamivudine, zidovudine
Abacavir
Abacavir, zidovudine, 
lamivudine
Tenofovir
Emtricitabine
Abacavir, lamivudine
Tenofovir, emtricitabine
GSK
Bristol-Myers Squibb
Bristol-Myers Squibb
GSK
GSK
GSK
GSK
Gilead Sciences
Gilead Sciences
GSK
Gilead Sciences
1987
1991
1994
1995
1997
1998
2000
2001
2003
2004
2004
Non-nucleoside reverse transcriptase inhibitors
Viramune
Rescriptor
Sustiva
Intelence
Nevirapine
Delavirdine
Efavirenz
Etravirine
Boehringer Ingelheim
Pfizer
Bristol-Myers Squibb
Tibotec
1996
1997
1998
2008
Protease inhibitors
Invirase
Crixivan
Norvir
Viracept
Kaletra
Lexiva
Reyataz
Aptivus
Prezista
Saquinavir
Indinavir
Ritonavir
Nelfmavir
Lopinavir, ritonavir
Fosamprenavir
Atazanavir
Tipranavir
Darunavir
Roche
Merck
Abbott Laboratories
Agoron 
Pharmaceutical s/Pfizer/Roche
Abbott Laboratories
GSK
Bristol-Myers Squibb
Boehringer Ingelheim
Tibotec
1995
1996
1996
1997
2000
2003
2003
2005
2006
Entry and fusion inhibitors
Fuzeon
Selzentry
Enfuvirtide
Maraviroc
Roche/Trimeris
Pfizer
2003
2007
Integrase inhibitors
Isentress Raltegravir Merck 2007
Multiclass combination
Atripla Efavirenz, emtricitabine, tenofovir.
Gilead Sciences/Bristol-Myers 
Squibb 2006
Table 2. Currently approved anti-viral drugs.85
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The earliest compounds were nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs) such as AZT and d4T. 88 Once tri-phosphorylated, these compounds inhibit the 
reverse transcription process which converts viral RNA into DNA. The development of 
non-nucleoside reverse transcriptase (NNRTIs) and protease inhibitors resulted in the 
possibility of highly-active antiretroviral therapy (HAART).89"91 This involves the 
simultaneous treatment with different classes of anti-viral compound, the typical 
combination being two NRTIs with either an NNRTI or a protease inhibitor. Provided the 
patient continues to take the drugs as prescribed, HAART has proven to be successful in 
reducing the viral load to undetectable levels in the bloodstream.92
Entry inhibitors have been developed which prevent HIV merging with host cells.93 ' 94 
For example, the peptidic drug Fuzeon acts at the fusion/uncoating stage and Maraviroc 
acts at an earlier binding stage. The initial binding step involves the interaction of HIV with 
one of two co-receptors, either CCR5 or CXCR4. Maraviroc acts by blocking the 
interaction with CCR5.
1.2.1 HIV Cell Entry
Binding of HIV to a host cell is summarised in Figure 4.95 Initially, the viral envelope 
glycoprotein gp!20 interacts with the CD4 receptor on the cell surface (Figure 4a). Once 
cell bound, the gp!20 interacts with either CXCR4 (in X4 strains) or CCR5 (in R5 strains) 
(Figure 4b). Gpl20 and gp41 are non-covalently associated and form a trimer on the virus 
surface.96 The interaction of gp!20 and the respective co-receptor leads to a conformational 
change within the gp!20-gp41 trimer, allowing gp41 to finally enter the cell (Figure 4c).97~
99
11
Viral 
RNA
Viral 
core
V
CO!
Cell 
membrane
Figure 4. HIV cell entry involving: (A) interaction of gp!20 with CD4 followed by (B) 
interaction of gp!20 with co-receptor CXCR4 or CCR5 and (C) cell entry of gp41
(reproduced from Nature Reviews Drug Discovery).95
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1.3 CXCR4 Antagonists
There have been numerous compounds developed to antagonise CXCR4 due to the 
potential for targeting the receptor as a drug target. The bicyclam class of compounds 
represent the most thoroughly investigated CXCR4 antagonists and are discussed here 
describing the development of the prototype bicyclam, AMDS 100.
1.3.1 Development of AMD3100
The bicyclam class of compounds was first reported in the late 1980s but were only 
considered as pharmaceutical candidates in the late 1990s. 100" 102 Several batches of 
commercial cyclam (1,4,8,11-tetraazacyclotetradecane, 1) were tested for their anti-HIV 
activity and they were found to be poor inhibitors of HIV replication in MT-4 cells. 
However, one sample showed a ten-fold increase in its antiviral activity compared to the 
other cyclam samples. This was the result of an impurity in the sample which was 
eventually identified as the bicyclam AMD 1657, L1 (Figure 5). This compound has an ECso 
value of 0.1-0.2 ug/mL and a selectivity index of > 5,000. 95 The selectivity index is a ratio 
of 50% cytotoxic concentration (CCso) to 50% antiviral effective concentration (EC5o). As a 
comparison, AZT, a current clinical drug used for HIV treatment has a selectivity index of 
> 1,000. 103
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NH HN
AMD3100 
2
Figure 5. Structures of cyclam (1), AMD1657 (L1) and AMD3100 (2).
AMD 1657 proved impossible to resynthesise at that time and so the synthesis of 
other derivatives was pursued. Notably however, a search of the literature for this report 
revealed a synthetic route to this compound in very low yield by Barefield et a/. 104 Through 
the systematic preparation of analogues of AMD 1657, AMDS 100 (Figure 5) was eventually 
synthesised.
AMDS 100 is a bicyclam composed of two cyclam rings tethered via an aromatic 
linker. It was originally developed by AnorMED and taken into clinical trials for HIV 
treatment. After AnorMED was taken over by Genzyme in 2006, AMDS 100 was recently 
successfully trialled for stem cell mobilisation and was granted PDA approval under the 
tradenamePlerixafor. 105' 106
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1.3.2 Synthesis of AMD3100
AMDS 100, as it would be later named, was originally synthesised by Fabrizzi and co- 
workers in order to investigate the potentially interesting redox properties of its transition 
metal complexes. 100 The original synthesis (Figure 6) employs protection-deprotection 
chemistry resulting in a relatively low overall yield when starting from cyclam. More 
recently, higher yielding and hence more economical synthetic routes to AMDS 100 have 
been reported in the literature and are also discussed here.
Fabrizzi and co-workers' synthetic route (Figure 6) begins with the preparation of 
compound L2 in moderate yield (56%) from the direct reaction of 1 with toluene sulphonyl 
chloride. Subsequent N-alkylation of the secondary amine with a-a'-p-xylenedibromide 
gave the tris-N protected bicyclam L3, which can be deprotected with H2SO4 to give 
AMDS 100, 2. The overall yield for this synthetic route is approximately 30%.
cNH HN CHCi3 Ts
•©-Br
K2C03 
CH 3CN
Figure 6. Synthetic route to AMD3100 (2).
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An almost identical route to that shown in Figure 6 has been reported by Yang et al. 
who have used a Irifluoroacetyl protecting group in preference to tosyl. 107 This method 
reports an improved yield of over 90% for the tris-protected equivalent of L3. The N- 
alkylation step with a-a'-/»-xylenedibromide is exactly the same as in Figure 6; however, 
deprotection is achieved with sodium hydroxide. The reported overall yield of over 70% is 
approximately 2-fold greater than the original synthesis.
Handel and co-workers have reported a facile route to AMDS 100 which exploits bis- 
aminal chemistry (Figure 7). 108 The cis product of bis-aminal 3 is prepared in quantitative 
yield and can be selectively mono-N-alkylated with an appropriate electrophile, such as a- 
a'-p-xylenedibromide in acetonitrile. This elegant route relies on the fact that the 
ammonium salt 4 precipitates out of solution once formed, which negates the possibility of 
any oligomer formation. Finally, the bis-aminal bridge is cleaved using a combination of 
hydroxylamine hydrochloride and sodium ethoxide, resulting in a total yield for the three 
step process of over 80%, which improves on the two previously discussed routes. In 
addition, this route has the advantage over those previously discussed in that it does not 
require any time consuming purification steps.
16
HN.
NH HN
(CHO)2 
CH3OH*
Figure 7. Synthetic route to AMD3100 utilising bis-aminal chemistry. 
1.3.3 Binding of AMD3100 to CXCR4
Bicyclams inhibit HIV replication by binding to CXCR4, the co-receptor used by X4 
strains for cell entry. De Clercq et al. and Bridger et al. have studied the structure-activity 
relationship of the bicyclams in detail and have concluded that two azamacrocyclic rings 
tethered by a para-substituted aromatic linker result in extremely potent anti-viral 
activity. 101 ' 102 ' 109' no Schwartz et al. have studied the molecular interactions of AMDS 100 
with CXCR4 in order to understand which residues are important for receptor binding.34
AMDS 100 binding to CXCR4 in competition with 125I-Met-CXCL12 in COS-7 cells 
showed an affinity of 74 uM and also competed against 125I-12G5 binding (Figure 8). In 
contrast to this, cyclam achieved an affinity of only 13 uM and was unable to displace 125I- 
12G5, even at mM concentrations.
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Figure 8. Competition binding experiments using AMD3100 (A) or cyclam (B) 
(reproduced from the Journal of Biological Chemistry).34
1.3.4 Effect of Asp and His Mutations on CXCR4 Binding
Receptor mutagenesis studies of histidine (His) and aspartate (Asp) residues in 
CXCR4 have been used to determine the main binding site in the CXCR4 receptor. 34 
Histidine and aspartate residues were chosen based on the assumption that each cyclam ring 
was doubly protonated under physiological conditions and could interact via hydrogen 
bonding or electrostatic attraction. Therefore, His 113, His203, His281 and His294 were 
individually mutated to alanine (Ala) and AsplTl, Asp 182, Asp 193 and Asp262 were 
individually mutated to asparagine (Asn).
The affinity of cyclam determined in competition for I25I-Met-CXCL12 binding was 
unaffected by each mutation except in the case of Aspl71, located in the extracellular
18
region of TM-IV (Figure 2, section 1.1.4). This mutation led to a 30-fold decrease in the 
binding of cyclam «(Figure 9b).
0-
0 -11 -10 -9 -8 -7 -6 -5 -4 -3 
log Jcompoundj (MJ
Figure 9. Effect of Asp to Asn substitution at positions 171 and 262 in CXCR4 on (A)
AMD3100 and (B) cyclam competition binding for CXCL12 (SDF-la) binding
(reproduced from the Journal of Biological Chemistry).34
AMD3100 binding was affected by the mutation of both AsplVl and Asp262, located 
in the extracellular region of TM-VI, but not significantly by any other mutation (Figure 
9a). In addition, AMD3100, like cyclam, was unable to compete for 125I-12G5 binding 
(Figure 10).
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Figure 10. Effect of Asp to Asn substitution at positions 171 and 262 in CXCR4 on 
competition for 12G5 binding (reproduced from the Journal of Biological
Chemistry).34
1.3.5 Binding Model of AMD3100
The 'free' cyclam ring has an overall 2+ charge under physiological conditions. 111 It 
has also been reported that the protonated cyclam can form direct, hydrogen-bonded 
stabilised complexes with carboxylate groups. 112 As previously mentioned, AsplTl is 
important for cyclam and AMDS 100 competition binding with CXCL12 for the CXCR4 
receptor. AMDS 100 binding to CXCR4 was also dependent on Asp262. Cyclam could bind 
to Asp262 but with very low affinity relative to AsplTl. When Aspl71 is eliminated (in the 
D171N mutation) the affinity decreases to 400 uM, which could represent the affinity of 
cyclam to Asp262. However, this could not be confirmed as the expression level of the 
D171N/D262N double mutation was too low.
In conclusion, given the fact that AMDS 100 binding is dependent on both Aspl71 
and Asp262 and can interact with carboxylate groups it is thought that one cyclam ring 
binds to Aspl71 and another one to Asp262.
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1.3.6 Binding Model of Metal Complexes of AMD3100
Este et al. have shown that the incorporation of one or more transition metal ions into 
the macrocyclic rings of AMDS 100 alters binding affinity to CXCR4 in the order:
zinc(II) ~ nickel(II) > copper(II) > AMDS 100 > cobalt(III) > palladium(II) 113
Although other studies have suggested that the free ligand of AMDS 100 has a higher 
binding affinity than its copper(II) complex, the zinc(II) complex increases binding affinity 
by between 6 to 36-fold depending on the radiolabelled ligand used.34' 114 Additionally, it 
has been suggested that the increased binding affinity of transition metal complexes could 
arise from a direct coordination interaction from only one macrocyclic ring with Asp262 
(Figure II). 114
uo 
(!)
CM
CM
c
O 
.0
0 -9 -8 -7 -6 -5 -4 
log[AMD3100(Me2+) n](M)
Figure 11. Effect of incorporation of one (open symbols) or two (closed symbols) 
nickel(II) or copper(II) ions in AMD3100 on wild-type CXCR4 (reproduced from
Biochemistry).114
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This is supported by the data presented in Figure 12, which shows that the metal 
enhancement can be eliminated by Asp262 mutation. Together, these data confirm that 
Asp262 is essential for binding but the interaction with Aspl71 is less well defined. It is 
possible that the receptor binding pocket may only allow the optimisation of one 
coordination interaction. Alternatively, hydrogen bonding interactions with the secondary 
amine nitrogen atoms of the metal complex may also be important. For example, a trans-III 
configuration can potentially form up to three hydrogen bonds with carboxylate oxygen
atoms. 115
0 -9 -8 -7 -6 -5 -4 
log[AMD3100(Me2+ ) n](M)
Figure 12. Effect of incorporation of two zinc(II), nickel(II) or copper(II) ions in
AMD3100 in competition with 125I-12G5 mAb in mutants (a) Aspl71 and (b) Asp262
CXCR4 receptor (reproduced from Biochemistry). 114
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1.3.7 Lysozyme Adducts of AMD3100 Complexes
Sadler and co-workers have reported solid state structures of protein adducts of 
AMDS 100 complexes with copper(II) and nickel(II) respectively. 116' I17 The CXCR4 
receptor has yet to be crystallised, and therefore lysozyme was used as a model. Lysozyme 
was chosen as it is readily crystallised and the active site contains carboxylates which are 
important residues in the binding of macrocyclic complexes to CXCR4.
[Cu22]4+ binds to lysozyme in two different sites with both macrocycles adopting 
trans configurations. 116 In one of the binding sites, both direct coordination (Cu-O 2.70 A) 
to AsplOl and hydrophobic interactions to Trp62 and Trp63 residues are important. In the 
second binding site, hydrophobic interactions towards Trpl23 dominate. Interestingly, no 
electron density was observed for the aromatic linker in the crystal structure, indicating that 
the two cyclam units identified in the two binding sites come from two separate molecules.
In a similar fashion to [Cu22]4+, the nickel(II) complex of AMD3100 has the two 
same binding sites on lysozyme as found in the copper(II) adduct. 117 In the first binding 
site, the nickel(II) coordinates directly to AsplOl and the macrocycle adopts a trans 
configuration which is close to Trp62 and Trp63. The macrocycle in the second binding site 
again adopts a trans configuration which interacts via hydrophobic stacking to Trpl23. 
There was also evidence of a third binding site which was due to uncomplexed nickel(II) 
binding to Asp52. The free nickel(II) was proposed to arise due to the low pH (4.5) of the 
medium.
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As a result of these studies, it has been suggested that trytophan residues could also 
be important in the binding of metal complexes of AMDS 100 to CXCR4 as they are 
involved in their binding to lysozyme.
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1.4 Therapeutic Potential of AMD3100
The role of the CXCR4/CXCL12 axis in the pathogenesis and aetiology of several 
diseases has been previously discussed (section 1.1). As a result, AMDS 100 has been 
evaluated for its therapeutic effect against HIV, inflammatory conditions, a range of 
cancers as well as a stem cell mobiliser for transplant patients undergoing 
chemoradiotherapy.41 ' 52'' 18' 122
1.4.1 HIV Studies
Time of addition experiments, where anti-viral drugs are added at different times after 
infection, have been used to determine which stage of the virus replicative cycle is affected 
by AMDS 100. 123 A stage between virus adsorption and reverse transcription was found to 
be affected by AMDS 100. Therefore, AMDS 100 must act at HIV fusion-uncoating and 
does not affect the binding of the virus to the CD4 receptor. AMDS 100 works by blocking 
viral entry once the virus has become cell bound. Este et al. suggested that the viral 
envelope gp!20 was important in the anti-HIV activity of AMDS 100. 124 In order to confirm 
this, viral resistance to AMDS 100 was developed by repeated passages of the virus in the 
presence of AMDS 100. The resistant virus would be expected to show several mutations 
across the gp!20, if it was indeed important in the cell entry process. It took more than 
sixty passages (300 days) in MT-4 cells for the virus to become 400-fold resistant to 
AMDS 100. Analysis of the resistant virus showed several mutations over the whole of the 
gp!20 but mostly in the V3 loop. Substitution of amino acids close to the disulphide 
bridges of the V3 and V4 loops have shown that the whole of the gp!20 (as opposed to
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certain amino acids in its 3D structure) is responsible for the resistance and sensitivity 
profile of HIV strains to AMD3100. 125
AMDS 100 was developed over a decade ago as a potent, selective inhibitor of HIV 
but not simian immunodeficiency virus (SIV) replication. This was initially surprising until 
it was discovered that SIV solely uses CCR5 to infect host cells. 126 AMDS 100 is potent in 
the nanomolar (1-10 nM) concentration range against HIV, showing a selectivity index of > 
100,000. 123 In addition, AMDS 100 is non-toxic up to 500 uM and shows activity against a 
variety of X4 but not R5 viral strains. 127' 128 Furthermore, AMDS 100 has been found to be 
active against some R5/X4 viral strains, which can use either receptor for cell entry. 129"132
AMDS 100 has proven to be active against X4 strains such as Ills (ICso 0.02 uM) and 
ROD, but is totally ineffective against R5 strains (Table 3). 129 This shows the specificity of 
AMDS 100 to CXCR4. In addition to these data, AMDS 100 has also been shown to reduce 
syncytia formation in HeLa cells infected with feline immunodeficiency virus (FIV) at a 
concentration of 0.1 uM. 133 In another report, AMDS 100 blocked syncytium formation and 
single-cell apoptosis in a dose dependent manner. The IC50 values were in the range 0.009 
to 0.24 ug/mL (data not presented). 134
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HIV-strain
HIV-1 III B
HIV-1 RF
HIV-1 NL4-3
HIV-2 ROD
HIV-1 BaL
HIV-1 SF-162
HIV-1 ADA
HIV-1 JR-FL
Co-receptor used
CXCR4
CXCR4
CXCR4
CXCR4
CCR5
CCR5
CCR5(CCR2b, CCR3)
CCR5 (CCR2b, CCR3)
ICSO / ng/mL
AMD3100">
5
3
7
> 25000
> 25000
> 25000
> 25000
CXCL12
20
50
100
55
> 1000
>1000
> 1 000
>1000
Table 3. AMD3100 inhibition of various HIV strains. 129
Moreover, [Zri22]4+ displays an activity 6-fold greater than AMDS 100 as an anti-HIV 
agent. A further study found that the zinc(II) and nickel(II) complexes of AMDS 100 
reduced syncytia formation in FIV infected cells with an ICso of 0.007 ug/mL and 0.03 
ug/mL respectively (AMDS 100 0.055 ng/mL). 133 Therefore, [Zn22]4+ was up to 8-fold 
more potent than AMDS 100.
1.4.2 Clinical Studies
The first human study with AMDS 100 was conducted in order to determine the 
safety, bioavailability and single dose pharmacokinetics of AMDS 100 from 1-160 ug/kg in 
healthy volunteers. 135 The drug was well tolerated in all patients with 50% of individuals 
having mild side effects of a gastrointestinal nature. AMDS 100 was well absorbed 
following subcutaneous injection (87% bioavailability); however, no drug was detectable in 
the blood stream following oral dose. Pharmacokinetic profiles were found to be dose 
dependent with an estimated half-life of 3.6 hours. In addition, it was observed that most 
patients experienced a transient, dose dependent increase in the white blood cell count 
within six hours of infusion. It was later confirmed that AMDS 100 dose-dependently 
mobilised stem cells from the bone marrow.2
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Phase II clinical trials were carried out to evaluate AMDS 100 for its safety, 
pharmacokinetics and anti-viral activity in HIV patients. 136 Forty patients with a high viral 
load (> 5000 copies/mL) of HIV RNA were enrolled with different HIV-phenotypes (30% 
SI, NSI 45% and 25% unknown). The drug was injected in doses over ten days by 
continuous intravenous infusion, with doses increasing from an initial 2.5 ugkg"1 !!" 1 to a 
maximum of 160 ugkg'V. Most patients who received the higher dose (80-160 ugkg'V1) 
had paresthesias and one patient (5 ngkg^h"1 ) suffered serious, possibly drug related 
thrombocytopenia. In addition, two patients (40 ugkg'V1 and 160 ugkg" 1 !!" 1 ) had 
unexpected (but not serious) premature ventricular contractions; however, it was later 
determined that these patients had had previous cardiac complications.
Overall, only one patient receiving the highest dose (160 ugkg"1 !!" 1 ) had a significant 
(0.9 logio copies/mL) HIV RNA decrease after day eleven. It was subsequently found out 
that this patient had the X4 viral strain and was years into his HIV infection. This finding 
shows that in future, more stringent examination of past medical records, virus strain and 
time into infection needs to be carried out in order to correctly determine the efficacy and 
effectiveness of anti-HIV drugs. Moreover, at the time of the clinical trials, the mode of 
action of AMDS 100 was not fully understood. Further testing of AMDS 100 as an anti-HIV 
drug was discontinued in favour of orally available^lternatives such as AMD070. 137
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1.5 Characteristics of Cyclam & Bicyclam Complexes
The role that cyclam complexes play in medicine has been reviewed by Liang and
1 *? fiSadler. This section introduces some of the properties and characteristics of metal- 
cyclam and metal-bicyclam complexes, concentrating particularly on palladium(II) and 
zinc(II) complexes as the palladium(II) complexes have proven to be totally ineffective 
against HIV replication, whereas the zinc(II) complexes are some of the most potent anti- 
Hi V candidates tested to date. 139
1.5.1 General Properties
Cyclam is known to form highly stable metal complexes with the majority of the first 
row transition metals, for example, its nickel(II) complex has a demetallation half-life of 
around 30 years in acidic media. 140 The flexibility of the macrocycle means that it can 
adopt the most thermodynamically stable configuration for a chosen metal ion. Metal ions 
with an ionic radius of less than 0.75 A afford the best fit into the macrocyclic cavity (e.g. 
first row transition metals). 138' 141 Once the metal is bound, each nitrogen atom becomes 
chiral, giving rise to six possible configurations that the macrocycle can adopt (Figure 
13). 142
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trans-N trans-M c/s-V
Figure 13. Metal complexes of cyclam can adopt up to six configurations (five trans
and a folded cis).
The six-membered chelate rings adopt either chair or twist boat conformations and 
the five-membered rings are either gauche or eclipsed. The trans-III configuration has the 
lowest energy, but trans-I becomes increasingly favourable as the metal coordination 
number decreases from six to five to four respectively. 143 The trans-IV and trans-V 
configurations are the least stable as a result of the twist boat conformation of their six 
membered rings. However, the trans-V can fold along its N-N diagonal to give the cis-V 
configuration, where the six membered rings adopt the lower energy chair conformation. 
The configuration adopted by a complex will depend greatly on the coordination number 
and donor preference of the metal ion and also on the presence of any additional donor 
groups on the macrocyclic moiety.
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1.5.2 Palladium(II) Complexes
Three palladium(II) complexes of cyclam, [Pdl](ClO4)2 , [Pdl]Cl2 and [Pd2l](OAc)4 
have been reported by Sadler and co-workers. 144 They all adopt the most stable trans-III 
macrocyclic configuration in the solid state, with each palladium(II) ion being square 
planar (Figure 14). [Pdl]Cl2 solely adopts trans-III configuration in solution.
N \.
Pd
Figure 14. Crystal structures of [Pdl](ClO4)2 and [Pdl]Cl2. Both adopt the trans-III
configuration.
In contrast to the previous two complexes, [Pdl](OAc)2 exhibits weak hydrogen 
bonding between a macrocyclic amine proton and an acetate counter ion; however, there is 
no direct interaction between acetate and the metal ion itself, the shortest Pd-O distance 
being 4.0 A.
The structure of [Pd2L1](OAc)4 has also been reported (Figure 15). 144 This was 
serendipitously synthesised and contains two macrocycles linked via a carbon-carbon bond. 
The free chelator of this complex was the original bicyclam AMD 1657, which proved to be 
an effective inhibitor of HIV viral replication. The macrocyclic rings both adopt the trans- 
III configuration in the solid state. The nickel(II) complex of this ligand is also known. 104
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Figure 15. Crystal structure of [Pd2L1](OAc)4.
The fact that palladium(II) complexes of cyclam only adopt the trans-III 
configuration in the solid state and do not appear to change configuration in solution could 
explain their lack of anti-HIV activity. In addition, the preferred square planar geometry of 
the palladium(II) complexes would not allow binding to aspartate residues in the CXCR4 
receptor, as this would involve the coordination number of the metal ion increasing from 
four to either five or six.
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1.5.3 Zinc(II) Complexes
Sadler and co-workers have reported that cyclam selectively binds zinc(II) in 
preference to other metal ions under physiological conditions. 145 As the blood plasma 
concentration of free zinc(II) ions is relatively high (20 uM), it is not unreasonable to 
assume that the zinc(II) complex of AMDS 100 can exist in vivo. 146 In this regard, 
AMDS 100 can be thought of as a pro-drug where it is injected into the body as the free 
chelator, binds to zinc(II) in the blood stream and then interacts with CXCR4 as the metal 
complex.
Sadler and co-workers have studied the solid state and solution behaviour of a range 
of zinc(II) complexes of cyclam and AMDS 100. I46' 14? The crystal structure of 
[Znl(OH2)2]2+ (Figure 16) reveals an octahedral coordination environment with four 
equatorial zinc-nitrogen bonds (2.08-2.12 A) and two axial zinc-oxygen bonds (2.27 A). 
The macrocycle adopts the trans-III configuration in the solid state.
Figure 16. X-ray crystal structure of [Znl(0112)2](OAc)2.
However, in solution the trans-I, trans-III and cis-V configurations are all observed 
by proton NMR. Initially only trans-III is detected but over time, the cis-V and trans-I
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configurations increase at the expense of trans-III. The equilibrium mixture consists of 
45.3% trans-III, 42.8% cis-V and 11.9% trans-I. Altering the pH of the solution also affects 
the proton NMR spectrum of [Znl(OH2)2]2+. Increasing the pH leads to an increase in 
trans-I and a reduction in cis-V. Trans-III remains unchanged and is therefore not affected 
bypH.
Aqueous solutions of [ZnlCb] have an equilibrium mixture of 11.2% trans-I, 79.6% 
trans-III and 9.2% cis-V. On addition of acetate, the amount of trans-III decreases and cis- 
V increases but trans-I stays constant as shown in Figure 17.
cis-V
[OAc] I [ZnlCl2]
Figure 17. Effect of acetate on the configuration of [ZnlCh] in aqueous solution 
(reproduced from Chemistry - A European Journal). 147
The structure of [Zn22](ClO4)4 in the solid state has not been determined but in 
solution, the equilibrium mixture consists of is 34% trans-III, 45% trans-I and 21% cis-V. 
Furthermore, the cis-V/trans-I configuration predominates. Addition of acetate to 
[Zn22](ClO4)4 changes the proton NMR spectrum. The effect of adding acetate is shown in 
Figure 18. The proportion of the cis-V/cis-V configuration increased from 0% to almost
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19% on addition of four molar equivalents of acetate. The proportion of the cis-V/trans-I 
configuration increased from 26% to 38%.
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Figure 18. Effect of acetate on the configuration of [Zn22](ClO4)4 in aqueous solution
(reproduced from Chemistry - A European Journal).147
The crystal structure of [Zn22(OAc)2]2+ (Figure 19), the zinc(II) complex of 
AMDS 100 has been reported. 146 The two macrocyclic rings adopt a cis-V configuration and 
are symmetrical with respect to the aromatic linker. The zinc(II) metal ion has a distorted 
octahedral geometry composed of two axial and two equatorial nitrogen atoms. Two 
bidentate acetate oxygen atoms also occupy equatorial coordination sites, completing the 
distorted octahedral geometry.
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Figure 19. X-ray crystal structure of [Zn22(OAc>2]2+ viewed from two angles.
On dissolution in aqueous solvent, the equilibrium mixture of [Zn22(OAc)2]2+ is 
composed of 58% cis-V, 35% trans-I and 7% trans-III (cis-V/trans-I 44%, cis-V/cis-V 
29%) (Figure 20).
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Figure 20. Time dependent configurational changes of [Zn22(OAc)2](OAc)2 in aqueous 
solution (reproduced from the Journal of the American Chemical Society). 146
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In conclusion, zinc(II) complexes of both cyclam and AMDS 100 can adopt a variety 
of macrocyclic configurations in the solid state and in solution. The configuration of the 
macrocycle could play a vital role in the anti-HIV activity of AMDS 100. For example, the 
ability of the macrocycle to adopt a cis-V configuration seems to improve antiviral potency; 
therefore, a possible reason why [Zn22(OAc)2]2+ is a potent anti-HIV agent is that it can 
adopt the cis-V configuration in solution.
The zinc(II) complexes discussed in this section bind strongly to acetate in order to 
complete a six-coordinate geometry, which could explain their impressive antiviral 
potency, as they would be expected to readily bind to aspartate residues in the CXCR4 
receptor. However, if acetate binding were crucial to receptor binding, the cobalt(III) 
complex of AMDS 100 would be expected to more effective than [Zn22(OAc)2]2+ as it is 
known that cobalt(III) binds to acetate more effectively than zinc(II).39 A plausible 
explanation of why the cobalt(III) complex of AMDS 100 is not as effective as 
[Zn22(OAc)2]2+ is that cobalt(III) complexes are kinetically inert and therefore may not be 
able to adopt the cis-V configuration in solution. Alternatively, the ligand exchange could 
occur sufficiently rapidly to display any significant protein binding.
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1.6 Configurationally Restricted Macrocycles
The previous section highlighted the importance of the configuration of the 
macrocyclic rings in relation to receptor binding. Configurationally restricted bis- 
macrocycles could be more potent in binding to CXCR4 when compared to AMDS 100 as 
they would only present one shape to the binding site. In addition, the ability of the 
macrocycle to retain its metal ion will be important for in vivo studies as demetallation 
could have serious side effects due to the toxicity of the metal ion. Therefore, complexes 
possessing increased kinetic stability would be desirable.
Two Configurationally restricted ligands have been used in this work and are 
discussed in later chapters (two and three respectively). An introduction to the chemistry 
which has been developed in order to prepare Configurationally rigid transition metal 
complexes with increased kinetic stability is presented here.
1.6.1 Molecular Organisation
Macrocycles are important in transition metal coordination chemistry for two reasons. 
Firstly, they can mimic biological ligands and secondly they can increase the 
thermodynamic and kinetic stabilities of metal complexes. The factors leading to the 
stability of metal complexes containing macrocyclic ligands can be grouped together under 
the title 'molecular organisation'. 148 Molecular organisation can be broken into two parts; 
complementarity and constraint.
Complementarity concerns the size, geometry and electronics between a metal centre 
and a ligand and has been defined by Lehn as "a congruence of shape and size factors and
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energetic or electronic compatibility between receptor and receptee, host and guest, or 
central atom and 'ligand". H9 Complementarity is first order for complex stability; it is 
always present in stable complexes but has a maximum value and can only be improved 
upon so much (Figure 21).
Electronics
Geometry
Size
Complementarity
Figure 21. The effect of complementarity on complex stability can only be increased to
a certain level.
Constraint deals with topology and rigidity. Constraint is said to be second order as it 
can be increased almost infinitely (Figure 22); constraint factors are the design factors that 
are employed in order to increase metal-ligand stability, provided that complementarity 
factors are maintained. 150 Topology concerns the interconnectedness of ligand donor atoms 
and can be explained by the chelate, macrocyclic and cryptate effects which are discussed
in the following sections. 151-153
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Figure 22. Effect of topology and rigidity on complex stability. 
1.6.2 The Chelate Effect
The chelate effect was originally reported by Schwarzenbach. 153 A model system was 
used to explain that compounds containing a chelate ring are more stable than compounds 
with separate donor groups. The chelate effect can be dealt with thermodynamically by 
considering entropy. A chelated complex is higher in binding entropy compared to the 
binding entropy of separate donor atoms. This can be seen in Figure 23 where on the right 
hand side there are three components including the chelated complex and on the left hand 
side there are only two components including the mono-dentate amino ligand.
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Figure 23. Entropy in the chelate effect. 
1.6.3 The Macrocyclic Effect
The macrocyclic effect was reported by Cabbiness and Margerum. 151 They made 
copper(II) complexes of L4 and L5 (Figure 24) and found that the stability was much 
greater in the macrocyclic ligand compared to the linear ligand.
NH HN
Me
Me'
Me
H
Figure 24. Linear and cyclic ligands used*by Cabbiness and Margerum.
The macrocyclic effect can be explained by the dissociation of the first donor atom 
from a metal centre. In a polydentate ligand, the terminal donor atom dissociates from the 
metal in an SN' mechanism. This is not possible in macrocyclic ligands because the ring 
does not possess an end and therefore has no 'end donor group'. Therefore a more
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complicated mechanism of dissociation must occur. The macrocyclic ligand rearranges 
itself and, in the protess, weakens one of the metal-donor atom bonds (Figure 25).
rx X)
chelate
Figure 25. First donor dissociation in chelate \s macrocycle (reproduced from 
Coordination Chemistry Reviews). 50
Ligand dissociation can then take place but the energy used in the rearrangement step 
means that dissociation is slow. The macrocyclic effect is due to the dissociation step, 
which is more hindered than binding. This stabilising effect is in addition to the previously 
mentioned chelate effect.
1.6.4 The Cryptate Effect
The cryptate effect was reported by Lehn and Sauvage. 152 They had been working 
with [2]-cryptates, a class of macrobicyclic ligands containing alkali and alkaline earth 
metal centres. It was found that the potassium complex of L6 (Figure 26) was several orders 
of magnitude more stable than that of many organic ligands.
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L6
Figure 26. Cryptate compound, L6, studied by Lehn and Sauvage.
The addition of a second ring to a macrocycle enhances the stability more than if a 
second macrocycle was added to a complex. The origin of the cryptate effect has not yet 
been agreed but it is generally accepted that both entropic and enthalpic issues are the key 
to understanding this phenomenon.
1.6.5 Ligand Rigidity
Rigidity also plays a vital role in the three effects previously mentioned. However, 
the stabilising effects due to rigidity factors have not been well treated, either theoretically 
or experimentally. Two concepts have been developed in order to describe rigidity; multiple 
juxtapositionalfixedness and preorganisation} 5*' 155
Multiple juxtapositional fixedness (MJF) was reported by Busch. 154 This theory 
addressed the rigidity of the ligand structure (i.e. donor fixedness) in the overall stability of 
complexes. MJF arises from the fact that stepwise donor atom dissociations from the metal 
centre are much slower in topologically complex ligands due to the lack of end groups.
The theory of preorganisation was developed by Cram et al. and describes the fact 
that ligands which are preformed in a size and geometry that are complementary to the
43
metal ion are more stable than ligands which are not. 155 If a ligand does not change its 
conformation upon metal binding it is said to be preorganised. Preorganisation is important 
as it increases the overall free energy of complexation. The entropic costs of complexation 
are said to be prepaid, as the preorganised ligand does not reorganise itself during 
complexation.
This prepayment of entropy in complexation explains why topologically more 
complex ligands form more stable complexes, provided that complementarity is 
maintained. Ligand rigidity is part and parcel of MJF and preorganisation and can be 
increased in order to get more stable complexes.
Ligands benefitting from the chelate, macrocyclic and cryptate effects are known and 
others have been synthesised in this work. The rigidity of the cyclam backbone can be 
increased by the addition of an ethylene linker. The kinetic stability imparted by the rigidity 
of their ligands should enable their transition metal complexes to remain intact in vivo, 
which is of great importance should the compounds ever be used in clinical studies. The 
synthesis and characterisation of the ligands used in this work is the subject of the 
following two chapters.
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Chapter 2. SYNTHESIS &
CHARACTERISATION OF PIPERAZINO
MACROCYCLIC COMPLEXES
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2.1 Side-bridged Tetraazamacrocycles
There are several methods that have been used in order to alter the structural 
characteristics of tetraazamacrocycles and their metal complexes. Here the structural effects 
of ring size, coordinating pendent arms and chemically modified macrocycles are 
introduced, concentrating particularly on rigidified macrocycles. The incorporation of an 
ethylene bridging moiety to the cyclam backbone can result in complexes of exceptional 
kinetic stability. The ethylene bridge can take two forms; firstly between two adjacent 
nitrogen atoms leading to a "side" bridge containing a piperazino unit (Figure 27) and 
secondly between non-adjacent nitrogen atoms which results in a "cross" bridge (chapter 
three).
Figure 27. Side-bridged macrocycle containing a piperazino moiety. Metal complexes
adopt the trans-II configuration.
The historical development of "side" bridged piperazino derivatives of cyclam and 
cyclen and a selection of their transition metal complexes are presented here. The synthetic 
methodology which has been used in order to incorporate these structurally modified
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compounds into bis-macrocyclic metal complexes will also be discussed in detail along 
with their transition metal complexes. Finally, this methodology has additionally been 
applied to tris-macrocyclic compounds and the synthesis of a series of copper(II) and 
zinc(II) complexes of these ligands will also be presented.
Changing the ring size of a macrocyclic unit can result in a significant change in 
stereochemistry and coordination geometry. For example, the majority of metal cyclam 
complexes adopt the most thermodynamically stable trans-III configuration with an 
octahedral metal ion, whereas the 16 membered-macrocycle, L7, allows the metal ion to be 
held in a tetrahedral geometry as a result of the more flexible macrocyclic cavity (Figure 
28). 156
HN
HN
Figure 28.16-membered macrocycle, L7.
The degree of substitution at the coordinating amine also affects the structure of 
macrocyclic complexes. For example, [CuL8]2+ assumes pentacoordinate geometry in 
aqueous solution but the less substituted [CuL9]2+ is square planar (Figure 29). 157 The 
addition of pendent arms can also affect the structural properties of macrocyclic metal 
complexes.
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Figure 29. Tetra-methyl (L8) and di-methyl (L9) cyclam.
A further factor which can be employed in order to affect the structure of macrocyclic 
complexes is the addition of a bridging unit between two of the nitrogen atoms. This 
bridging unit can also impart structural rigidity to the complex and results in so-called 
configurationally "reinforced" macrocycles.
2.1.1 Synthetic Development of Side-bridged Cyclam
The first side-bridged derivative of cyclam was synthesised by Wainwright nearly 30 
years ago. 158 This low yielding method involved the direct reaction of cyclam with 
dibromoethane (Figure 30). The yield and purity of this reaction were both poor due to the 
fact that the reaction is self-limiting. The acid formed after substitution protonates the 
unreacted amine and results in quarternisation.
48
,NH HN^ ^N^ HN, 
Br
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1 Lio
Figure 30. Wainwright's synthesis of side-bridged cyclam, L10. 
Another route to L10 was developed by Yamamoto and Maruoka. 159 They made use 
of the glyoxal condensate of cyclam, 3, and reduced this using diisobutyl aluminium 
hydride (DIBAL) (Figure 31). This proved to be a much cleaner route together with a more 
satisfactory yield compared to Wainwright's original synthesis.
HI\U 
DIBAL
HN
3 L10
Figure 31. Yamamoto and Maruoka's synthesis of side-bridged cyclam, L10
One of the drawbacks of the synthetic strategies covered so far is that they cannot 
easily be adapted to give macrocycles containing pendent arms. Pendent arms can change 
the properties of metal complexes and they are also a necessary precursor in the synthesis 
of bis-macrocyclic compounds, such as AMDS 100. This problem was solved by Kolinski 
who appended 3 with both methyl and benzyl pendent arms (Figure 32), where the
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respective ammonium salt precipitates out of acetone with acceptable yields of around
60%. 160
R-X
L11 where R = CH3 |_13 where R = CH3 
L12 where R = CH2Bz |_14 where R = CH2Bz
Figure 32. Synthesis of side-bridged cyclam (L13 and L14) incorporating a pendent
arm.
Subsequent reduction of the ammonium salt with sodium borohydride results in the 
reinforced macrocycles L13 and L14. Interestingly, the trans conformer of 3 does not react at 
all with sodium borohydride.
Kolinski also prepared the first side-bridged cyclam containing two pendent arms 
when he formylated the secondary amine of L13 under reductive animation conditions to 
give L15 (Figure 34). 160 Kaden expanded on this work and has made copper(II) and 
nickel(II) complexes of Kolinski's compounds as well as a further example of a bis- 
alkylated side-bridged macrocycle, L17 (Figure 33). 161 This route involved the reaction of 
cyclam with diethyl oxalate to give the bis-amide L16 . Subsequent acylation followed by 
reduction leads to L17 which contains only tertiary amine groups.
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CH3COCI, NEt3 , CH2CI2 , r.t. 
2) BH3.SMe2 , reflux
Figure 33. Synthesis of a side-bridged cyclam (L 17) possessing two ethyl pendent arms. 
2.1.2 Metal Complexes of Side-bridged Cyclam
Although there are examples of several cyclam ligands containing side bridges, there 
are relatively few structures of their transition metal complexes in the literature. A search of 
the CSD reveals that fourteen complexes have been reported in total consisting of eleven 
copper(II) complexes, two chromium(III) complexes and a sole zinc(II) complex. Three of 
the copper(II) complexes have been reported by Kaden and co-workers. 161 They have 
crystallised the copper(II) perchlorate complexes of ligands L15 and L17, which are either 
four or five-coordinate including the coordination of a water molecule.
A wide library of side-bridged metal complexes containing a variety of pendent arms 
has been synthesised by the Archibald group following modifications of Kolinski's 
procedure. It is interesting to note that the alkylation pattern has an influence on the 
configuration of the macrocyclic backbone. For example, a mono-alkylated ligand (e.g. 
L13) gives the trans-II configuration whereas the bis-alkylated ligand (e.g. L17) results in the 
macrocycle adopting the unusual trans-IV configuration.
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The copper(II) perchlorate complexes of L15 and L17 are both pentacoordinate, 
bonding to the four nitrogen atoms as well as an axial water molecule. The macrocyclic 
nitrogen atoms form almost perfect planes in both and the copper(II) centre sits out of the 
plane by 0.33 and 0.34 A, respectively. The macrocycle takes up a trans-IV configuration 
where the two alkyl arms can be described as being cis to each other.
The copper(II)-nitrogen bond lengths in [CuL15(OH2)] 2+ are in the range 1.94(1) to 
2.09(1) A. The fifth donor site is occupied by a solvent water molecule with a copper(II)- 
oxygen bond distance of 2.235(5) A (Figure 34).
L15
161Figure 34. X-ray crystal structure of [CuL15(OH2)] 2+
In the second example, [CuL17(OH2)]2+, the copper(II)-nitrogen bond lengths are 
almost identical to the previous structure (2.034(2)-2.047(2) A) as is the copper(II)-oxygen 
distance at 2.226(2) A (Figure 35).
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17
Figure 35. X-ray crystal structure of [CuL17(OH2)]2V61 
2.1.3 Synthetic Development of Side-bridged Cyclen
Following the original preparation of side-bridged cyclam, the first cross-bridged 
example of the smaller macrocycle cyclen, L18, was reported by Ramasubbu and 
Wainwright. 162 In an analogous manner to the synthesis of L10, they reacted L18 directly 
with 1,2-dibromoethane with potassium hydroxide in benzene (Figure 36).
,NH
SNH
-Br
Br-
18 19
Figure 36. Synthesis of side-bridged cyclen, L19.
Although no reaction yields are reported, L19 is the major product, in addition to a 
small amount of the di-bridged derivative. L19 could be separated from the minor impurity
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by fractional sublimation. The ratio of 1,2-dibromoethane to cyclen had no affect on the 
product obtained. In contrast to the several side-bridged cyclam compounds, this remains 
the only side-bridged mono-cyclen compound in the literature, although there has been a 
bis-macrocyclic derivative reported recently.
Handel and co-workers have reported the synthesis of a range of bis-macrocyclic 
compounds containing side-bridged cyclen (Figure 37). 108
rv-TS -
o, m, p
X = CH, N
.1
\_y \j'
L20
Figure 37. Synthesis of a side-bridged bis-cyclen ligand.
This preparation provides a further indication of the utility of bis-aminal 
methodology in the synthesis of tetraazamacrocycles. The two step procedure starting from 
L20 proceeds in overall yields ranging from 54% with the pyridine linker group upto 78% 
with the meta substituted aromatic linker.
2.1.4 Metal Complexes of Side-bridged Cyclen
Although the preparations of copper(II), zinc(II), cadmium(II) and lead(II) complexes 
of L19 have been claimed, it is only a single nickel(II) complex which has received any 
discussion in the literature. 163 Given the number of metal complexes of ethylene bridged 
cyclam ligands, it is surprising that these compounds have not attracted the same level of 
attention. The nickel(II) perchlorate complex of L19 was initially prepared by Ramasubbu
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and Wainwright although the crystal structure was reported later by Hancock et a/. 162' 163 
No reaction yields "were reported for the complexation, although the UV-vis spectrum 
consisted of a spectral band centred at approximately 400 nm, indicating a square planar 
coordination geometry in aqueous solution. The single crystal X-ray structure of [NiL19] + 
confirms the square plane with nickel(II)-nitrogen bond lengths in the range 1.852(7) to 
1.877(7) A (Figure 38). In addition, the nickel(II) centre sits out of the mean nitrogen plane 
by 0.2 A. A further interesting aspect to note is that the piperazino unit adopts an almost 
perfect boat conformation in the solid state.
,NL HN,
HN'
L19
Figure 38. X-ray crystal structure of [NiL19]2+.19-.2+ 163
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2.2 Synthetic Aims
The prior synthesis of side-bridged macrocycles by other research groups has been 
discussed but these methods had not been applied to bis-macrocycles, although the bis- 
cyclen compound has since been reported (2006). I08 It has been known since the mid 1990s 
that bis-macrocyclic compounds (such as AMDS 100) are effective antagonists of the 
CXCR4 receptor. However, the bis-macrocycles reported in the literature contain cyclam 
rings and are therefore not configurationally restricted. They can adopt a number of 
configurations in solution depending on factors such as pH and acetate concentration. 146 
Therefore, a configurationally restricted bis-macrocycle could prove to have beneficial 
properties with regards to receptor binding as it would only present a single shape to the 
receptor binding site.
In order to synthesise configurationally restricted bis-macrocycles, a modification of 
the synthetic route reported by Handel (chapter one, section 1.3.2) was proposed (Figure 
39). The proposed route makes use of the cis conformer of glyoxal cyclam and Kolinski's 
sodium borohydride reduction.
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Figure 39. Proposed synthetic route to bis-side-bridged cyclam, 5.
This route has proved to be both successful and more importantly repeatable. The 
synthetic route proceeds in overall yields of around 50% for the two step process and is the 
subject of the next section.
57
2.3 Synthetic Discussion
2.3.1 Bis-aminal Precursors
The glyoxal condensate of cyclam, 3. was prepared according to literature methods 
and proceeds in a quantitative yield. 164 The reaction is carried out at relatively low 
temperature (-10°C) to prevent the formation of oligomers. A crystal structure of 3 has 
previously been reported (Figure 40). 165 The rigid bis-aminal bridging moiety fixes the 
geometry of the macrocycle with the aminal protons located cis to each other. This results 
in the folded geometry of the macrocycle where each ring system adopts a chair 
conformation. Therefore, there are two endo nitrogen lone pair of electrons which face into 
the ligand fold and two exo nitrogen lone pairs of electrons which face out of the ligand 
fold (Figure 40). Consequently, the exo lone pairs are reactive towards electrophilic attack 
whereas the endo lone pairs are unreactive as they are protected by the cavity of the ring 
system.
Figure 40. X-ray crystal structure of 3 from two different views. 165
Single crystals of protonated 3 with two different counteranions have been grown 
during this work. The first example containing a perchlorate anion is shown in Figure 41.
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oFigure 41. X-ray crystal structure of 3.2HCIO4.
In accord with the previously reported structure, each six membered ring adopts a 
chair conformation and the aminal hydrogens are located cis to each other. 165 The 
protonated nitrogen atoms form two separate hydrogen bonds with perchlorate counter 
anions. The average N-H O distance is 2.795 A and the average OH distance is 1.986 A.
C(1)-N(1)
C(7)-N(4)
C(8)-N(4)
C(10)-N(1)
C(11)-N(4)
C(11)-N(1)
Bond length /
A
1.504(2)
1.467(3)
1.468(3)
1.508(2)
1.424(2)
1.538(2)
N(1)-C(1)-C(2)
N(4)-C(7)-C(6)
N(4)-C(8)-C(9)
N(1)-C(10)-C(9)
N(4)-C(11)-C(12)
N(4)-C(11)-N(1)
Bond angle / °
108.51(13)
109.08(15)
113.01(17)
109.86(15)
112.75(14)
112.35(13)
C(1)-N(1)-C(10)
C(1)-N(1)-C(11)
C(10)-N(1)-C(11)
C(11)-N(4)-C(7)
C(11)-N(4)-C(8)
C(7)-N(4)-C(8)
Bond angle / °
111.99(13)
111.09(12)
109.05(14)
113.93(16)
112.02(15)
114.78(15)
Table 4. Selected bond lengths and angles for 3.2HC1O4.
The second example with a zinc(II) chloride anion was grown via slow diffusion from 
methanol (Figure 42). The unit cell reveals one cyclam unit together with a zinc(II) chloride 
counterion. The zinc(II) centre adopts a tetrahedral geometry with a coordinated water 
molecule completing the tetrahedron. Additionally, the water forms a hydrogen bond with 
one of the nitrogen atoms in the macrocycle, the O-H N distance being 2.748 A (OH
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distance 1.874 A, Table 5). The two aminal hydrogen atoms are located cis to each other 
which is in agreement with the structure published by Gluzinski et a/. 165 As expected, each 
of the four 6-membered rings adopt the chair conformation in the solid state.
The major difference between the two protonated crystal structures appears to be that 
the first one is di-protonated whereas the second is only mono-protonated with a 
]" counter anion.
O-/
Figure 42. X-ray crystal structure of 3.H[ZnCl3(OH2)].
60
Bond length
/A
Bond angle
1°
Bond angle
1.477(2) 109.44(15) 108.91(16)
C(7)-N(4) 1.462(3) N(4)-C(7)-C(6) 10.59(16) C(7)-N(4)-C(8) 10.10(14)
C(8)-N(4) 1.477(2) N(4)-C(8)-C(9) 111.26(17) 110.03(4)
1.484(2) 1.30(15) 107.44(5)
1.467(2) 112.39(15) 117.34(2)
1.472(2) 10.21(14) 103.01(4)
2.0009(15) 112.17(14) 112.284(18)
2.2227(5) 109.50(15) CI(3)-Zn(l)-CI(2) 105.65(2)
Zn(l)-Cl(3) 2.2574(5) 111.31(16)
Zn(l)-CI(2) 2.2873(5) 109.52(15)
Table 5. Selected bond lengths and angles for 3.H[ZnCl3(OH2)].
Alkylation with para-xylene dibromide in a 2:1 ratio was then carried out in either dry 
acetonitrile or dry THF. The choice between these two solvents has no significant impact 
on the reaction yield as long as they have been freshly dried. Literature reaction times for 
this reaction are seven days; however, we have found that no reduction in yield (90%) is 
observed if the reaction is stopped and worked up after three days. 164 The bis-ammonium 
salt, 4, precipitates out of solution and can be filtered off and washed with diethyl ether.
2.3.2 Reductive Ring Cleavage
160Compound 4 can be reduced following Kolinski's route for mono-macrocycles. 
The success of this reaction depends on the quality and the amount of hydride reducing 
agent employed. Optimum results were obtained when twenty molar equivalents of sodium 
borohydride were used per macrocycle. Compound 5 is symmetrical in nature as indicated 
by the aromatic region of the proton NMR spectrum where there is only a singlet peak 
present. A mechanism for the reduction has been proposed by Kolinski and is shown in 
Figure 43. 160 Cleavage of the quaternary nitrogen to carbon bond results in the formation of
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a highly unstable tricyclic aminal, L20, which is either reductively cleaved or hydrolysed on 
aqueous work up.
H- N. N: -OH
N N HN N HN
L20
Figure 43. Mechanism of hydride reduction.
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2.4 Configurationally Restricted Zinc(II) Complexes
Three zinc(II) complexes of 5 have been prepared in reasonable yields. The choice of 
counterion was dictated by the following factors; (1) acetate is a strongly coordinating 
anion and, in addition, could potentially mimic the interaction with CXCR4 aspartate 
residues, (2) chloride has different coordinating properties compared to acetate (which was 
important for proposed EXAFS characterisation) and finally, (3) perchlorate was chosen as 
these anions are weakly coordinating and also have crystal packing properties which could 
be beneficial for single crystal growth.
Complexes were prepared by mixing a methanolic solution of ligand and a slight 
excess of metal salt. The chloride and perchlorate salts of the ligand precipitated out of 
solution and were collected via filtration, whereas the acetate salt remained in solution and 
was purified by size exclusion chromatography. One of the overriding concerns of the 
synthesis of the metal complexes was sample purity and therefore the precipitates were 
rigorously washed. As a result, the yields are relatively low (~ 55%), however, literature 
yields for the complexations of related mono-macrocycles are also in the range 50-70%. 161
Single crystals of [Zn25(OAc2)]2+ were obtained by slow evaporation from a 
methanolic solution, however, attempts to crystallise the chloride and perchlorate 
complexes were not successful. The following section describes the characterisation of 
[Zn25(OAc2)]2+ in both the solid state (X-ray crystallography) and aqueous solution 
(NMR).
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2.4.1 X-ray Crystal Structure of [Zn25(OAc2)] 2+
The X-ray crystal structure of [Zn25(OAc2)]2+ (Figure 44) has an asymmetric unit 
containing only one macrocyclic ring. The two zinc(II) atoms are identical and are related 
by crystallographic symmetry with the macrocyclic framework adopting the equivalent of a 
trans-II configuration. The zinc(II) ion is six-coordinate, adopting a distorted octahedral 
geometry composed of four nitrogens from the macrocycle and two oxygens from the 
acetate counterion. Acetate oxygen atoms are bound in an anisobidentate manner; one bond 
being 2.112(3) A with a longer interaction at 2.407(4) A. The distorted octahedral geometry 
is completed by the four nitrogen atoms from the rigid macrocyclic backbone which have 
bond lengths in the range of 2.091(3) to 2.228(3) A (Table 6).
Figure 44. X-ray crystal structure of [Zn25(OAc)2] 2+ (A) highlighting the angle
between the two macrocycles (B).
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Although there are no previous examples of zinc(II) complexes of side-bridged 
cyclams, the Zn-N bond lengths are within the expected range for cyclam type 
compounds. 166 The [Zn22]4+ equivalent structure has Zn-N bond lengths of 2.071(2) to 
2.252(2) A. Unbound acetate anions are present in disordered positions in the 
asymmetric unit, which show no interaction with the macrocyclic cation.
Zn(l)-N(4)
Zn(l)-N(2)
Zn(l)-0(l)
Zn(l)-N(l)
Zn(l)-N(3)
Zn(l)-0(2)
Bond length
/A
2.091(3)
2.106(3)
2.112(3)
2.166(2)
2.228(3)
2.407(4)
N(4)-Zn(l)-N(2)
N(4)-Zn(l)-0(l)
N(2)-Zn(l)-0(l)
N(4)-Zn(l)-N(1)
N(2)-Zn(l)-N(l)
0(l)-Zn(l)-N(l)
N(4)-Zn(l)-N(3)
N(2)-Zn(l)-N(3)
Bond angle/
0
117.91(12)
133.57(12)
102.38(13)
100.10(11)
84.86(11)
105.82(11)
69.44(12)
83.85(12)
0(l)-Zn(l)-N(3)
N(l)-Zn(l)-N(3)
N(4)-Zn(l)-0(2)
N(2)-Zn(l)-0(2)
0(l)-Zn(l)-0(2)
N(l)-Zn(l)-0(2)
N(3)-Zn(l)-O(2)
Bond angle /
o
94.58(11)
158.40(10)
85.97(13)
156.11(13)
56.31(14)
90.74(11)
106.79(12)
Table 6. Selected bond lengths and angles for [Zn25(OAc)2]2+.
The coordination of the acetate anion corresponds to the proposed interaction of each 
of the macrocyclic units with the CXCR4 receptor (Aspl71 and Asp262). Interestingly, the 
zinc(II) ion is significantly displaced from the plane of the four nitrogen atoms (0.74 A) and 
protrudes from the cavity, thus enhancing the interaction with the bound acetate.
The fact that the zinc(II) ion sticks out of the cavity and readily binds to acetate in the 
solid state could be a key factor in the interaction with CXCR4. This hypothesis depends on 
the macrocyclic configuration being maintained in aqueous solution. To assess the 
configuration in solution it was necessary to undertake high field NMR studies.
2.4.2 NMR Characterisation of [Zn25(OAc2)] 2+
The restricted nature of the macrocycle complicates the proton NMR spectrum of 
[Zna5(OAc2)]2+ due to an increased number of inequivalent protons, resulting in a series of
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overlapping peaks which necessitated the use of high field NMR techniques to fully assign 
the spectrum. This work was carried out in collaboration with Prof. Peter Sadler (University 
of Warwick), making use of a variety of NMR techniques, including 2D HSQC NMR.
The [ 1H, 15N] HSQC NMR spectrum of [Zn25(OAc2)]2+ at room temperature (Figure 
45) reveals only a single peak which corresponds to the secondary amine in each 
macrocycle and indicates that only a single configuration exists in aqueous solution. In 
contrast to these data, the equivalent zinc(II) complex of AMDS 100 shows multiple peaks 
due to there being several macrocyclic configurations and NH environments present in the 
equilibrium. 146 This equilibrium can be altered by varying the concentration of acetate 
present.
SINGLE N-H 
ENVIRONMENT
o
<02 -'H (ppm)
Figure 45.2D NMR of [Zn25(OAc)2] 2+.
However, this is not the case with [Zn25(OAc2)]2+, where there were no observable 
changes to the NMR spectrum when the counterion was varied. The NMR data (Figure 46), 
together with the single crystal X-ray structure, appear to be consistent with both
66
macrocyclic units uniquely adopting the trans-II configuration in the solid state and in 
solution.
4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 ppm
3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 ppm
Figure 46. Aliphatic region of the JH NMR of [Zn25(OAc)2] 2+ recorded at 800 MHz.
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2.5 Configurationally Restricted Copper(II) Complexes
Three copper(II) complexes of 5 have been prepared in a similar fashion to the 
zinc(II) complexes discussed previously. Complexes were prepared by mixing a methanolic 
solution of ligand and a slight excess of metal salt. [Cu25(OAc)2]2+ was purified by size 
exclusion chromatography as was [CtfeSCyCfe after firstly filtering off trace impurities. 
The chromatographic purification of the copper(II) complexes was much easier in 
comparison to the zinc(II) complexes due to the simple fact that the compounds are 
coloured and can be seen running down the column. In contrast, [CuiSKClO^ precipitated 
out of solution and was collected via filtration. Again, the desire for highly pure complexes 
meant that yields of the complexes were lower (60-70%) than anticipated, however, these 
are comparable to literature yields on similar, mono-macrocyclic ligands. 161
Single crystals of both [Cu25](ClO4)4 and [CuiSC^]* were grown via ether diffusion 
into a methanolic solution. The following section describes the characterisation of these 
two complexes in the solid state.
2.5.1 Characterisation of [Cu25](ClO4)4
The single crystal structure of [CuiS]4"1" (Figure 47) contains two macrocyclic units, 
and like [Zn25(OAc)2]2+, the macrocyclic framework is in a trans-II configuration. In 
contrast to [Zna5(OAc)2]2+, however, the copper(II) ions in each ring are not 
crystallographically equivalent to each other but their environments are very similar. They 
both adopt a tetrahedrally distorted square planar geometry, with Cu-N bond lengths 
ranging from 1.855(11) to 2.048(14) A in one ring and 1.849(11) to 2.266(11) A in the 
second (Table 7).
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Figure 47. X-ray crystal structure of [Cu25] .
Cu(l)-N(4)
Cu(l)-N(3)
Cu(l)-N(l)
Cu(l)-N(2)
Cu(2)-N(8)
Cu(2)-N(7)
Cu(2)-N(5)
Cu(2)-N(6)
Bond Length / A
1.855(11)
1.885(9)
2.002(5)
2.048(14)
1.849(11)
1.950(7)
1.988(5)
2.266(11)
N(4)-Cu(l)-N(3)
N(4)-Cu(l)-N(l)
N(3)-Cu(l)-N(l)
N(4)-Cu(l)-N(2)
N(3)-Cu(l)-N(2)
N(l)-Cu(l)-N(2)
N(8)-Cu(2)-N(7)
N(8)-Cu(2)-N(5)
N(7)-Cu(2)-N(5)
N(8)-Cu(2)-N(6)
N(7)-Cu(2)-N(6)
N(5)-Cu(2)-N(6)
Bond Angle / °
81.4(6)
99.4(4)
154.1(5)
160.9(5)
97.1(6)
90.3(4)
79.1(6)
104.9(5)
160.3(3)
162.8(4)
97.4(4)
84.1(3)
Table 7. Selected bond lengths and angles for [Cu25]4+.
An example of a mono-side-bridged copper(II) complex reported by Kaden and co- 
workers, [CuL13]2+, also has two independent copper(II) environments in the asymmetric 
unit. 161 The Cu-N bond lengths are similar to [Cu25]4+, being in the range 1.979(4) to 
2.016(4) A in one ring and 1.980(3) to 2.010(3) A in the second. Analogous to [Cu25]4+, the 
copper(II) is also four-coordinate in the solid state (Figure 48). The macrocyclic framework 
is in a trans-II configuration, where the methyl and hydrogen arms are sitting trans to each
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other. The copper(II) ion sits in the plane of the four nitrogen atoms, the deviation from the 
best plane being 0.070 and 0.007 A respectively.
Figure 48. X-ray crystal structure of [CuL 13] 2+.
The metal-nitrogen bond lengths in [Cu25]4+ are, as expected, somewhat shorter than 
in [Zn25(OAc)2]2+ and, in addition, there is no significant interaction between the copper(II) 
centre and the counter anion. A further interesting comparison between [Cu25]4+ and 
[Zn25(OAc)2]2+ is the degree to which the macrocyclic units are rotated from each other. 
The macrocyclic rings in [Zn25(OAc)2]2+ could be described as being trans to each other, 
whereas in [Cu25]4+ they could be described as being cis to each other. This is demonstrated 
by the difference in metal-metal distance, which is 11.6584(10) A in [Zn25(OAc)2]2+ but 
closer at 10.9121(17) A in [Cu25]4+. This can be explained further by considering the bond 
angle between the two nitrogen-carbon bonds next to the aromatic linker (Figure 49). In 
[Zn25(OAc)2]2+ this angle is 180.00(55)° whereas in [Cu25]4+ it is 1.80(77)°. These angles 
are created by defining three planes through the crystal structure. Two of the planes are 
taken through the centre of the carbon-nitrogen bonds in each macrocyclic unit respectively
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and the third is taken as the plane of the phenyl linker. The angle between the plane of the 
carbon-nitrogen bond and the plane of the phenyl moiety is 87.80(23)° in [Zn25(OAc)2]2+ 
crystal and 89.47(61)° in the [Cu25]4+ structure.
Figure 49. X-ray crystal structure of [Cu25]4+ highlighting the angle between the two
macrocycles.
The UV-vis of [Cu25]4+ shows a broad band at 554 nm. /his is a higher value than is 
usually observed for square planar copper(II) cyclam complexes, which can be attributed to 
the tetragonal distortion of the copper(II) centre. A more appropriate comparison is with 
[CuL13]2+ which has an absorption maximum at 556 nm in aqueous solution. 161 Five-co­ 
ordinate copper(II) complexes are known to exhibit a band at around 600 nm. 167 There was 
no shift in the band at 554 nm on addition of sodium acetate. For example, dissolution in a 
2 M solution of sodium acetate showed only a marginal shift to 560 nm. Although the UV- 
vis data suggests a four-coordinate copper(II) species in solution, no firm conclusions can 
be drawn from these experiments.
2.5.2 Characterisation of [Cu25Cl2]Cl2
Unlike the previous metal complexes, this X-ray structure suffered from disorder in 
the unit cell. Two symmetry independent structural types occupying the same space in the
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asymmetric unit were determined. In contrast to the four-coordinate [Cu25]4+, the copper(II) 
centre is five-coordinate and is best described as being in a square-based pyramidal 
coordination environment, the base consisting of the four macrocyclic nitrogen atoms with 
a bound chloride counter anion in the apical position (Figure 50).
Figure 50. X-ray crystal structure of [Cu25Cl2] 2+ showing one disordered position.
The copper(II)-nitrogen bond lengths are in the range 1.891(15) to 2.139(16) A 
(Table 8) which is in agreement with [Cu25]4+. Again, the macrocycle adopts the equivalent 
of a trans-II configuration in the solid state. The metal-metal distance of 11.5705(16) A is, 
as expected, longer than in [Cu25]4+ as the two macrocycles are located in the equivalent of 
a trans position relative to each other (Figure 51). This distance is similar to that found in 
[Zn25(OAc)2]2+. As with the previous two crystal structures, the angle between the two 
macrocycles can be determined. The same three planes are defined and result in an angle of 
ca. 180°, similar to [Zn25(OAc)2]2+, with any deviation being attributed to the disorder in 
the structure. The angle between the plane of the carbon-nitrogen bond and the plane of the 
phenyl moiety is 88.200(99)°, which is similar to the two previously discussed complexes.
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Figure 51. X-ray crystal structure of [Cu 25Cl2] + highlighting the angle between the
two macrocycles.
Cu(l)-N(2b)
Cu(l)-N(3b)
Cu(l)-N(lb)
Cu(l)-N(4b)
Cu(l)-N(2)
Cu(l)-N(3)
Cu(l)-N(l)
Cu(l)-N(4)
Cu(l)-Cl(l)
Bond length / A
1.891(15)
2.004(11)
2.089(14)
2.136(15)
1.999(11)
2.088(11)
2.112(9)
2.139(16)
2.4131(11)
N(2)-Cu(l)-N(3)
N(2)-Cu(l)-N(l)
N(3)-Cu(l)-N(l)
N(2)-Cu(l)-N(4)
N(3)-Cu(l)-N(4)
N(l)-Cu(l)-N(4)
N(2)-Cu(l)-Cl(l)
N(3)-Cu(l)-Cl(l)
N(l)-Cu(l)-Cl(l)
N(4)-Cu(l)-Cl(l)
Bond angle / °
98.0(5)
88.1(4)
164.8(4)
132.3.(5)
68.5(5)
97.2(5)
108.9(3)
90.5(3)
100.8(2)
116.5(4)
Table 8. Selected bond lengths and angles for [Cu25Cl2] 2+
73
2.6 Side-bridged Tris-macrocycles
The bis-macrocycles which have been discussed previously could be extended to a 
tris-macrocyclic ligand (Figure 52). The three ringed derivative can take one of two forms, 
either a linear combination containing two aromatic linker groups or a single aromatic 
linker in a 1,3,5-substituted framework (Figure 52). The cyclam derivatives of L21 and L22 
have been reported by Lindoy and co-workers, although L21 was originally synthesised by 
Sune/a/. 168- 170
L21
|_22
Figure 52. Tris-macrocycle (A), linear tris-macrocycle (B) and side-bridged derivative
(C).
Sun et al. prepared ligand L21 in a three step synthesis starting from cyclam. They 
protected the macrocycle with tosyl chloride according to a method reported by Parker and 
co-workers. 171 The tris-protected macrocycle, L2, is then reacted with the 1,3,5-tris-benzyl 
derivative, L23, (Figure 53) to give L24 which can be purified via column chromatography.
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The final step is the deprotection of the tosyl groups with HBr in acetic acid. The pure final 
product, L21 , is obtained following work up with an ion exchange column. Yields for 
individual reactions are not available although the overall yield has been reported to be 
34%.
-NH HN.
NH HN
.NTs HN.
TsCI, NEt3 
CHCI3
L2
L23
K2C03 
CH3CN
HBr
AcOH
L22 L24
Figure 53. Synthetic route Wtris-cyclam, L22.
Copper(II), zinc(II) and palladium(II) complexes of L22 are known, but are prepared 
in relatively low yield (54% for Cu, 30% for Zn and 35% for Pd), although the only 
reported crystal structure is of a nickel(II) complex. 168' 172 The single crystal structure of 
[Ni3L22](ClO4)e is of relatively poor quality as a result of crystal degradation in the 
synchrotron X-ray source. The nickel(II) ion adopts an essentially square planar geometry
75
(Figure 54) although there is some long range interaction with perchlorate resulting in a 
pseudo-octahedral environment in the solid state. This long range interaction is broken 
down in solution, as evidenced by the UV-vis spectrum, which reveals a four-coordinate 
geometry (Xmax 463 nm) in aqueous solution.
Figure 54. X-ray crystal structure of [Ni3L22](ClO4)6.172
These tris-compounds have not been further developed into configurationally 
restricted ligands. In this work, an example of a tris-macrocycle containing an ethylene side 
bridge, 6, has been synthesised and copper(II) and zinc(II) complexes produced.
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2.6.1 Synthesis of 6
The proposed synthetic route to 6 involves a similar strategy to that which has proven 
to be successful for the previously discussed bis-macrocycles (Figure 55). The prescursor to 
the desired ligand is the 1,3,5-tris bromo compound L28, which was supplied by Dr Steve 
Archibald.
Figure 55. Proposed synthetic scheme to 6.
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The addition of 3 to L23 was carried out in an identical manner to the respective bis- 
macrocycle with the* combination of the two reagents in dry acetonitrile over a five day 
period. The isolated reaction yield is 90% which was the same as was observed for the bis- 
compound. The reduction of 7 with sodium borohydride results in an oily yellow product in 
an impressive yield of over 75%. Although the proton NMR spectrum of 6 is quite difficult 
to interpret fully, the aromatic region consists of a multiple! which integrates to the 
expected three protons. A further indication that the reduction has proceeded smoothly is 
the loss of the doublets at approximately 5 ppm, which are due to the diastereotopic N*- 
CH2 protons. Carbon NMR and the mass spectrum of 6 are more informative and suggest 
that the reduction had worked as expected. The carbon NMR spectrum reveals fifteen 
carbon environments, which can be split into two aromatic carbons, eleven N-a-carbons 
and two N-p-carbons as expected.
2.6.2 Transition Metal Complexes of 6
A series of zinc(II) and copper(II) complexes of ligand 6 has been prepared in an 
analogous fashion to the complexes of 5 discussed previously. The zinc(II) complexations 
proceed in similar reaction yields of between 70 and 80%, whereas the copper(II) 
complexations proceed in lower yields of between 60 and 70%. The NMR spectra of the 
three zinc(II) complexes were difficult to interpret at 400 MHz but were essentially 
identical to each other. The aromatic region of the spectrum contained a singlet which 
integrated to three protons. This is expected of a 1,3,5-linked aromatic system and suggests 
that the complexation procedure had a purifying effect. In addition, the diasterotopic N-CHa 
protons reappear at ca. 5 ppm as a result of the rigidity imparted by the zinc(II) 
complexation.
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Three copper(II) complexes were prepared and in the absence of any suitable single 
crystals have been characterised by EXAFS. This is covered in greater detail in chapter four 
but the complexes are either four or five-coordinate in the solid state and adopt essentially 
the same coordination environment as the related bis-complexes. The UV-vis studies on the 
copper(II) complexes of 6 were also identical to those recorded for the copper(II) 
complexes of 5. For example, [Cu36](ClO4)e shows a broad transition centred at 555 nm in 
aqueous solution.
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2.7 Conclusions
A synthetic route to a bis-macrocyclic compound containing a piperazino or a side 
bridge, 5, has been developed. This route has proven to be reproducible in approximately 
50% yield for the three step procedure. This is the first example of a bis-macrocyclic 
cyclam based compound incorporating a piperazino unit to be reported, although a similar 
cyclen based compound has been independently synthesised by another group.
The X-ray crystal structure of [Zn25(OAc)2]2+ is the first example of a trans-II 
configurationally restricted macrocyclic complex to be reported. Additionally, it is also the 
first example of a configurationally restricted bis-macrocyclic transition metal complex in 
the literature. Furthermore, NMR studies on [Zn25(OAc)2]2+ confirm that the trans-II 
configuration is maintained in aqueous solution.
The X-ray crystal structures of [Cu2SCl2]2+ and [Cu25](ClO4)4 reported here are the 
first examples of copper(II) bis-macrocyclic complexes. The two complexes are 
significantly different from each other, for example [C^SCk]2* adopts a five-coordinate, 
square-based pyramidal geometry, whereas [Cu25](ClO4)4 adopts a four-coordinate, square 
planar geometry. The two structures reported here reflect the rich coordination chemistry of 
copper(II) and expand the current knowledge of copper(II) macrocyclic complexes.
The synthetic route to 5 has been extended to include the synthesis of 6. This is the 
first example of a tris-macrocyclic compound incorporating a piperazino moiety. 
Copper(II) and zinc(II) complexes of 6 have been prepared and appear to have similar 
coordination environments to their bis-macrocyclic relatives.
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Chapter 3. SYNTHESIS &
CHARACTERISATION OF CROSS-BRIDGED
MACROCYCLIC COMPLEXES
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3.1 Cross-bridged Tetraazamacrocycles
An alternative to the "side" bridged piperazino macrocycles discussed in the previous 
chapter are the "cross" bridged cyclam derivatives which contain an ethylene bridge 
between non-adjacent nitrogen atoms. These compounds have been termed "adamanzanes" 
and have received attention primarily due to their potential as radiopharmaceutical 
chelators due to the extreme kinetic stability displayed by their copper(II) complexes. One 
drawback of these systems compared to their side-bridged counterparts is the length of time 
of their syntheses. The reductive ring cleavage step for the "cross" bridged analogue takes 
fourteen days compared to a couple of hours for its "side" bridged relative.
The framework of the cross-bridged cyclam results in the four nitrogen lone pairs 
converging into the macrocyclic cavity and thus making them suitable ligands for 
complexes adopting a folded cis-V configuration (Figure 56).
Figure 56. Cross-bridged cyclam. Metal complexes adopt the cis-V configuration.
There are numerous examples of cross-bridged cyclam ligands in the literature 
containing a variety of pendent arms; however, they have yet to be applied to bis-
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macrocycles. This chapter introduces the synthesis of cross-bridged cyclams, focusing on 
examples possessing methyl and/or benzyl pendent arms, their transition metal complexes 
and also the methodology used to incorporate these systems into novel bis-macrocycles.
3.1.1 Synthetic Development of Cross-bridged Cyclam
The first example of a cross-bridged cyclam derivative was reported by Weisman et 
al. (Figure 57) in 1990 who exploited the regio-selectivity of the bis-aminal, 3, which has 
been previously discussed (chapter two, section 2.3). 173 The bis-methyl salt, L26, is formed 
in 85% yield based on the addition of methyl iodide. The addition of the first methyl group 
proceeds rapidly, however, the second addition is relatively slow and requires longer 
reaction times. Subsequent reduction with sodium borohydride over a fourteen day period 
results in the cross-bridged ligand, L27, in an impressive 90% yield. The overall yield for 
the three stage process is around 60% which is comparable to the previously discussed side- 
bridged ligands.
"/CHs
'& 
CH3 I [ 7 1 NaBH4
NT "N N 
' '
L26 L27 
Figure 57. Synthesis of the first cross-bridged cyclam, L27.
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This synthetic route has been expanded to cover ligands which contain two benzyl 
arms. 174 The reaction* scheme is identical to Figure 57, except that benzyl bromide is used 
instead of methyl iodide. The debenzylation step proceeds in yields ranging from 75-93% 
with the reduction yield being comparable to that of L27 (83-96%). One advantage of 
preparing the di-benzyl species is that it can be debenzylated via hydrogenolysis to leave a 
cross-bridged cyclam with two secondary amine sites (e.g. L28, Figures58 and 59) which 
can be further reacted. This methodology has proven to be successful for incorporating a 
variety of pendent arms, including ter/-butyl bromoacetate. These compounds have found 
use as synthetic precursors for bifunctional chelators and also complexing radioactive 
copper(II). 175
3.1.2 Metal Complexes of Cross-bridged Cyclam
In contrast to the relatively few transition metal complexes of side-bridged cyclam 
ligands, there have been numerous reported complexes of cross-bridged ligands, mainly by 
the groups of Weisman, Busch and Hubin and each one has revealed the expected cis-V 
configuration. 150' 174 This section highlights the structures of the known zinc(II) and 
copper(II) complexes of cross-bridged cyclams, again focusing on the examples containing 
either methyl or benzyl pendent arms.
A search of the CSD reveals that there are 25 reported crystal structures of cross- 
bridged cyclam complexes possessing methyl, benzyl or no pendent arms. These can be 
broken down into six copper(II), five manganese(III), two nickel(II), two zinc(II), two 
manganese(II), two iron(II) complexes and one each of palladium(II), gallium(III), 
cadmium(II), mercury(II), cobalt(II) and copper(I).
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Niu et al. have reported the only two crystal structures of zinc(II) cross-bridged 
cyclam complexes. 176 The zinc(II) ion in the first structure, [ZnL28(OH2)(u-Cl)ZnCl3] is in 
a distorted octahedral geometry, with bonds to the four macrocyclic nitrogen atoms and a 
solvent water molecule (Figure 58). The octahedron is completed by a bridging chloride 
from a [ZnCU]2" counter anion. The zinc(II)-nitrogen bonds are in the range 2.119(6) to 
2.170(5) A and a long range zinc(II)-chloride bond is observed at 2.629(2) A.
Figure 58. X-ray crystal structure of [ZnL28(OH2)(u-Cl)ZnCl3].
The second example is also of L28 but the crystal structure reveals a dimer with two 
bridging chloride counter anions present (Figure 59). The zinc(II) ion again adopts a 
distorted octahedral coordination environment with zinc(II)-nitrogen bond lengths in the 
range 2.133(5) to 2.185(4) A. The two bridging chlorides both have zinc(II)-chloride 
distances of 2.527(1) A.
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Figure 59. X-ray crystal structure of [ZnL28(n-Cl)]22+.
Three copper(II) complexes of cross-bridged cyclam derivatives possessing methyl or 
benzyl arms are known, with the metal centre adopting either a square-based pyramidal or 
distorted octahedral geometry. The copper(II) complex [CuL29Cl]+ was prepared by 
Weisman et al. over a decade ago (Figure 60). 177 The five-coordinate geometry is 
composed of the four macrocyclic nitrogens (Cu-N bond lengths 2.082(3)-2.188(3) A) and 
one bound chloride counter anion (Cu-Cl distance 2.296(1) A). Interestingly, there is an 
agostic interaction with an ortho-hydrogen from one of the benzyl arms with a bond 
distance of 2.74 A.
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L29
Figure 60. X-ray crystal structure of [CuL29Cl]+.
Hubin and co-workers have reported the copper(II) hexafluorophosphate complex of 
L29 (Figure 61). 178 In contrast to the previous structure, this complex adopts a square-based 
pyramidal geometry, where the base consists of three nitrogens and a bound acetonitrile 
solvent molecule. Sitting at the apex of the pyramid is the fourth macrocyclic nitrogen 
atom. The copper(II)-nitrogen bond lengths are in the range 2.049(3) to 2.142(3) A. The 
flexible benzyl arms are folded in order to accommodate the acetonitrile molecule which 
completes the five-coordinate geometry in the absence of a coordinating counter anion.
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L29
Figure 61. X-ray crystal structure of [CuL29(NCCH3)] 2+.
The bis-methyl copper(II) chloride complex, [CuL27Cl]+, adopts a similar 
coordination geometry to [CuL29(NCCHs)]2+ except that the acetonitrile is replaced with a 
chloride counter anion (Figure 62). 179 Again, the axial position is occupied by a 
macrocyclic nitrogen atom.
27/-CH+Figure 62. X-ray crystal structure of [CuI/'CI] .
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3.1.3 Synthetic Development of Cross-bridged Cyclen
The first cross-bridged example of the smaller macrocycle cyclen was reported by 
Bencini et al. in the early 1990s. 180 The preparation involves the prior synthesis of the bis- 
methylated cyclen derivative, L38, which was reported by Ciampolini et al. a decade 
before. 181 This seven step synthesis (Figure 63) involves two separate protection- 
deprotection steps (firstly with phthaloyl/HCl and secondly with tosyl/fkSC^) and the 
formylation of a secondary amine. The protection of L33 with tosyl chloride followed by 
recrystallisation from ethanol results in the bis-tosyl protected product, L34, in 82% yield. 
The sodium salt of deprotonated L35 is then used in situ with bis(2-chloroethyl)- 
methylamine in dry dimethylformamide to result in the cyclised bis-methylated cyclen, L37, 
in 40% yield. Deprotection of the tosyl groups is achieved with concentrated sulphuric acid 
and the free amine ligand is obtained via extraction from chloroform. The tetra- 
hydrobromide salt of L38 is obtained in 90% yield by the addition of hydrobromic acid to 
an ethanolic solution of the free ligand.
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Figure 63. Synthetic route to bis-methyl cyclen, L38.
Reaction of L38 with oxalyl chloride and triethylamine results in the formation of the 
bis-amide, L39, in 29% yield following recrystallisation from cyclohexane (Figure 64). The 
protonated cross-bridged cyclen, L40, is then obtained via reduction with diborane in dry 
THF and the subsequent addition of HCI. Pure L40 is obtained via recrystallisation from an 
ethanol/water mixture in 65% yield.
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Figure 64. Synthesis of cross-bridged cyclen, L40.
Weisman et al. have reported the preparation of a di-benzyl derivative of cross- 
bridged cyclen based on their elegant synthesis using bis-aminal methodology. 177 The 
route is identical to the one shown in Figure 57, except that the starting material is the 
smaller 12-membered macrocycle. The formation of the bis-aminal, L20, proceeds in lower 
yield (63-79%) compared to 3, presumably as a result of the smaller macrocyclic cavity. 
The benzylation of the bis-aminal and its subsequent reduction with sodium borohydride 
proceed in good yields (69-96% and 87-99% respectively). The one disadvantage of this 
synthesis in comparison to that of Bencini et al. is the time the reactions take. The Bencini 
synthesis can be completed in a few days whereas the Weisman method can take up to 16 
days. However, the Weisman method does benefit from the fact that it delivers pure 
products without the need for any significant purification.
Handel and co-workers have expanded on this work and have published the synthesis 
of a series of cross-bridged bis-cyclen ligands (Figure 65). 108 They have used xylyl arms in 
the ortho, meta and para positions as well as a 2,6-pyridine example.
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Figure 65. Synthesis of cross-bridged bis-macrocycle.
The hydride reduction is dependent on the regioisomer of the xylyl linker group. For 
example, the ortho and meta compounds give yields of over 90%, whereas the para 
substituted linker has a yield of only 60%. This is comparable to the yields obtained in this 
work for hydride reductions on 4. Just like the cross-bridged cyclam ligands, these 
compounds exhibit proton sponge properties as evidenced by proton NMR spectroscopy, 
which reveals a NH4^ resonance at ca. 12 ppm.
3.1.4 Metal Complexes of Cross-bridged Cyclen
There are relatively few transition metal complexes of cross-bridged cyclens in the 
literature; a search of the CSD reveals there are sixteen crystal structures of cross-bridged 
cyclen compounds containing benzyl, methyl or no pendent arms. The most common metal 
complex is iron(III) with four examples, followed by two zinc(II) and two manganese(II) in 
addition to one each of nickel(II), indium(II), cadmium(II), mercury(II), copper(II), 
cobalt(II), cobalt(III) and manganese(III). The following section details the reported 
copper(II) and zinc(II) complexes of cross-bridged cyclen derivatives possessing either 
methyl or no pendent arms.
There are only two zinc(II) complexes of cross-bridged cyclen in the literature, one 
possessing two methyl pendent arms and a second without pendent arms, containing two
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secondary amine sites. 182' 183 The structure of [ZnL40Cl2] has been published by Hubin et 
al. Two independent molecules which do not interact with each other are found in the 
unit cell. Each zinc(II) ion adopts a distorted octahedral coordination environment in the 
solid state (Figure 66) with zinc(II)-nitrogen bond lengths ranging from 2.217(2) to 
2.260(2) A in one molecule and from 2.222(2) to 2.246(2) A in the second. There are two 
bound chloride counter anions present (zinc(II)-chloride distance range 2.3763(7) *- 
2.3837(7) A) completing the six-coordinate geometry.
H3C.
|_40
Figure 66. X-ray crystal structure of [ZnL40CI2J.
In the second example, [ZnL41(OH2)2]2+, reported by Niu et al, no pendent arms are 
present and the zinc(II) metal ion is six-coordinate in the solid state (Figure 67). 183 The 
zinc(II)-nitrogen bond lengths are shorter (2.133(5)-2.139(4)) A and the disordered 
octahedral geometry is completed by two water molecules located cis to each other, the 
zinc(II)-oxygen bond lengths being 2.123(4) A. Due to the smaller ligand cleft, the metal 
ion clearly sits outside of the mean plane of the four macrocyclic nitrogen atoms. This is
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evidenced by the angle between the two axial nitrogen atoms and the zinc(II) ion, which is 
only 156.8(3)°.
Figure 67. X-ray crystal structure of [ZnL41(OH2)2]2+.
The only known copper(II) complex of cross-bridged cyclen, [CuL40(NCCH3)2]2+, 
contains two methyl pendent arms. 182 The structure is similar to the zinc(II) example 
discussed above with the copper(II) adopting a distorted octadedral geometry and the donor 
atoms are composed of the four macrocyclic nitrogen atoms plus two bound acetonitrile 
solvent molecules (Figure 68). The copper(II)-nitrogen bond lengths are in the range 
2.061(2) to 2.238(4) A. The presence of the acetonitrile molecules were unexpected as the 
chloride complex used to grow the crystals was expected to give a five-coordinate structure.
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Figure 68. X-ray crystal structure of [CuL40(NCCH3)2] 2+.
Handel and co-workers have reported the synthesis of a series of copper(II) 
complexes containing the cross-bridged cyclen moiety (Figure 65). 108 These tricyclic 
macrocycles have been prepared with both mono- and bis-metallic complexes, although no 
crystal structures have been solved. Interestingly, when the complexation is carried out at 
low temperature (~ 0°C), the ratio of copper(II) to ligand never exceeds 1:1, indicating that 
the second complexation is difficult under these conditions. In fact, no further metallation 
occurred within a week. Conversely, when the complexation was performed at elevated 
temperatures (or when a large excess of metal salt was used) the expected bis-metallic 
complex was obtained. This phenomenon has been attributed to the basic nature of the 
constrained macrocycles, where one of the rings is protonated and, as a result, electrostatic 
repulsion lowers reactivity.
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3.1.5 Kinetic Sta bility of Cross-bridged Macrocycles
The cross-bridged macrocycles are rigid and therefore have complex stabilities, 
which are much greater than simple macrocycles. The short cross-bridge gives their 
transition metal complexes added rigidity constraint. Another characteristic of these ligands 
is that the bridgehead atoms are also donor atoms. This further increases rigidity, especially 
in small macrobicycles.
The stability of the resulting transition metal complex can be determined by recording 
their metal dissociation half lives. This can be achieved via UV-vis spectroscopy for 
copper(II) complexes or NMR spectrometry for zinc(II) complexes. [CuL27]2+ is much 
more stable than [CuL40]2+ as determined by their respective ligand dissociation half-lives. 
The half-life of [CuL27]2+ in 1M HC1O4 is estimated to be over 6 years (pseudo first order 
rate constant of dissociation = 3.5 xlO"9 s" 1 ) whereas that of [CuL40]2+ is only 30 hours 
(pseudo first order rate constant of dissociation = 6.4 xlO"6 s" 1 ). [CuL40]2+ is also more rigid 
than [CuL27]2+, due to the decreasing size of the macrocyclic cavity on going from cyclam 
to cyclen ligands.
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3.2 Synthetic Aims
In order to prepare a novel cross-bridged cyclam derivative, it was proposed to make 
a modification of Weisman and co-workers' reduction procedure. The reasoning behind 
preparing a constrained bis-macrocycle and the synthetic route to compound 4 was 
highlighted in section 2.2. The proposed route (Figure 69) involves reacting methyl iodide 
with 4 followed by reduction with sodium borohydride. This synthesis has been designed in 
collaboration with Dr Tim Hubin (Southwestern State University, Oklahoma, USA).
Figure 69. Proposed synthetic route to cross-bridged bis-cyclam, 9.
The synthesis of 9 has proven to be successful and proceeds in an overall yield of just 
over 50% for the four stage route. This is similar for the route to the side-bridged 
compounds discussed in the previous chapter even though there is an extra reaction step 
included. As mentioned previously, the main drawback of this synthetic route is the length
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of time needed for the final reduction step. Another problem is the "proton sponge" nature 
of the final compound, 9, which means that care must be taken to avoid contact with 
moisture as the ligand protonates rapidly. However, this problem can be solved by making 
the HC1 salt of the ligand for storage.
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3.3 Synthetic Discussion
3.3.1 Bis-aminal Precursors
The route to 4 has been covered previously (chapter 2, section 2.3.1). The rigid nature 
of the macrocycle means that there is only one site for further electrophilic attack. The 
addition of an alkyl halide is slow and is also complicated as the starting material *is 
insoluble in the reaction solvent. This results in the need for a large excess of a small, 
reactive, alkyl halide such as methyl iodide and long reaction times. Compound 8 was 
prepared by adding 100 equivalents (50 per reactive site) of methyl iodide to a suspension 
of 4 in acetonitrile. This mixture was left for fourteen days at room temperature, and as the 
reaction proceeds, it is interesting to note that the initial white suspension is replaced by a 
brown solution. This can be attributed to the anion metathesis of iodide replacing bromide. 
This is confirmed in the mass spectrum of 8 which reveals a peak at m/z 959 which can be 
assigned to the loss of iodide.
3.3.2 Reductive Ring Cleavage
The bis-alkylated compound, 8, can be reduced according to the method previously 
described by Weisman and co-workers. 173 Our modification of this synthesis proceeded 
with only twenty equivalents of reducing agent per macrocycle, whereas the literature 
method required fifty molar equivalents of sodium borohydride. The reduction mechanism 
has been reported and involves the initial formation of an iminium ion (Figure 70), 
followed by hydride attack to leave a tricyclic intermediate. 173 This is further attacked by 
hydride to result in the bicyclo[6.2.2] derivative.
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Figure 70. Mechanism for double ring expansion.
The yields obtained for 9 are appoximately 70%, which is slightly lower than the 
reported yields; however, this can be attributed to the fact that there are two macrocycles 
present in our system so a reduced yield would be expected. The free ligand can be 
protonated by bubbling HC1 gas into an ethanolic solution of 9. The resulting yellow solid 
was then subjected to elemental analysis which revealed, somewhat surprisingly, that there 
were seven HCl's present instead of the expected eight.
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3.4 Transition Metal Complexes
The transition metal complexation of cross-bridged cyclam ligands is significantly 
more challenging compared to the side-bridged analogues discussed in the previous 
chapter. Primarily, this is due to the "proton sponge" properties of the cross-bridged 
ligands. This is a result of the extremely basic nature of the macrocyclic cavity. Protons 
will compete with metal ions for the macrocyclic cavity and, therefore, rigorously dried 
solvents are required for the synthesis. The choice of solvent also has a significant effect on 
the reaction, for example, the zinc(II) complexation will only succeed in DMF. The zinc(II) 
compounds discussed later in this work (chapter five) have been synthesised by Hubin and 
his research group, and therefore, the synthesis of the these will not be discussed here. The 
following section details the syntheses of two copper(II) complexes of 9 and their 
purification. Unfortunately, no single crystals of these complexes were obtained during the 
course of this work.
3.4.1 Copper(II) Complexation
Both copper(II) acetate and copper(II) chloride complexes of 9 were synthesised. 
Similar to the side-bridged complexes, acetate was chosen as a counter anion as it is a 
strongly coordinating anion and could also potentially mimic the interaction with aspartate 
residues on the CXCR4 surface. Chloride was chosen as a counter anion as it has desirable 
properties for X-ray Absorption Spectroscopy characterisation, which will be discussed 
later in this work (chapter four).
Complexation was achieved by mixing a dry methanolic solution of 9 with a slight 
excess of metal salt. The crude products were both purified by size exclusion
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chromatography to give the desired complex. The yield obtained for [Cu29Cl2]Cl2 was a 
disappointing 36%; however, this was due to the fact that a green impurity came down the 
sephadex column with the desired blue band. In contrast, the literature yields for copper(II) 
cross-bridged cyclam derivatives are generally around 65%. 174 This complex was run down 
the size exclusion column five times in order to maximise the purity of the product. The 
UV-vis spectrum revealed a very broad d-d transition centred at 622 nm, which is 
consistent with a five-coordinate geometry. This is expected as it falls in the range of the 
absorption maxima of [Cu2L29]2+ (675 nm) and [Cu2L27]2+ (596 nm).
The hexafluorophosphate salt can be prepared by adding ammonium 
hexafluorophosphate. [Cu29Cl2]2+ was dissolved in a minimum amount of ethanol and an 
ethanolic solution containing a 2.2-fold excess of NttjPFe was added. [Cu29Cl2](PF6)2 
rapidly precipitated out of solution and was isolated after filtration and washing with 
diethyl ether. As expected, no changes in the UV-vis spectrum are observed on replacing 
two of the unbound chlorides. Mass spectrometry reveals a peak at m/z 390 which 
corresponds to the loss of two hexafluorophosphate counter anions; however, the 
compound cannot be seen in the accurate mass spectrum. This can be put down to a 
common problem with ESI mass spectrometry. The low resolution ESI technique is "soft" 
and large molecules such as the copper(II) complex in question can readily be identified, 
whereas the accurate mass collection is a "hard" technique and, as a result, larger molecules 
are broken up during the course of the experiment and are not observed in the spectrum.
The [Cu29(OAc)2]2+ complexation differed from the chloride one above in that it 
remained in solution during the course of the reaction. Additionally, the colour of the 
solution was green throughout, as opposed to the blue solution observed for the chloride
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species. The crude green product was again purified via size exclusion chromatography. A 
brown impurity ran down the column before the desired green band was collected. The 
yield of complexation (54%) is higher than [Cu29Cl2]2H", which is in agreement with the 
side-bridged acetate complexes previously discussed. The UV-vis spectra of 
[Cu29(OAc)2]2+ reveals a broad d-d transition, similar to [Cu29Cl2]2+; however there is a 
bathochromic shift in the absorption maxima to 661 nm.
3.4.2 EXAFS Analysis
Unfortunately, all attempts to obtain single crystals of these two copper(II) complexes 
were unsuccessful. Therefore, they have been characterised using X-ray absorption 
spectroscopy. An in depth look at these results can be found in chapter four; however a 
brief summary of the EXAFS work is included here.
The EXAFS and XANES spectra of [Cu29Cl2]2+ and [Cu29(OAc)2]2+are essentially 
identical to each other in the solid state. This suggests that the copper(II) metal ion adopts 
the same five-coordinate environment in each complex, coordinating to four nitrogen donor 
atoms and either a chloride or oxygen containing counter anion respectively. Copper(II)- 
nitrogen bond distances were determined to be just over 2.0 A. In [Cu29(OAc)2]2+, the 
copper(II)-oxygen was best fitted to a distance of 1.96(2) A; however, in [Cu29Cl2]2+ the 
copper(II)-chloride was further out at 2.26(2) A. These data are consistent with the crystal 
structures reported by Hubin and co-workers (Figures 61 and 62), where the copper(II) 
adopts a square-based pyramidal coordination environment in which the base consists of 
three nitrogen donors in addition to the counter anion. One of the macrocyclic nitrogen 
atoms sits in the apical position completing the five-coordinate geometry.
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3.5 Conclusions
A synthetic route to a bis-macrocyclic compound containing an ethylene cross bridge 
moiety has been developed. This route proceeds in an overall yield of over 50% for the four 
step procedure and adds to the ever increasing use of bis-aminal methodology in 
macrocyclic chemistry. In comparison to the synthetic route to 5, this route is more time- 
consuming; however it leads to transition metal complexes of greater kinetic stability. This 
could be a useful property for in vivo studies, as the metal ion will be retained in the 
macrocyclic cavity for longer and thus potentially being less toxic.
Two copper(II) complexes of 9 have been prepared in relatively low yield. However, 
the complexes were of sufficient purity to carry out biological testing and also EXAFS 
analysis. EXAFS suggests that the copper(II) coordination environments in each complex 
are five-coordinate with a single bond to either chloride or oxygen in addition to the four 
macrocyclic nitrogen atoms. Given that previously described cross-bridged copper(II) 
complexes (of L27 and L29) reported by Hubin et al. adopt five-coordinate square-based 
pyramidal geometries with a longer range axial nitrogen from the macrocycle, it is 
reasonable to assume that [Cu29Cl2]2+ and [Cu29(OAc)2]2+ adopt similar coordination 
environments.
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Chapter 4. X-RAY ABSORPTION
SPECTROSCOPIC ANALYSIS OF
COPPER(II) COMPLEXES OF 5 AND 9
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4.1 Background
X-ray Absorption Spectroscopy (XAS) can be broken down into two separate 
entities; X-ray Absorption Near Edge Structure (XANES) and Extended X-ray Absorption 
Fine Structure (EXAFS) (Figure 71). Although X-ray absorption has been around since the 
1930s, EXAFS experiments only became common-place almost forty years later. 184' 185 The 
first EXAFS experiments using synchrotron radiation were conducted by Kincaid and 
Eisenberger in the mid 1970s. 186 EXAFS can give structural information on transition metal 
complexes which are not amenable to X-ray crystallography and for this reason it is the 
method of choice to study the copper(II) and zinc(II) complexes in this work. Furthermore, 
EXAFS experiments can be conducted in solution, enabling the coordination environments 
of the metal complexes to be studied in solution. In addition, the relative affinity of various 
counter anions to the transition metal ion can be studied. This section details the 
information which can be obtained from EXAFS, the theory behind the technique and a 
brief example of how EXAFS data is interpreted in practice.
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Figure 71. Cr K-edge XAS spectrum of CrO2Cl2 at 10 K.
The XANES region (Figure 71) can consist of pre-edge features (e.g. a ls-3d 
transition) which can give information on the coordination geometry and oxidation state of 
the atom of interest. The example in Figure 71 is of CrOaCk which reveals an intense ls-3d 
transition due to the tetrahedral environment. For the macrocyclic complexes in this work, 
the oxidation states of the metal ions are already known so the EXAFS experiment will be 
more informative. EXAFS gives information about the coordination number of the metal 
ion, bond distances and the type of the surrounding atoms.
EXAFS is an excellent technique for studying compounds which are not crystalline, 
and maybe applied to disordered solids and even solutions. When used in transmission or 
fluorescence mode, the technique is not surface sensitive at the transition metal K-edge as 
the X-rays can penetrate through the sample if it has been properly prepared. As the metal 
complexes discussed in chapters two and three have proved difficult to crystallise, EXAFS
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was chosen to further study their structural characteristics in the solid state. In addition, 
EXAFS will give valuable data about the complexes in aqueous solution. EXAFS 
experiments are relatively trivial to conduct, with the caveat that you have access to an 
appropriately intense source of tunable X-rays (i.e. synchrotron radiation). Beam-time was 
applied for and granted to conduct experiments on these complexes at the Daresbury 
Laboratory Synchrotron Radiation Source (SRS).
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4.2 XAS Theory
4.2.1 X-ray Absorption
An atomic nucleus or a core level electron (e.g. Is) can absorb X-ray photons of a 
certain energy according to the photo-electric effect. When the incident X-ray energy is 
below the binding energy of the core electron (e.g. Is), the electron can be promoted 
(photoexcitation) to a higher valence state which will subsequently drop back down to the 
ground state. When the X-ray energy exceeds the binding energy, the core electron can be 
ejected into the continuum (photoionisation) (Figure 72).
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Figure 72. Schematic representation of the photo-electric effect.
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EXAFS is essentially the measure of p, (absorption coefficient) against X-ray energy 
above the edge, n is a measure of the probability that an X-ray will be absorbed by a core 
electron and decays exponentially as a function of energy. However, at a specific energy, 
the core electron will absorb enough energy in order to reach the continuum and a large 
increase in (j. is the result (Figure 71). This energy is known as the "edge" and is 
characteristic of the element in question, which results in another advantage of EXAFS, it 
being an element specific technique. The oscillations above the "edge" are the result of the 
interference between the outgoing photo-electron and the part of it that is back-scattered 
from neighbouring atoms. Therefore, EXAFS can be thought of as a type of electron 
diffraction; however, the source of electrons is the atom which has absorbed the X-ray 
photon in the first place. 187 The backscattered wave contains information about the 
distance, number and type of atoms it has interacted with and so does the EXAFS 
oscillation. This is the origin of the structural information gathered from EXAFS.
Once the core electron has been excited, the result is a core hole, a photo-electron and 
the excited atom which then decays by one of two main mechanisms; X-ray fluorescence or 
the Auger effect (Figure 73). In X-ray fluorescence, a higher energy electron drops down a 
level to fill the core hole, and in the process, ejecting an X-ray photon of defined energy 
(hv) which is characteristic of the atom in question. Therefore, this can be used to identify 
atoms in solution using fluorescence detection. The Auger effect is a two electron process 
where one electron drops down to fill the core hole and the second is emitted into the 
continuum (Figure 73b) with characteristic energy of the orbital from where it has come. In 
addition, there is a third decay mechanism called secondary electron emission, which deals 
with the holes left behind by the fluorescence and Auger routes. This can be quite
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complicated as it deals with a whole range of processes which may well not have defined 
energies.
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Figure 73. Schematic representation two decay mechanisms: X-ray fluorescence (A)
and the Auger effect (B).
4.2.2 Data Collection
The EXAFS experiments which were conducted during this work were carried out at 
the Daresbury SRS on either station 7.1 or 16.5. Solid samples were run in transmission 
mode using ion chambers with samples diluted in boron nitride and pressed into pellets. 
Solution samples were run in fluorescence mode, where the sample cells were fitted with 
kapton windows. The aqueous solutions were frozen in liquid nitrogen before data 
collection. Both the solid and solution experiments were carried out at 80 K. The spectra 
were averaged (3 or 4 for solid, ca. 10 for solution) and calibrated (first maximum of the 
first derivative of the Cu K-edge of copper foil (8979.0 eV)) using PAXAS. The data were
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modelled using EXCURVE98. For a more detailed experimental procedure, see 
experimental section (chapter eight, section 8.1.2)
4.2.3 Data Reduction
The raw data collected in an EXAFS experiment is a plot of X-ray photon energy 
against the absorption coefficient, JLI (Figure 71) and these data need to be reduced into 
something more meaningful. This can be divided up into four different sections; pre-edge 
subtraction, post-edge subtraction, A3 weighting and finally the Fourier transform (FT) of 
the EXAFS data. Each step is discussed below.
The pre-edge subtraction can be thought of as a removing the background and any 
instrument function from the data. This is modelled to decay exponentially as if no sample 
were present (Figure 74), and is usually done by fitting a quadratic expression to ji below 
the "edge" and extrapolating it beyond to higher energies. Following this step, the data are 
normalised so that the y axis is on a scale of 0-1. This accounts for a single X-ray 
absorption which is a useful assumption for the data reduction process.
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Figure 74. Summary of the EXAFS data reduction process.
To extract the EXAFS oscillations from the normalised absorption, what is known as 
the atomic component is removed. As spectra of free atoms are hard to obtain, this is 
approximated by either a higher order polynomial or a spline which consists of a series of 
coupled polynomials (Figure 74). During this process, the abscissa scale is converted from 
photon energy (eV) to £-space (A"1 )
As the intensity of the EXAFS signal decreases with energy, the data towards the end 
of an experiment need to be weighted (Figure 74) so that the fitting uses all of the data. 
This is conventionally taken to be a t? weighting, i.e. all the data-set is multiplied by A3 , and 
the result of this treatment is the EXAFS for the complex of interest (Figure 74).
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The final step in the analysis of EXAFS data is to take the FT of the EXAFS signal 
(Figure 74). This invblves going from &-space in A"1 to r-space in A. Each peak in the FT 
corresponds to a coordination sphere of atoms, which allows bond distances to be 
determined.
4.2.4 Data Modelling
The final step in the EXAFS analysis is fitting a theoretical model to the experimental 
data. The collected experimental data are initially modelled against a suitable set of 
structural parameters, such as those obtained from X-ray crystallographic data of related 
structures or molecular modelling studies. The experimental data are then fitted to the 
model system by varying the structural parameters until a best least-squares fit is obtained 
(Figure 75). This gives the experimental data an R value, indicating the quality of the result. 
In addition, the modelling process leads to statistical uncertainties in the structural 
parameters being calculated.
t 20-
23456
r/A
Figure 75. Cr K-edge EXAFS (left) and FT (right) of CrO2Cl2 at 10 K.
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In order to model the data using software such as EXCURVE98, the user defines the 
number of shells to be included and the atom type. For example, the first coordination shell 
in this work would be expected to be four nitrogen atoms. This is repeated for the second 
coordination shell, which could be one or two oxygen atoms or a chloride in the zinc(II) 
and copper(II) complexes in this study. Provided that the collected data are of sufficient 
quality, bond distances should be obtained with an accuracy of ± 0.02 A for the first 
coordination shell. The modelled data will be able to reliably differentiate between atoms 
whose atomic numbers differ by ten or more. For example, chloride and oxygen could be 
distinguished, whereas oxygen and nitrogen could not.
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4.3 Aims of EXAFS Experiments
The aim of the EXAFS work is the characterisation of transition metal complexes in 
the solid state but also in aqueous solution. The first experimental step would be to confirm 
that EXAFS would give data that are comparable to the parameters obtained from X-ray 
crystallographic studies.
Although it is expected that the compound's EXAFS signal would be identical for the 
solid and solution experiments, EXAFS measurements would be able to confirm this. For 
the chloride and perchlorate complexes, the solution EXAFS signal would change if they 
underwent a change in geometry on the addition of acetate, provided that the acetate 
interacted with the metal ion. Therefore, these experiments could be used as a probe to 
investigate acetate binding, which has biological significance as the bis-macrocyclic 
complexes are believed to interact with aspartate residues on the CXCR4 receptor. In 
addition, short poly-aspartate peptides or a protein with aspartate or glutamate residues on 
the surface could be used in an EXAFS study to model the binding interaction with the 
receptor. The recombinant CXCR4 protein is not easy to obtain in sufficient stable 
quantities to carry out such studies.
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4.4 XAS Characterisation of Copper(II) Complexes of 5
For the majority of complexes, three EXAFS experiments were performed. Firstly the 
solid state data were collected in transmission mode and two aqueous solutions were 
collected in fluorescence mode. The aqueous solution of complex was split into two and an 
excess of sodium acetate was added to one and left for twenty- four hours to equilibrate (this 
was mainly due to beam time considerations as the complexes should reach equilibrium 
rapidly). This section details the results of the EXAFS studies. There are very few reported 
X-ray absorption spectroscopic studies of bis-macrocyclic complexes. Only a single 
example of [Cu22]4+ has been described which is relevant to this work, although [NJ22]4+ 
has also been reported. 188' 189 Both of these complexes have been analysed in the solid state 
and therefore, there are no reports on solution EXAFS of bis-macrocyclic complexes in the 
literature.
The zinc(II) complexes of 5 and 9 have been studied, however, due to time 
constraints, the results are not included in this work. Early analysis of [Zna5(OAc)2]2+ 
suggests that the EXAFS work is in agreement with the solution NMR and X-ray 
crystallography data.
4.4.1 XAS Analysis of [Cu25](ClO4)4
In the absence of any X-ray data on the copper(II) bis-macrocyclic complexes, the 
appropriate starting point for modelling the data obtained for [Cu25] (€104)4 was the single 
crystal X-ray structure of the mono-copper(II) complex, [CuL42]2+ (Figure 76), although
single crystals of [QfeSCyCfe and [Cu25](ClO4)4 were obtained subsequently to the 
EXAFS studies. On comparison of the modelled EXAFS data with the single crystal X-ray
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structure, it is observed that the average copper(II)-nitrogen bond lengths are identical to 
each other. However, an additional feature is observed in the EXAFS model, which could 
be a result of water binding to the copper(II) ion.
42
Figure 76. [CuL42] (€104)2 was used as a starting point for the analysis of
[Cu25](CI04)4.
The XANES region of [Cu25](ClO4)4 (solid, aqueous solution and solution containing 
an excess of sodium acetate) are essentially the same, the only significant difference being 
a slight loss in resolution of the solution samples relative to the solid sample (Figures 77 
and 78), which is consistent between samples and so appears to be an effect of dissolution. 
Also included in Figure 77 is the XANES of [Cu36](ClO4)6 which shows that the trimeric 
species adopts the same coordination environment as the dimeric complex.
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Figure 77. Cu K-edge XANES spectra of [Cu25](ClO4)4 and [Cu36](ClO4)6 in the solid
state at 80 K.
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Figure 78. Cu K-edge XANES spectra of [Cu25](ClO4)4 derivatives in solution at 80 K.
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Similar to the XANES spectra, the EXAFS and FT data of the solid and two aqueous 
solutions are essentially identical, although there is a reduction in signal to noise on 
dissolution (Figure 79).
The solid state data were modelled first and the FT revealed an intense feature at 
2.00(2) A (Table 9), that was assigned to four nitrogen atoms. A copper(II)-oxygen 
interaction was modelled at a distance of 2.38(2) A, which was not observed in the X-ray 
crystal structure. Peaks at longer distances in the FT are due to the carbon atoms from the 
macrocyclic backbone.
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Figure 79. Cu K-edge EXAFS (left) and FTs (right) of solid [Cu25](ClO4)4 (top), 
aqueous solution (middle) and excess acetate solution (bottom) at 80 K.
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On dissolution, there is little change in both the EXAFS and the FTs, indicating that 
the local environment is very similar in each case. The copper(II)-nitrogen bond distances 
are essentially the same (2.00(2) A vs. 2.00(2) A). There were no significant changes in the 
EXAFS on adding acetate to the solution. This is in agreement with the UV-vis spectrum 
which does not alter, even when two hundred molar equivalents of acetate per copper ion 
were added.
Cu-N4 Cu-O, Cu-C2 Cu-C7 Cu-C8 EfVV Rb (%)
Solid
rc /A
2o2d /A2
1.996(3)
0.0091(4)
2.375(15)
0.0178(46)
2.710(8)
0.0088(21)
2.862(14)
0.0347(8)
3.347(9)
0.0306(33) -0.6(4) 15.7
Aqueous solution
r/A
2o2 /A2
2.000(6)
0.0093(8)
2.374(21)
0.0127(60)
2.732(18)
0.0097(50)
2.868(30)
0.0396(3)
3.348(18)
0.0303(65) 0.13(90) 28.1
Excess acetate solution
r/A
2<r2 /A2
2.006(5)
0.0099(8)
2.338(25)
0.0156(64)
2.721(23)
0.0153(8)
2.862(30)
0.0397(3)
3.351(20)
0.0353(76) -0.06(88) 28.7
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Fermi 
levels, (b) R = [J | XT - XE | k3dk/J | k3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2o2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses.
Table 9. Refined EXAFS parameters for [Cu25](ClO4)4 in the solid state, aqueous
solution and acetate solution.
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4.4.2 XAS Analysis of [Cu25(OAc)2](OAc)2
The XANES and EXAFS spectra of [Cu25(OAc)2](OAc)2 (Figure 80) are slightly, but 
significantly, different from those of [Cu25](ClO4)4, the shoulder at ca. 9000 eV 
disappearing in the acetate complex. The trimeric species [Cu36(OAc)3](OAc)3 is shown to 
have the same coordination environment as [Cu25(OAc)2](OAc)2 in the solid state.
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Figure 80. Cu K-edge XANES spectra of [Cu25(OAc)2](OAc)2 and 
[Cu36(OAc)3](OAc)3 in the solid state at 80 K.
In a similar fashion to the perchlorate complex discussed previously, on dissolution 
there are minimal changes in the XANES spectra (Figure 81). There is, however, a slight 
loss of resolution in the solution data. The solution containing an excess of sodium acetate 
is included for completeness and, as expected, no change was observed.
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Figure 81. Cu K-edge XANES spectra of [Cu25(OAc)2](OAc)2 derivatives in solution
at 80 K.
The EXAFS of [Cu25(OAc)2](OAc)2 was best fitted to a model containing four 
copper(II)-nitrogen bonds at an average distance of 2.02(2) A in the solid state (Figure 82). 
The interaction with the acetate counter anion was modelled to a single copper(II)-oxygen 
at a distance of 2.51(3) A (Table 10). It is generally considered that axial interactions in 
copper(II) tetraamine complexes of greater than 2.5 A should not be considered as bonds. 190 
The copper(II)-oxygen distance in [Cu25(OAc)2](OAc)2 falls at the boundary of this 
distance.
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Figure 82. Cu K-edge EXAFS (left) and FTs (right) of solid [Cu25(OAc)2](OAc)2 (top), 
aqueous solution (middle) and solution containing excess acetate (bottom) at 80 K.
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Cu-N4 Cu-0, Cu-C2 Cu-C7 Cu-C8 Efa /V
R"
(%)
Solid
r/A
2o2 /A2
2.024(3)
0.0118(5)
2.507(37)
0.0362(160)
2.757(13)
0.0087(25)
2.926(17)
0.0389(62)
3.375(12)
0.0359(42)
-0.18 
(42) 15.1
Aqueous solution
r/A
2o2 /A2
2.005(3)
0.0100(5)
2.455(46)
0.0394(48)
2.749(12)
0.0081(24)
2.897(13)
0.0394(48)
3.365(12)
0.0351(46) -0.1(42) 17.3
Excess acetate solution
r/A
2<r2 /A2
2.011(4)
0.009(5)
2.376(38)
0.0296(103)
2.739(12)
0.0089(30)
2.893(19)
0.0397(2)
3.369(12)
0.0300(44)
-0.50 
(63) 20.9
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Fermi 
levels, (b) R = [J | XT - JCE I k3dk/J | k3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2o2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses.
Table 10. Refined EXAFS parameters for [Cu25(OAc)2](OAc)2 in the solid state and
aqueous solution.
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4.4.3 XAS Analysis of [Cu25Cl2](PF6)2
The data obtained from [Cu25(OAc)2](OAc)2 were used as a starting point in the 
analysis of [Cu25Cl2](PF6)2 . Again, the XANES of the tris complex was identical (Figure 
83).
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Figure 83. Cu K-edge XANES spectrum of [Cu25Cl2](PF6)2 and [Cu36Cl3](PF6)3 in the
solid state at 80 K.
The XANES spectra of [Cu25Cl2](PF6)2 and [Cu25(OAc)2](OAc)2 are subtly but 
significantly different to each other. The chloride and perchlorate complexes are essentially 
the same, the shoulder at ca. 8978 eV being characteristic of a four coordinate (D4h) 
copper(II) geometry. 188' 191> 192 The shoulder is not present in the acetate species, indicating 
a more five-coordinate character. Later on in the study, the X-ray crystal structure of 
[Cu25Cl2](PF6)2 was determined, which has very similar copper(II)-nitrogen and copper(II)-
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chloride bond distances. Once again, on dissolution the XANES spectra were identical as 
seen in Figures 84 arid 85.
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Figure 84. Cu K-edge XANES of [Cu25Cl2](PF6)2, [Cu25(OAc)2](OAc)2 and 
[Cu25](ClO4)4 in the solid state at 80 K.
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Figure 85. Cu K-edge XANES of [Cu25Cl2](PF6)2 derivatives in solution at 80 K.
The EXAFS of [Cu25Cl2](PF6)2 was best modelled to a Cu-N4 interaction at an 
average of 2.02(2) A (Figure 86) with a longer copper(II)-chloride distance of 2.54(3) A 
(Table 11). On dissolution, the signal to noise decreased as expected and the copper(II)- 
nitrogen distance (2.01(2) A) remained essentially the same. Peaks at longer distances were 
composed of copper(II)-chloride and copper(II) carbon interactions. The addition of acetate 
to the aqueous solution has no effect on the EXAFS signal, indicating that chloride is not 
displaced by acetate under these conditions.
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Figure 86. Cu K-edge EXAFS (left) and FTs (right) of solid [Cu25Cl2](PF6)2 (top) 
aqueous solution (middle) and solution containing excess acetate (bottom).
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Cu-N4 Cu-Cl, Cu-C2 Cu-C7 Cu-C8 E fa /V
Rb
(%)
Solid
rc /A
2o2d /A2
2.0175(2)
0.0112(3)
2.544(14)
0.0238(28)
2.706(12)
0.0085(23)
2.841(9)
0.0325(43)
3.395(7)
0.0380(27)
-0.08 
(34) 9.7
Aqueous solution
r/A
2o2 /A2
2.008(4)
0.0189(6)
2.542(20)
0.0164(41)
2.695(25)
0.0084(61)
2.851(19)
0.0314(75)
3.374(13)
0.0312(47)
-0.17 
(66) 21.5
Excess acetate solution
r/A
2a2 /A2
2.018(4)
0.0081(6)
2.519(33)
0.0316(104)
2.735(24)
0.0085(48)
2.885(27)
0.0392(114)
3.379(17)
0.0335(65) -1.1(6) 22.3
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Ferrm 
levels, (b) R = [I | ff - yE \ k3dk/J | k3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2o2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses.
Table 11. Refined EXAFS parameters for [Cu25Cl2](PF6)2 in the solid state, aqueous
solution and with excess acetate.
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4.5 XAS Characterisation of Copper(II) Complexes of 9
The EXAFS of [Cu29(OAc)2]2+ and [Cu29Cl2]2+ have been discussed previously 
(chapter three, section 3.4.2), however, a detailed account is presented here. The solution 
data were collected in an analogous fashion to the side-bridged complexes in the previous 
section.
2+4.5.1 XAS Analysis of [Cu29(OAc)2]
The EXAFS spectrum of [Cu29(OAc)2]2+ in the solid state reveals an average 
copper(II)-nitrogen bond length of 2.10(2) A and a copper(II)-oxygen bond at 1.96(2) A 
(Figure 87). The UV-vis spectrum of [Cu29(OAc)2]2+ also suggests a five-coordinate 
geometry surrounding the copper(II) centre. These data indicate that [Cu29(OAc)2]2+ adopts 
a similar structure to the reported crystal structures of related copper(II) complexes (chapter 
three section 3.4.1).
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Figure 87. Cu K-edge EXAFS (left) and FT (right) of [Cu29(OAc)2] 2+ in the solid state
at 80 K.
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On dissolution in water, the EXAFS undergoes minor changes but is still essentially 
the same when statistical errors are taken into account. The Cu-N4 bond distances remain 
the same (2.08(2) A vs. 2.10(2) A) (Table 12) and the first coordination sphere is completed 
by a copper(II)-oxygen interaction at 1.95(2) A (Figure 88). The bond lengths determined 
by EXAFS are in good agreement with those of the reported crystal structures of related 
copper(II) complexes, [CuL27]2+ and [CuL29]2+.
Cu-N4 Cu-0 Cu-C2 Cu-C7 Cu-C8 Efa /V Rb (%)
Solid
rc /A
2o2d /A2
2.096(7)
0.0157(12)
1.959(13)
0.0128(25)
2.750(29)
0.0311(90)
2.940(8)
0.0150(10)
3.480(8)
0.0209(16) 0.47(50) 19.0
Aqueous solution
r/A
2o2 /A2
2.079(8)
0.0116(18)
1.949(32)
0.0177(85)
2.724(28)
0.0232(110)
2.934(9)
0.0132(17)
3.465(10)
0.0189(28) 0.31(55) 22.3
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Fermi 
levels, (b) R = [I ] xT - %E \ k3dk/| | k3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2c2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses.
Table 12. Refined EXAFS parameters for [Cu29(OAc)2]2+ in the solid state and
aqueous solution.
—— Experiment
-O- Theory
Figure 88. Cu K-edge EXAFS (left) and FT (right) of [Cu29(OAc)2]2+ in aqueous
solution at 80 K.
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4.5.2 XAS Analysis of [Cu29Cl2] 2+
Initial analysis of [Cu29Cl2]Cl2 suggested that there was a counter anion impurity 
containing copper(II) chloride (i.e. [CuCl3]~) To prevent this impurity affecting the EXAFS 
analysis, the chloride complex was treated with sodium hexafluorophosphate before the 
EXAFS studies were undertaken. This was achieved by mixing the chloride complex with 
2.2 molar equivalents of sodium hexafluorophospl.^e in methanol, stirring at room 
temperature for ten minutes and filtering off the resultant solid. The EXAFS of [Cu29Cl2]2+ 
revealed an intense peak which indicates the presence of a copper(II)-chloride interaction at 
2.26(2) A (Figure 89). This distance is significantly shorter than that observed in 
[Cu25Cl2]2+ which can be explained by the fact that in [Cu29Cl2]2+ the chloride occupies an 
equatorial position and would therefore be expected to form a shorter bond than in 
[Cu25Cl2]2+, where the chloride occupies an axial position.
—— Experiment
-O- Theory
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Figure 89. Cu K-edge EXAFS (left) and FT (right) of [Cu29Cl2](PF6)2 in the solid state
at 80 K.
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Similar to [Cu29(OAC)2]2+, the best fit of the first coordination shell consisted of a 
Cu-N4 at an average of 2.06(2) A. The second coordination sphere is completed by two sets 
of Cu-C distances at 2.70(3) A and 2.93(3) A respectively (Table 13).
Cu-N4 Cu-CI Cu-C2 Cu-C7 Cu-Cs E f"/V Rb (%)
Solid
rc /A
2o2d /A2
2.063(6)
0.0203(10)
2.260(3)
0.0050(5)
2.695(27)
0.0341(1)
2.929(8)
0.0189(13)
3.449(6)
0.0173(14) 2.4(4) 11.9
Aqueous solution
r/A
2o2 /A2
2.094(18)
0.0146(39)
2.246(14)
0.0095(44)
2.732(66)
0.0333(360)
2.962(14)
0.0086(31)
3.455(24)
0.0246(75) 0.30(13) 30.2
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Fermi 
levels, (b) R = [J | xT - %E | K3dk/J | K3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2o2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses.
Table 13. Refined EXAFS parameters for [Cu29Cl2](PF6)2 in the solid state and
aqueous solution.
If we compare the XANES region of the [Cu29(OAc)2]2+ and [Cu29Cl2]2+ solid 
samples (Figure 90), we find that the two are almost identical, indicating that the copper(II) 
environments are the same in both, apart from the copper(II)-chloride distance is longer 
than the copper(II)-oxygen distance, as expected. This implies the swapping of chloride 
with oxygen with no other changes in the copper(II) coordination environment.
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Figure 90. Cu K-edge XANES of [Cu29Cl2]2+ and [Cu29(OAc)2]2+ in the solid state at
80 K.
[Cu29Cl2](PF6)2 is less soluble in water than [Cu29Cl2]Cl2 and therefore, an excess of 
sodium chloride was added to the aqueous solution sample to assist in dissolution of the 
sample by exchange of the hexafluorophosphate anion for chloride The solution was 
filtered through a pad of celite filter aid to remove trace solids before the EXAFS 
experiment was performed. The solid and solution EXAFS are identical (Figure 91) and are 
consistent with the XANES analysis.
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Figure 91. Cu K-edge EXAFS (left) and FT (right) of [Cu29Cl2]Cl2 in aqueous solution
at 80 K.
2+4.5.3 Anion Displacement Experiments With [Cua9Cl2]
A second sample was prepared by adding an excess of sodium acetate to 
[Cu29Cl2](PFe)2 and dissolving in water. After filtering through a pad of celite, the EXAFS 
experiment was carried out in fluorescence mode. It would be expected that if 
[Cu29Cl2](PF6)2 interacted with the acetate counter anion, any change in coordination 
geometry would be observed in the EXAFS data. If the chloride counter anion was replaced 
by acetate, the EXAFS signal should overlap with that of the acetate complex previously 
discussed. This is indeed what is observed for this complex (Figure 92).
The solution EXAFS signal is identical to the [Cu29(OAc)2]2+ solution EXAFS 
(Figures 91 and 92), where the first coordination sphere is composed of a Cu-N4 shell at 
2.07(2) A and a copper(II)-oxygen distance of 1.93(2) A.
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Figure 92. Cu K-edge EXAFS (left) and FT (right) of [Cu29Cl2](PF6)2 in aqueous
solution at 80 K with acetate added.
In the solution containing an excess of sodium acetate, there will still be chloride ions 
present which could potentially interfere with the results of the EXAFS experiment by 
scattering the X-ray beam, which has the effect of making the signal to noise ratio worse 
and therefore, the data less well resolved. In order to negate this potential problem, an 
excess of silver(II) acetate was added to the solution of [Cu29Cl2]2+. This should have the 
effect of removing the free chloride counter ions from solution in the form of insoluble 
silver(II) chloride which can be removed by filtration.
After filtration through a pad of celite filter aid, the EXAFS spectrum was obtained in 
fluorescence mode (Figure 93). The data are quite noisy, which is attributable to the low 
concentration of copper(II) in the solution sample. The EXAFS signal is essentially 
identical to the [Cu29(OAc)2]2+ solution previously discussed which confirms that there was 
no scattering interference in the EXAFS spectrum from any chloride ions.
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Figure 93. Cu K-edge EXAFS (left) and FT (right) of [Cu29Cl2](PF6)2 in aqueous 
solution at 80 K with silver(H) acetate added.
Cu-N4 Cu-O Cu-C2 Cu-C7 Cu-C8 Efa /V Rb (%)
[Cu29(OAc)2] 2+ Solidf
rc /A
2a2d /A2
2.096(7)
0.0157(12)
1.959(13)
0.0128(25)
2.750(29)
0.0311(90)
2.940(8)
0.0150(10)
3.480(8)
0.0209(16) 0.47(50) 19.0
[Cu29(OAc)2 ] 2+ Aqueous solution'
r/A
2o2 /A2
2.079(8)
0.0116(18)
1.949(32)
0.0177(85)
2.724(28)
0.0232(110)
2.934(9)
0.0132(17)
3.465(10)
0.0189(28) 0.31(55) 22.3
[Cu29Cl2] 2+ with excess NaOAc
r/A
2o2 /A2
2.070(9)
0.0112(20)
1.929(33)
0.0182(99)
2.727(22)
0.0092(52)
2.938(11)
0.0111(18)
3.452(12)
0.0192(37) 1.48(6) 25.8
[Cu29Cl2] 2+ with excess Ag(OAc)2
r/A
2o2 /A2
2.060(10)
0.0111(20)
1.912(50)
0.0277(182)
2.688(17)
0.0034(39)
2.926(11)
0.0074(18)
3.448(16)
0.0176(45) 1.9(7) 31.7
(a) Ef is single refined parameter to reflect differences in the theoretical and experimental Fermi 
levels, (b) R = [J | xT - yE \ k3dk/J | k3dk] x 100%. (c) The estimated systematic errors in EXAFS 
bond lengths are ± 1 % for well-defined coordination shells, (d) 2o2 is the Debye-Waller factor, (e) 
Standard deviations in parentheses, (f) Solid and solution data repeated for completeness and 
clarity.
Table 14. Summary of EXAFS parameters for [Cu29(OAc)2] 2+ and [Cu29Cl2] 2+ 
derivatives in the solid state and various aqueous solutions.
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4.6 Conclusions
EXAFS has been used in order to study the metal complexes of 5 and 9. Data for 
[Cu25](ClO4)4 in the solid state were found to be identical to the structure determined by X-
f
ray crystallography, confirming that the EXAFS data can be compared to X-ray 
crystallography.
Interestingly, the copper(II) complexes of 5 were not affected by addition of acetate 
which is in contrast to literature reports on related zinc(II) complexes of AMDS 100. 146 The 
changes in the AMDS 100 complexes are due to the rearrangement of the macrocyclic 
backbone in the presence of acetate. However, in the configurationally rigid complexes, the 
EXAFS will only be significantly different if the copper(II) coordination environment is 
altered in the presence of acetate. UV-vis studies on the copper(II) complexes of 5 support 
these findings, even with the weakly coordinating perchlorate counter anion. Given that 
these data suggest the complexes do not bind to acetate, it is still believed that the metal 
complexes interact with aspartate residues to bind to CXCR4 due to the proximity of 
acetate residues in the binding cleft and the fact that these complexes do bind to CXCR4 
(chapter five).
In the absence of any X-ray crystal structures of complexes of 9, EXAFS has been 
employed as the primary structural characterisation technique. The coordination 
environment of the copper(II) ions in both [Cu29Cl2]2+ and [Cu29(OAc)2]2+ is five- 
coordinate, with an axial interaction with a macrocyclic nitrogen atom. This distance is 
shorter than would be expected due to the rigidity of the macrocycle. The XANES region of 
the spectra indicated that the two complexes were identical in structure with oxygen
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replacing chloride in the fifth coordination site. The counter anion has been shown to 
occupy an axial position in the complexes of 5, at a longer distance than in complexes of 9, 
where the counter anion occupies an equatorial position. In contrast to the complexes of 5, 
the EXAFS signal of [Cu29Cl2]2+ in aqueous solution underwent a change on the addition of 
acetate. The solution EXAFS of [Cu29Cl2]2+ with excess acetate present was found to be 
identical to the [Cu29(OAc)2]2+ aqueous solution. This indicates that [Cu29Cl2]2+ shows a 
greater affinity for acetate exchange than the complexes of 5, which is somewhat surprising 
as in the later case, a long range axial anion is being substituted which would be expected 
to be more favourable than replacing an equatorial counter anion.
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Chapter 5. BIOLOGICAL ASSAYS: 
COMPETITION BINDING, ANTI-VIRAL
ACTIVITY AND CALCIUM SIGNALLING
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5.1 CXCR4 Antagonism
Having synthesised two bis-macrocyclic ligands containing ethylene bridges and a 
range of their transition metal complexes, characterised them in both the solid state and 
aqueous solution, the next step in the research was to conduct a variety of assays on these 
compounds to test their biological properties. To begin, an antibody displacement assay 
was designed to confirm that the compounds bind to CXCR4 as they are expected to. Jurkat 
cells were found to express a high level of CXCR4. These assays have been carried out by 
Abid Khan, a member of the Archibald group in collaboration with Dr John Greenman 
(Medical Research Laboratory, University of Hull) and a brief summary of the results are 
presented below. A detailed account of these assays has been published. 193 The anti-viral 
potency and calcium signalling properties of a selection of compounds has also been 
determined in collaboration with a group headed by Prof. Erik De Clercq in Leuven, 
Belgium. The results from these assays are discussed here in addition to a structure-activity 
relationship analysis.
The strength of antagonist binding to a receptor was analysed by two methods. 
Firstly, a method of displacing the antagonist from the CXCR4 surface with monoclonal 
antibodies (mAbs) and secondly, competing the antagonist with mAbs that have been raised 
to specifically bind to the receptor in question. There have been similar experiments carried 
out on AMDS 100 and its metal complexes. 194 However, these assays were not identical to 
ours and therefore, AMDS 100 and its copper(II) and zinc(II) complexes were synthesised 
and included in this study as controls (see experimental section for synthetic details). 
Compounds 5 and 9 and their metal complexes were tested against four different mAbs
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which bind to different epitopes of CXCR4; however, only the results from the 12G5 mAb 
are included here as this binds to CXCR4 in a similar position to AMD3100. The results 
from these assays have been previously reported, but a brief summary is relevant to this 
work and as such is included here. 193
5.1.1 Displacement Assay
To summarise the assay itself, it is best to break the procedure down into four steps. 
To begin with, the Jurkat cells expressing CXCR4 are incubated with a very large excess of 
antagonist compound (20 uM) which saturates the receptor. After half an hour, excess 
compound is washed off. The cells are then incubated for an hour with a primary mAb 
which is specific to CXCR4, before a secondary (fluorescently tagged) mAb is added which 
binds to the primary mAb. The final step in the assay is to quantify the fluorescence 
intensity via flow cytometry, which can be extrapolated in order to calculate the % binding 
inhibition of each antagonist compound. An example of a flow cytometry plot is shown in 
Figure 94. The negative control (purple) represents zero mAb binding and the positive 
control (red) represents total mAb binding. Therefore, the more effectively a compound 
competes for receptor binding, the closer it will be to the negative control. In terms of 
interpreting the results from the assay, the higher the % binding inhibition, the more of the 
compound binds to CXCR4.
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Key Name Parameter
-control.001 FL1-H
+ Control 717.019 FL1-H
L2 717 010 FL1-H
11 717 009 FL1-H
Figure 94. Typical flow cytometry plot showing negative control (purple), positive 
control (red) and two different antagonists (blue and green).
The displacement assay confirms that all of the ligands and their metal complexes 
bind to CXCR4 under the conditions employed (Figure 95). Each metal complex inhibited 
12G5 binding more effectively than AMDS 100, except [Cu25]4+, which showed similar 
inhibition to AMDS 100. Considering the free ligands (i.e. with no metal present), 
AMDS 100 is significantly more effective than 5 which, in turn, is significantly more 
effective than 9.
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Figure 95. Summary of mAb 12G5 binding to CXCR4 in the prescence of bound
antagonists.
The metal complexes tested all inhibited 12G5 binding at approximately 100% 
(Figure 95), which means that when statistical errors are considered, they cannot be 
distinguished from each other. This means that the displacement assay with 12G5 is not 
ideal as it fails to conclude which complex binds most effectively to CXCR4. In order to 
probe the binding inhibition further and differentiate between compounds, a competition 
binding assay was designed. 193
5.1.2 Competition Binding Assay
The competiton binding assay was carried out in a similar fashion to the displacement 
assay described above except that the antagonist was added at the same time as the mAb 
and a lower concentration (1-10 uM) of antagonist was used. The antibodies compete with 
the synthetic compound for receptor binding and the property which is usually reported is 
the ICso, the concentration required to inhibit 50% of mAb binding.
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The ICso values of the ligands and selected complexes are summarised in Table 15. In 
agreement with the displacement assay, the IC5o values reveal that the metal complexes are 
more effective than the free ligands. Compounds 5 and 9 are less effective than AMDS 100 
and, in fact, the cross-bridged cyclam, 9, failed to achieve 50% inhibition at all. It is clear 
from these data that [Cu29]4+ inhibits mAb binding more effectively than the other 
complexes tested. Interestingly, [Cu22]4+ shows comparable inhibition to AMDS 100 which 
is in contrast to literature results. 114
Compound
[Cu29] 4+
[Zn22] 4+
[Zn29] 4+
[Zn251 4+
[Cu25] 4+
[Cu22] 4+
AMD3100
5
9
IC50 / HM
0.18
0.25
0.25
0.26
0.33
0.35
0.37
17.03
n/a
IC90 / nM
0.85
1.36
1.35
1.52
2.85
2.39
4.26
> 17.03
n/a
Table 15. ICso and IC90 values of compounds tested.
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5.2 Anti-HIV Assays
Having confirmed that the complexes bind to CXCR4, it was desirable to send a 
selection of them to be tested for their anti-HIV properties. These experiments were carried 
out by Dr Christophe Pannecouque, a member of the research group headed by Prof. Erik 
De Clercq at the Rega Institute for Medical Research, Katholieke Universiteit in Leuven, 
Belgium. Compounds 5 and 9 and their complexes have been subjected to a tetrazolium 
based colorimetric assay for detecting the potency of anti-HIV compounds. 195' 196 This 
assay has been widely employed over the last twenty years and will be briefly described 
below in addition to the results obtained in this study.
5.2.1 Tetrazolium Based Coloriraetric Assay
The assay records the replication of HIV in MT-4 cells over a period of five days. 
Therefore, the procedure can be separated into three steps; a) infection b) incubation and c) 
evaluation. The method relies on the HIV-induced cytopathogenic effect and measures the 
number of cells infected with HIV.
As a control, the HIV is allowed to replicate without adding any anti-viral compound. 
A stock solution of HIV is added to the cells, which are then incubated at 37°C for five 
days. The cells are checked every twenty-four hours for the cytopathogenic effect. After 
five days, the number of infected cells is measured. The accepted measure is known as the 
CCIDso (50% cell culture infective dose). This is the amount the HIV stock solution must 
be diluted by in order to infect 50% of the cells in the assay.
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A stock solution containing the anti-viral compound is added to the MT-4 cells in the 
96-well plate and the concentration of each well is diluted as required. An excess of HIV 
(100-300 x CCIDso) is then added and the cells are left to incubate for five days in a 
humidified atmosphere at 37°C. After five days, the viability of the cells is examined via 
the MTT assay. 197
5.2.2 MTT Assay
Left alone, the HIV will multiply rapidly and only a handful of cells, if any, will 
remain viable after the five day period. The addition of an anti-HIV compound will prevent 
or reduce viral replication and, as a result, cell survival will be enhanced. This can be 
measured spectrophotometrically. The yellow 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) is reduced by mitochondrial enzymes to formazan 
which is a blue colour (Figure 96).
MTT
Figure 96. Reduction of MTT to formazan.
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One disadvantage of using MTT instead of other tetrazolium salts is that organic 
solvents must be introduced in the analysis due to the fact that the formazan produced is 
insoluble in cell culture medium. However, this can actually be advantageous as it means 
that acidified Triton-X 100 has to be added to the cells, which inactivates the HIV. 
Therefore, people who are carrying out the assay are not at risk of HIV infection.
The ICso of the anti-viral compound can then be determined and is defined as the 
concentration of the compound that is required to reduce the absorbance of the control 
sample by 50%. For compounds which are themselves coloured (for example the metal 
complexes in this work), their colour is taken into account when determining their anti-viral 
properties. Reference compounds are also included in the assays, which include AZT, 
heparin and dextran sulphate.
AMDS 100 and its transition metal complexes have previously been analysed using 
this assay and found to be in the order:
[Zn22]4+ > 2.8HC1 > [Cu22]4+
These complexes have been synthesised and included in this work as reference 
compounds. Therefore, the ICso and CCso values reported here may not be exactly the same 
as reported literature values.
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5.2.3 Anti-viral Activity of Ligands
The units of ICsos and CCsos obtained from this assay are ug/mL. Therefore, before 
compounds can be compared to one another, the units must be converted to uM. The anti­ 
viral potency of the three protonated ligands against a range of viral strains is shown in 
Table 16. The compounds have been tested against a range of HIV strains, including an 
AMD3100 resistant virus (JM3100R) and a CCR5 dependent virus (MAC251). MAC251 is 
an SIV strain and the compounds tested in this assay were all ineffective against this virus 
(data not included). Ills and ROD viral strains are examples of HIV-1 and HIV-2 
respectively. HIV-2 is a less virulent sub-type than HIV-1; however, HIV-2 predominates 
in sub-Saharan Africa. Standard deviations are included in the data where two or more 
experiments have been carried out.
Compound
AMD3100113
5
9
Strain
JM3100R
ROD
Ills
JM3100R
ROD
Ills
JM3100R
ROD
Ills
Av. IC50 / uM
0.53
0.042
0.018
> 100
10.84
3.27
>100
> 94.71
9.47
SD
-
-
-
-
3.00
0.86
-
-
-
Av. CC50 / uM
-
-
-
> 100
>100
> 100
>100
> 100
> 100
SD
-
-
-
-
-
-
-
-
-
Selectivity Index
-
-
-
-
>10
>32
-
> 1
> 11
Table 16. Anti-HIV activity of ligands in MT-4 cells.
AMDS 100 is more potent than both 5 and 9. The results for 5 and 9 reveal that 5 is 
more active than 9, particularly against the ROD viral strain where the cross-bridged 
compound, 9, didn't register an ICso value under the experimental conditions employed. 
These data are consistent with the 12G5 mAb competition binding assay in the previous 
section.
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5.2.4 Anti-viral Activity of Copper(II) Complexes
A range of copper(II) complexes of the three bis-macrocyclic ligands have been 
subjected to the anti-HIV assay and these data are detailed in Table 17.
Compound
[Cu22](C104)4
[Cu22]Cl4
[Cu25](C104)4
[Cu25Cl2 ]Cl 2
[Cu29Cl2](PF6)2
Strain
JM3100R
ROD
Ills
JM3100R
ROD
HI B
JM3100R
ROD
IIIB
JM3100R
ROD
IH B
JM3100R
ROD
IIIB
Av. IC50 
\iM
1.22
0.24
0.053
0.58
0.08
0.043
11.96
0.1032
0.0160
3.75
0.0403
0.0190
0.0391
0.0183
0.00491
SD
-
0.13
0.010
-
0.03
0.010
2.32
0.0373
0.0024
2.18
0.0068
0.0037
0.0086
0.0012
0.00183
Av. CC50 
HM
>125
> 125
>125
50
50
50
> 125
> 125
>125
> 125
> 125
> 125
>125
> 125
>125
SD
-
-
-
14.78
14.78
14.78
-
-
-
-
-
-
-
-
-
Selectivity 
Index
> 105
>535
>2424
86
624
1160
>11
> 1308
>8436
>27
>2555
>5419
>3424
>7315
> 27263
Table 17. Anti-HIV activity of copper(II) complexes in MT-4 cells.
Apart from [Cu22]Cl4, all of the copper(II) complexes were found to be non-toxic to 
the MT-4 cells in the assay, with CCso values in general being greater than 125 uM.
For the two copper(II) complexes of 5, the choice of counter anion does not affect the 
anti-HIV activity against the Ills viral strain. However, [CifeSCbJCla shows slightly more 
potency than [Cu25](ClO4)4 against the ROD strain. These data suggest that the choice of 
counter anion has little affect on anti-viral activity. In comparison to the copper(II) 
complexes of AMDS 100, the copper(II) complexes of 5 are more potent against Ills and 
ROD strains, however, they display poorer activity against the AMDS 100 resistant virus.
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[Cu29Cl2](PFg)2 was found to be the most active copper(II) complex in this assay. For 
example, against the IIIB strain [Cu29Cl2](PF6)2 is an order of magnitude more potent than 
[Cu25Cl2]Cl2 and against the ROD viral strain, [Cu29Cl2](PF6)2 shows between 2- and 6- 
fold greater activity in comparison to the copper(II) complexes of 5. In addition, the 
selectivity index of [Cu29Cl2](PF6)2 is also greater in comparison to the copper(II) 
complexes of 5 and AMDS 100.
The anti-HIV activity of the copper(II) complexes can be summarised as below:
[Cu29]4+ > [Cu25]4+ ~ [Cu22]4+
It is interesting to note that [Cu29Cl2](PF6)2 shows activity against the AMDS 100 
resistant virus in the nanomolar concentration range (ICso 39 nM). This is discussed in 
further detail in the next section.
5.2.5 Activity of [Cu29Cl2](PF6)2 Against AMD3100 Resistant Virus
[Cu29Cl2](PFe)2 was unexpectedly found to be potent against the AMDS 100 resistant 
viral strain JM3100R in the anti-HIV assay. It is known that AMDS 100 and its transition 
metal complexes bind to CXCR4 via interactions with aspartate residues on the receptor 
surface. Compounds 5 and 9 and their complexes are similar to AMDS 100 and would be 
expected to bind in an analogous manner. Therefore, a further test was carried out against 
the AMDS 100 resistant virus with varying concentrations of antagonist both in the presence 
and absence of AMDS 100 (Figure 97) in order to investigate the binding site competition. 
As the concentration of AMDS 100 increases, less [Cu29Cl2](PF6)2 will be bound to AsplTl 
and Asp262 and its activity should decrease accordingly. However, if we consider the
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activity of [Cu29Cl2](PF6)2 at 0.2 ug/mL, it is clear that it actually increases as the 
concentration of AMDS 100 increases. This suggests that [Cu29Cl2](PF6)2 has a slightly 
different binding site than AMDS 100.
NL43/WT
AMDres
AMDres+1^g/ml AMD 
AMDres+S^ig/ml AMD 
AMDres+25|jg/ml AMD 
AMDres+125pg/mlAMD
0.00032 0.0016 0.008 0.04 0.2 1 
Concentration [CujSCIJfPFg)^
125
Figure 97. Inhibition of AMD3100 resistant HIV replication at varying concentrations
of both [Cu29Cl2](PF6)2 and AMD3100.
The mechanism by which the AMDS 100 resistant virus infects cells is unknown. 
However, it could be due to its ability to replace AMDS 100 already bound to either Aspl71 
or Asp262. Alternatively, the resistant virus may not be able to displace [Cu29Cl2](PFe)2 as 
easily as AMDS 100 due to [Cu29Cl2](PF6)2 forming a more stable complex with either 
Aspl71 or Asp262 (or both).
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5.2.6 Anti-viral Activity of Zinc(II) Complexes
In addition to the copper(II) complexes, a range of zinc(II) complexes of the three 
bis-macrocyclic ligands have been tested in the anti-HIV assay and these data are detailed 
in Table 18. Again, all compounds were inactive against the MAC251 virus as expected 
(data not included).
Compound
[Zn22]Cl4
[Zn22](C104)4
[Zn25(OAc)2](OAc)2
[Zn25](C104) 4
[Zn29](OAc)2(PF6)2
[Zn29](PF6)2Cl 2
Strain
JM3100R
ROD
HIu
JM3100R
ROD
Hie
JM3100R
ROD
IIIB
JM3100R
ROD
Hie
JM3100R
ROD
IHB
JM3100R
ROD
Hie
Av. IC50 / 
HM
0.10
0.056
0.012
0.102
0.144
0.010
0.119
0.00339
0.00208
0.13
0.030
0.0057
3.08
0.76
0.25
0.011
0.0059
0.024
SD
-
0.050
0.002
-
0.093
0.008
0.038
0.00106
0.00087
-
0.015
0.0034
-
0.22
0.20
0.002
-
0.020
Av. CC50 / 
HM
51.29
51.29
51.29
> 100
>100
> 100
52.15
52.15
52.15
62.51
62.51
62.51
> 108.02
> 108.02
> 108.02
59.63
59.63
59.63
SD
-
-
-
-
-
-
4.00
4.00
4.00
7.16
7.16
7.16
-
-
-
2.69
2.69
2.69
Selectivity 
Index
513
916
4274
> 1264
>895
> 12892
438
15383
25072
481
2084
10967
>35
> 142
>432
5421
10107
2485
Table 18. Anti-HIV activity of zinc(II) complexes in MT-4 cells.
The anti-HIV activity of the zinc(II) complexes of 5 against the ROD and Hie viral 
strains were consistent, with an ICso of approximately 3 nM being achieved. This is 
significantly more potent than the zinc(II) complexes of AMD3100 and also an order of 
magnitude more active than the copper(II) complexes of 5 discussed above. Both 
[Zn25(OAc)i](OAc)2 and [Zn25](ClO4)4 were found to be toxic to MT-4 cells; however, the 
selectivity indices were in the order of 15000-25000.
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The data obtained from the assay with the two zinc(II) complexes of 9 are somewhat 
inconsistent. For example, [Zn29](PF6)2Cl2 is active against the ROD viral strain, whereas 
[Zn29](OAc)2(PF6)2 is (relatively) inactive. A discrepancy in the relative toxicities of the 
two complexes is also observed. For example, [Zn29](OAc)2(PF6)2 is non-toxic but 
[Zn29](PF6)2Cl2 is toxic (CC50 ~ 60 uM).
In general, the zinc(II) complexes of 9 are less potent than their side-bridged 
counterparts. [Zn29](OAc)2(PF6)2 and [Zn29](PF6)2Cl2 are also poorer inhibitors of HIV 
replication than the copper(II) complexes of 9 discussed above. The anti-HIV activity of the 
zinc(II) complexes can be summarised as below:
[Zn25]4+ > [Zn22]4+ > [Zn29]4+
5.2.7 Anti-viral Properties in PBMCs
In an extension of the anti-HIV studies in MT-4 cells, a selection of antagonists has 
been tested for their anti-viral activity in peripheral blood mononuclear cells (PBMCs), 
which have been extracted from human blood samples. PBMCs are found in the immune 
system and contain CD4+ cells. For this reason, they have been widely used in HIV 
research as they represent the most realistic assay for anti-viral testing.
The ICso values of anti-HIV compounds are expected to be higher (i.e. less active) in 
these cells than in MT-4 cells due to the fact that PBMCs will express a number of 
receptors on their surfaces which may not, in all cases, include CXCR4. The data from a 
selection of compounds in this work are shown in Table 19.
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Compound
5
|Zn 221Cl4
[Zn25](CI04)4
[Cu 29Cl2 ](PF6)2
Strain
Hie
1 1 IB
III B
HlB
Av. ICSO / 
liM
93.49
0.12
0.52
0.013
SD
-
0.08
-
0.002
Av. CCso / 
uM
93.49
> 96.92
> 135
> 133.86
SD
-
-
-
-
Selectivity 
Index
-
>808
>260
> 10297
Table 19. Anti-HIV activity of selected compounds in PMBCs.
These data confirm that the ICso values are, as expected, higher in PBMCs than in 
MT-4 cells. For example, [Cu29Cl2](PFg)2 is approximately 2.5-fold less active in PBMCs. 
In agreement with the anti-viral study, 5 is significantly less active than the metal 
complexes of both AMDS 100 and 9. [Cu29Cl2](PFe)2 is the most active compound to be 
tested in this study, recording an IC$o value of 13 nM. The most significant difference 
between the two assays is with [Zn25](ClO4)4 which is two orders of magnitude less potent 
in PBMCs. The compounds were all found to be ineffective against a CCR5 viral strain 
(BaL) as expected (data not included).
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5.3 CXCL12 Induced Ca2+ Signalling
The intracellular calcium concentration ([Ca2+]j) is maintained at approximately 100 
nM by a number of mechanisms. CXCL12 binding to CXCR4 causes a series of events 
which results in an increase of [Ca2+]j to over 1 mM. This is an important mechanism for 
GPCR communication pathways. The presence of an antagonist will prevent CXCL12 
binding to CXCR4 and therefore, [Ca2+]j will be kept low. This leads to the possibility of 
calculating the % of bound antagonist. The method used for determining ICso values of 
calcium signalling is briefly described below. These experiments were carried out by Dr 
Dominique Schols, a member of the research group headed by Prof. Erik De Clercq at the 
Rega Institute, Katholieke Universiteit in Leuven, Belgium.
5.3.1 Measurement of Intracellular Calcium Concentration
Fura-2 is a commercial indicator which binds to free calcium ions inside cells. The 
excitation wavelength of Fura-2 is different when bound to calcium and when not. 
Therefore, the ratio of bound to unbound intracellular calcium can be determined. A 
method for determining the ICso values of antagonist compounds has been reported by 
Wuytse/a/. 198
U87.CD4.CXCR4 cells are loaded with Fura-2 and incubated at 37°C for thirty 
minutes. Cells are then stimulated with either buffer (control) or varying concentrations of 
antagonist, followed by CXCL12 at a concentration designed to induce the maximum 
release of [Ca2+], (100 seconds after first stimulus). The fluorescence of Fura-2 is recorded 
at two different wavelengths (X^x 340 and 380 nm, 7^m 510 nm) and the level of [Ca2+]j is 
calculated according to an equation reported by Grynkiewicz et a/. 199 Similar to the
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previously described experiments, the IC50 is defined as the concentration of antagonist 
required to inhibit 50% [Ca2+]j in response to the addition of CXCL12.
5.3.2 Calculated IC50 Values
The ICso values of a selection of compounds in cells which express both CXCR4 and 
CCR5 are shown in Table 20. All of the compounds are inactive against the cells that 
express CCR5, as expected. Maraviroc, a CCR5 antagonist which has recently been 
approved for HIV treatment (September 2007), is included as a control sample.
Against the cells that express CXCR4, 9 was found to be essentially inactive, failing 
to register an ICso under the conditions of the experiment. It is interesting to note that 
AMDS 100 is more effective than a number of metal complexes and is significantly more 
active than its copper(II) complexes.
Compound
9
[Cu22](C104)4
[Cu22]Cl4
[Cu25](C104)4
[Zn291Cl4
[Cu29Cl2 ](PF6)2
[Zn25](C104)4
[Zn22]Cl4
[Zn221(C104)4
AMD3100
Maraviroc
IC50 / HM 
(U87.CD4.CXCR4)
> 83814
106.20
56.08
47.48
4.64
4.64
4.01
2.71
2.48
18.67
> 1000(ug/mL)
IC50 / uM 
(U87.CD4.CCR5)
> 838.14
> 1027.68
> 77 1.69
> 1079.75
> 855.50
> 1070.84
> 1083.44
> 775.37
> 1031.36
> 794.47
2.09 (ug / mL)
Table 20. Calcium signalling IC50s for a selection of compounds.
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5.3.3 Correlation between anti-HIV Activity and Calcium Signalling
(? 
The data from the anti-viral assay and the calcium signalling assay can be correlated
using linear regression analysis. This involves taking the log of the IC5o of each compound 
tested and plotting the two assays against one another. Only the transition metal complexes 
have been included in the correlation as 5 was not run in the calcium signaling assay and 9 
failed to register an IC5o in the same assay. The correlation between the complexes is poor 
due to the fact that [Zna9Cl2]2+ does not fit the data (not shown). This could be due to an 
impurity in one of the samples of [Zn29]4+. However, if this complex is removed from the 
dataset, the correlation is found to be good (Figure 98).
2 -
g, ^ 1-5 \
s
n
0.5 -
-3 -2.5 -2 -1.5 -1 -0.5
log anti-HIV (NL43/WT) activity
Figure 98. Correlation between ICso anti-HIV activity vs ICso calcium signalling
excluding [Zn29]Cl4.
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5.4 Structure Activity Relationships
In order to establish the structural relationships between compounds, the mechanism 
of action of the antagonists must be known. It is widely accepted that AMDS 100 and its 
metal complexes bind to CXCR4 via interaction of the carboxylate arms of the receptor 
surface amino acids Aspl71 and Asp262 with the macrocyclic amine groups.34 It has also 
been suggested that an additional interaction with Glu288 is important for receptor 
binding.200 As the compounds in this work have similar structures to AMDS 100, it is 
thought that the mechanism of action will be identical. Therefore, it is important to consider 
the factors which can affect receptor binding. A number of aspects are believed to be 
important, for example:
a) Stereospecific hydrogen bonding; it has been shown that cyclam is protonated at 
physiological pH. 111 As a result, hydrogen bonding can occur between the amine 
functions on the macrocyclic ring and the carboxylate groups on the receptor 
surface.
b) Electrostatic interactions; CXCR4 has a surface charge of -9 (section 1.1.4), 
therefore, the positively charged AMDS 100 (+4) and its metal complexes (in 
general, +4) can interact via direct electrostatic interactions. However, this 
mechanism appears to be of less importance for metal complexes as the 
palladium(II) complex of AMDS 100 is inactive against HIV.
c) Macrocyclic configuration; the rich configurational chemistry of cyclam has been 
discussed previously (section 1.5) and the configuration of the macrocycle could 
play an important role in anti-HIV activity.
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d) Transition metal coordination environment; on the complexation of transition 
metal ions, a coordinate bond between the metal ion and oxygen atoms on the 
receptor carboxylate groups can be formed. These bonds would be expected to be 
stronger than any hydrogen bonding interactions. In addition, the coordination 
preferences of the metal ion itself will play a crucial role in receptor binding.
e) n-n hydrophobic interactions; although lower in energy, the stacking of aromatic 
groups between the aromatic ring of the ligands and the phenyl rings on CXCR4 
amino acid residues could potentially occur. Sadler and co-workers have 
suggested that hydrophobic interactions with tryptophan are important for the 
binding of copper(II) cyclam to lysozyme. 116
The rest of this chapter is devoted to a discussion of the structure of the ligands, their 
copper(II) and zinc(II) complexes and suggested explanations for their anti-viral activities.
5.4.1 Free Ligands
The activity of the three ligands in this work has been tested in an anti-HIV assay and 
has found to be in the order:
AMD3100>5>9
The difference in the activities of the ligands can be rationalised in terms of their 
varying ability to hydrogen bond to aspartate residues on the CXCR4 surface. AMDS 100 
has six secondary amine sites and is the most active ligand (Figure 99a). However, on the 
introduction of an ethylene bridge this number decreases, resulting in fewer secondary 
amine sites. 5 has only two secondary amine groups and as a result is expected to be less
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active than AMDS 100 (Figure 99b). This is confirmed in the anti-HIV assay. Furthermore, 
9 lacks any secondary amine sites and, therefore, would be expected to be a poorer inhibitor 
than 5 (Figure 99c). This is particularly evident against the ROD viral strain where 9 is 
approximately 9-fold less active than 5. Additionally, in the competition binding assay, 9 
failed to achieve 50% inhibition. However, further investigation would be necessary to 
confirm this theory, taking into account the degree of protonation of each ligand at 
physiological pH.
B
Figure 99. Ability of bis-macrocyclic ligands to H-bond to CXCR4.
The different activities can also be regarded by the degree of flexibility of the 
respective macrocyclic units. For example, AMDS 100 possesses the most flexible 
macrocyclic units of the three ligands and is also the most active. This could be due to the 
ability of the macrocycles to adopt a favourable conformation for receptor binding.
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Alternatively, the piperazino moiety formed by an ethylene bridge between two adjacent 
nitrogen atoms provides some rigidity to 5; however, the macrocycle as a whole is still 
reasonably flexible. In contrast, the ethylene bridge between non-adjacent nitrogen atoms 
physically locks the macrocyclic units in place, meaning that 9 has the least flexible ligand 
of the three tested.
It has been reported that, upon transition metal complexation, the activity of bis- 
macrocyclic compounds increases, presumably due to direct coordination bonding being a 
predominant interaction in place of stereospecific hydrogen bonding. 114 The metal 
complexes in this study are also more potent inhibitors of HIV replication than their 
respective ligands. For example, 9 is not very potent, however, [Cu29Cl2](PF6)2 was found 
to be one of the most active compounds in this study. This highlights the important role that 
the transition metal plays in the anti-HIV activity of bis-macrocyclic complexes and also 
suggests that hydrogen bonding may not be essential for receptor binding (of complexes).
5.4.2 Copper(II) Complexes
The anti-HIV activity of the copper(II) chloride complexes in this work has been 
discussed and has been found to be in the order:
[Cu29Cl2]2+ > [Cu25Cl2]2+ > [Cu22]Cl4
The copper(II) ion in [Cu25Cl2]2+ adopts a five-coordinate, square-based pyramidal 
coordination environment in the solid state as ascertained by X-ray crystallography 
(although there is evidence from the EXAFS studies that [Cu25Cl2](PF6)2 is only four- 
coordinate in the solid state, it is [Cu25Cl2]Cl2 that has been tested in the anti-HIV assay).
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Although no X-ray structure of [Cu29Cl2]2+ exists, there are examples of mono-macrocyclic 
copper(II) complexes (e.g. L27 and L29) that have been structurally characterised (section 
3.1.2). The copper(II) ion in these complexes also adopt five-coordinate, square-based 
pyramidal geometries and it would be expected that [Cu29Cl2]2+ adopts the same 
coordination environment.
The major difference between the copper(II) chloride complexes of 5 and 9 is the 
position of the bound counter anion (Figure 100). In [CuaSCy2"1", the square-base consists 
of the four nitrogen atoms of the macrocycle and the axial position is occupied by the 
chloride (Figure lOOa). In contrast, in [Cu29Cl2]2+, the square-base consists of three 
nitrogen atoms and a chloride and the axial position in this case is the fourth macrocyclic 
nitrogen atom (Figure lOOb).
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Figure 100. Schematic representation of copper(II) coordination environments in
[Cu25Cl2]2+ (A) and [Cu29Cl2]2+ (B).
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As has already been discussed, it is believed that the ability of the complexes to 
inhibit HIV replication depends on their respective abilities to bind to CXCR4. Binding of 
the two complexes to CXCR4 is achieved via the exchange of the bound chloride counter 
anion for the aspartate residues on the receptor surface. The solution EXAFS of [Cu29Cl2]2+ 
suggested that, on addition of acetate, the chloride counter anion was directly replaced by 
an oxygen from acetate. This can be represented as in Figure 100. As copper(II) is a d9 
metal ion, the coordination preferences of the metal result in axial bonds which are weaker 
than the four equatorial bonds. Therefore, it is anticipated that, once bound to CXCR4, 
[Cu29Cl2]2+ will be more difficult to displace than [C^SCk]2"1" as the complex formed 
should be thermodynamically more stable due to aspartate being bound to an equatorial 
site. In addition, the [Cu29]4+ complex with aspartate will be kinetically more stable than 
the [Cu25]4+ aspartate complex. Consequently, [Cu29Cl2]2+ will be the most active complex 
of the two. The anti-HIV assay confirms that [Cu29Cl2](PF6)2 is more potent than 
[Cu25Cl2]Cl2 .
5.4.3 Zinc(II) Complexes
The anti-HIV activity of the zinc(II) acetate complexes in this work has been 
discussed and has been found to be in the order:
[Zn25(OAc)2]2+ > [Zn29(OAc)2]2+ > [Zn22(OAc)2]2+
The zinc(II) ion in [Zn25(OAc)2]2+ adopts a distorted octahedral coordination 
environment in the solid state as ascertained by X-ray crystallography. Although the X-ray 
crystal structure of [Zn29(OAc)2]2+ has not been determined, the zinc(II) complex of L43 
(Figure 101) has been structurally characterised. This crystal structure of [ZnL43(OAc)]+
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shows the zinc(II) ion also adopts a six-coordinate, distorted octahedral geometry with a 
bidentate acetate cottnter anion.201 [Zn29(OAc)a]2+ would be expected to adopt the same 
coordination environment around each zinc(II) ion on binding to the aspartate residues.
Figure 101. Cross-bridged ligand L43.
The major difference between the two structures is the position the metal ion occupies 
in relation to the macrocycle. For example, in [Zn25(OAc)2]2+, the zinc(II) ion sits out of 
the macrocycle whereas in [Zna9(OAc)2]2+ it is held inside the macrocyclic cavity like a 
shell. Similar to the copper(II) complexes discussed above, another difference between 
[Zn25(OAc)2]2+ and [Zn29(OAc)2]2+ is the position of the bound counter anion (Figure 102). 
In [Zn25(OAc)2]2+, there is essentially a square-base consisting of the four nitrogen atoms 
of the macrocycle, leaving an open face above the plane for a bidentate acetate counter 
anion (Figure 102a). In contrast, the metal ion in [Zn29(OAc)2]2+ adopts a less distorted 
octahedral environment where two of the cis sites are available for the bound counter anion 
(Figure 102b).
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Figure 102. Schematic representation of the zinc(II) coordination environment in 
[Zn25(OAc)2]2+ (A) and [Zn29(OAc)2]2+ (B).
Unlike copper(II), zinc(II) is a d10 metal ion and as a result has fewer coordination 
preferences. Therefore, the coordination geometry of the metal ion will be less important in 
this case. This means that the configuration of the macrocycle will play an important role in 
the relative activities of the zinc(II) complexes. Another reason why the macrocycle will 
play an important role is the fact that on receptor binding, the acetate counter anion will be 
replaced by an aspartate on the CXCR4 surface (i.e. replacing a bidentate oxygen donor 
with a bidentate oxygen donor). The activity of the zinc(II) complexes could simply be 
explained on steric grounds. As has already been stated, in [Zn25(OAc)2]2+, the zinc(II) ion 
resides outside the mean plane of the macrocycle, and as a result could be in a more 
accessible position to bind to CXCR4 aspartate residues in comparison to [Zn29(OAc)2]2+ 
where the zinc(II) is held inside the macrocyclic cavity. The higher activity of 
[Zn25(OAc)2]2+ could also be attributed to thermodynamics, where the zinc(II) complex of 
5 could form a stronger coordination bond to CXCR4 than the zinc(II) complex of 9. This 
hypothesis needs to be investigated further, possibly using molecular modelling 
calculations.
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5.5 Conclusions
Compounds 5 and 9 and their copper(II) and zinc(II) complexes have been found to 
bind to CXCR4 as shown in an antibody displacement and competition binding assay. The 
transition metal complexes are significantly more effective in binding than AMDS 100. 
Additionally, the ligands and complexes are potent inhibitors of HIV replication as shown 
by a tetrazolium-based assay.
The anti-HIV activity of three ligands has been explained by their relative ability to 
hydrogen bond to CXCR4. As expected from prior work, potency is vastly improved on the 
complexation of transition metal ions such as copper(II) or zinc(II). 114 This highlights the 
importance of coordination bonding to anti-HIV potency. [Zn25(OAc)2](OAc)2 was found 
to be the most active compound tested in this work, followed by [Cu29Cl2](PF6)2- The 
much greater activity of [Cu29Cl2](PF6)2 compared to 9 suggests that hydrogen bonding 
plays little role in the binding to CXCR4 for the metal complex, as 9 is the least active 
compound tested in this study whereas [Cu29Cl2](PF6)2 is one of the most active. 
[Cu29Cl2]2+ and [Zn25(OAc)2]2+ both show greater activity than their AMDS 100 
equivalents which confirms that the strategy of configurationally restricting the macrocycle 
has improved the binding interaction of the complex with the receptor.
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Chapter 6. TOWARDS THE SYNTHESIS OF
ASYMMETRICAL BIS-MACROCYCLES
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6.1 Background
The configurationally restricted bis-macrocycles discussed in the previous chapters 
are symmetrical and relatively facile synthetic routes to each compound have been 
developed. This work could be extended to the synthesis of asymmetrical ligands; for 
example a bis-macrocycle containing one side-bridged macrocycle and one cross bridge 
ring. The synthesis of these ligands is much more challenging in comparison to the ones 
discussed previously. This chapter presents a synthetic route to one example of an 
asymmetrical bis-macrocyclic derivative, the synthetic methodology developed during the 
course of this work and crystal structures of intermediate compounds which have been 
obtained.
6.1.1 Asymmetrical Bis-macrocycles
A synthetic route to a selection of asymmetric bis-macrocyclic compounds using bis- 
aminal chemistry has been reported by Handel and co-workers. 164 Figure 103 details the 
synthesis of one example containing a cyclam ring and a cyclen ring tethered by a 1,4- 
aromatic linker. The attack of 3 by the bis-electrophile is controlled as the ammonium salt 
has low solubility in solvents such as benzene or THF. The asymmetric bis-macrocycle, 
L45, can then be prepared by reacting the ammonium salt, L44, with a slight excess of a 
second bis-aminal (Figure 103) followed by deprotection with hydroxylamine to give L46 . 
This method has been shown to work well provided that the less reactive bis-aminal is used 
in the first step.
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Figure 103. Synthesis of asymmetrical bis-macrocycle, L46.
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6.2 Synthetic Rationale
In order to synthesise an asymmetrical configurationally restricted bis-macrocyclic 
ligand, the route shown in Figure 104 was proposed. The initial compound in this scheme is 
a side-bridged macrocyclic derivative containing an alkyl bromide pendent arm. The route 
to this compound is proposed in Figure 105. The addition of a primary alkyl bromide to 3 
has been discussed in chapter two (section 2.3.1) and would be expected to proceed 
smoothly. The next step could be varied in different ways in order to create the desired 
macrocycle. For example, the bis-aminal bridge could be removed entirely to leave a 
cyclam ring, or it could be directly reduced with sodium borohydride to give another side- 
bridged unit. The route shown in Figure 104 highlights the cross-bridged macrocycle and 
consists of an initial reaction with methyl iodide followed by reduction to give a bis- 
macrocycle containing both a side and a cross-bridged ring.
12
Figure 104. Proposed synthetic route to an asymmetrical bis-macrocycle.
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Figure 105. Proposed synthetic route to 10.
The route to 10 starts off with the addition of 4-(methylbromo)benzoate to 3 followed 
by reduction with sodium borohydride according to our established method. One aspect that 
needs consideration is the remaining secondary amine on the macrocyclic backbone of 
compound 15. This group could potentially undergo an intramolecular reaction at a later 
stage with the bromo pendent arm and, as a result, needs to be protected. Subsequent 
reduction of the ester to give 17 followed by bromination should result in the desired 
compound.
Although the first two steps of the proposed route proceeded as expected, the 
alkylation of 15 has proven to be more difficult than initially anticipated; the following 
section details the various methods that have been attempted to prepare 16 during the 
course of this work and discusses other methods that could be employed in order to prepare 
the desired compound.
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6.3 Synthetic Discussion
6.3.1 Attempted Preparation of 16
During the course of this work, several methods of alkylating compound 15 have 
been attempted. The routes which have been tried are summarised in Figure 106. This 
section includes a discussion of these syntheses, summarises failed reactions and finally 
reports the successful synthesis of 16 via a nickel(II) template reaction.
. Ni(CIO4)2
2. nBuLi, CH3I
3. NaCNR = CH3 or CH3CH2 
16 where R = CH3
Figure 106. Summary of the attempted preparation of 16.
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6.3.1.1 Direct Alkylation I
There are numerous literature procedures for the alkylation of secondary amines with 
primary alkyl halides. 100' 202' 203 Therefore, initial attempts to alkylate 15 with methyl iodide 
followed these methods, using potassium carbonate as base and a good solvent for SN2 
reactions such as acetonitrile (Figure 107).
R o 
16 where R = CH3
Figure 107. Alkylation of 15.
Unfortunately, all attempted syntheses following these methods proved to be 
unsuccessful in terms of isolating a pure product. Varying the amount and the nature of the 
base, the concentration of the reactants, the reaction temperature and the choice of solvent 
(to DMF and DCM) had no effect on the purity of the product obtained. The likely problem 
with direct alkylation is the formation of alkylated ammonium species. This is observed in 
the mass spectrum of impure 16, where a peak of m/z 403 indicates an extra methyl group is 
present.
One of the major problems encountered with these side-bridged macrocycles is 
purification. For example, they are not mobile on silica or alumina plates and therefore, 
cannot be separated by SiO2 or A12O3 column chromatography. The oily nature of the
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products results in difficulty in recrystallisation and finally, their high boiling points 
prevent vacuum distillation being a viable option.
The problem of alkylated ammonium species has also been encountered by Kotek and 
co-workers who have reported the synthesis of L49 (Figure 108).204 The direct alkylation of 
L47 with either ethyl bromoacetate or ter/-butyl bromoacetate under similar conditions to 
those described above led to the formation of the mono-quaternised derivative L49 after 
acidic hydrolysis. This has been attributed to the fact that the secondary amine is involved 
in a hydrogen bonding network with the two unreactive tertiary amines, leaving the third 
tertiary amine to be the reactive site towards electrophilic attack as this lone pair either 
points away from the macrocyclic cavity or is too far away to participate in the hydrogen 
bonding network.
BrCH2COOH
Et2°
HOOC >L N
|_49
49Figure 108. Alkylation of L results in the unexpected compound, L .
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6.3.1.2 Reductive Animation
The addition of a methyl arm to the alkylated side-bridged macrocycle L13 has been 
reported by Kolinski (chapter two, section 2.1.1). 160 This involved the reductive amination 
of the secondary amine with formaldehyde and sodium cyanoborohydride. This method has 
been followed on the systems in this work (Figure 109) but, as with the direct alkylation 
method previously discussed, a pure product could not be isolated.
H2CO
NaCNBH3 
CH3COOH
15
Figure 109. Reductive amination of 15. 
6.3.1.3 Acylation & Reduction
Kaden has reported the synthesis of the alkylated bis-side-bridged cyclam, L17, 
(chapter two, section 2.1.1). 161 It was envisaged that this methodology could be applied to 
our system (Figure 110) in order to avoid the previously discussed problems which had 
been encountered in the attempts to prepare compound 16.
179
19
Figure 110. Acylation of 15 and subsequent reduction of intermediate 18.
This route also has the potential advantage that the reduction of the intermediate 
amide derivative, 18 (which was not isolated), would also reduce the ester functionality of 
the pendent arm, thus negating the need for a further reduction step in the route. 
Unfortunately, the attempts at this reaction were unsuccessful and all that could be isolated 
was a crude mixture of multiple products as shown by proton NMR spectrometry. Attempts 
at purification of 19 were again ineffective due to the reasons mentioned above.
6.3.1.4 Direct Alkylation II
The previously discussed methods for alkylating 15 have all relied on the ester 
containing pendent arm being present from the outset. As these reactions proved to be 
unsuitable it was decided to alter our strategy and try to append the ester functionality to a 
side-bridged cyclam already containing a methyl group. The proposed route is shown in 
Figure 111. The mono-methyl side-bridged compound, 21, has been reported by 
Kolinski. 160 The published synthetic route to this compound was followed and crystal 
structures of 20 and 21 have been obtained.
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Figure 111. Proposed alternative synthetic route to 16.
Methylation of 3 was achieved in almost quantitative yield by dripping methyl iodide 
into an acetone solution of 3. The ammonium salt, 20, precipitates out of solution and can 
be collected by filtration. Single crystals of 20 (Figure 112) were grown from a methanolic 
solution and, as expected, the four six-membered rings are in the chair conformation. The 
overall structure is very similar to the two structures of 3 previously discussed (chapter two, 
section 2.3.1), which is not entirely unexpected as there is only the addition of a methyl 
group between the two compounds.
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Figure 112. X-ray crystal structure of 20.
Reduction of 20 with an excess of sodium borohydride was successful and resulted in 
the isolation of 21 in excellent yield (81%). Interestingly, it was noted that 21 can be 
purified in a two-stage process with the addition of nickel(II) and its subsequent removal 
using sodium cyanide. Single crystals of purified 21 were grown from methanol and its X- 
ray crystal structure has been determined (Figure 113). The unit cell consists of the 
macrocycle and two solvent molecules of crystallisation. The piperazino moiety adopts a 
chair conformation, in contrast to the related compound, L17, which was crystallised by 
Kaden and co-workers and adopts a boat conformation. 161 Additionally, 21 is neutral in the 
solid state.
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Figure 113. X-ray crystal structure of 21.
The reactivity of the sterically bulky ester containing alkyl bromide would be 
expected to be lower than that of methyl iodide and leads to the possibility that further 
quaternisation of the macrocycle would not occur as had happened previously. However, 
the addition of 4-(methylbromo)benzoate using similar conditions as described earlier 
proved to be ineffective in giving a clean product. The fact that the side-bridged compound 
does not run on TLC plates means that reaction progress cannot be monitored by these 
means. The proton NMR spectrum of 16 reveals a messy aromatic region instead of the 
desired rooftop effect for the 1,4-di substituted phenyl ring.
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6.3.2 Cross-bridged Cyclam
Having explored several proposed routes to the desired mono-macrocyclic 
compound, 16, it was decided to change synthetic strategy and attempt to prepare a cross- 
bridged mono-macrocycle, 23. The secondary amine position can be alkylated in a two step 
process utilising bis-aminal methodology (Figure 114). The ester salt, 14, can be alkylated 
with an excess of methyl iodide to give the bis-salt, 22. This could then be reduced to give 
the cross bridge compound, 23, which contains the ester pendent arm together with a 
methylated tertiary amine. It is also possible that the ester arm would be reduced over the 
fourteen day reduction time to result in 24. This would actually be advantageous to this 
scheme as it would cut down on the number of steps and lead to an increase in the overall 
yield.
H3C
24
Figure 114. Proposed synthetic route to 25.
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The first step of this sequence involving the addition of methyl iodide to 22 proceeds 
over a seven day period in quantitative yield. As with the addition of methyl iodide to 3 
(chapter three, section 3.3.1), the initial milky suspension is replaced by an orange solution 
as the reaction progresses, which is attributed to the counter anion metathesis of iodide and 
bromide. This is confirmed in the mass spectrum of 22, where the observed molecular ion 
peak (m/z 386) is the di-cation with the loss of two iodides. Reduction of 22 with an excess 
of sodium borohydride over fourteen days should lead to the formation of 23; however, the 
attempts resulted in a crude product which could not be purified further. Further reduction 
of the impure product with lithium aluminium hydride had no effect in isolating pure 24 
either. In conclusion, further work is required to optimise this synthetic route.
6.3.3 Nickel Template Reactions
Whilst searching for synthetic procedures for the alkylation of secondary amines, an 
alternative preparation of 16 was found in the literature. Kaden and co-workers, following a 
modification of a reaction initially reported by Barefield et al., prepared the side-bridged 
macrocycle, L15, in a three step process via the nickel(II) complex (Figure 115). 161 ' 205
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Figure 115. Kaden's synthesis of L15.
The initial nickel(II) complexation of L13 proceeds in reasonable yield (65%), 
resulting in a complex which can be deprotonated by nBuLi in dry DMSO solvent. The 
reported orange solution undergoes a colour change to blue after the addition of nBuLi. 
Addition of methyl iodide results in the reappearance of the orange solution which was 
added into a saturated ethanolic solution of ammonium hexafluorophosphate to aid the 
precipitation of an orange solid. After recrystallisation, the reported yield of L15 is 62%.
In this work, the method could be adapted in one of two ways in order to synthesise 
16. Firstly, the nickel(II) complex of 21 could be alkylated with 4-(bromomethyl)benzoate 
or, alternatively, the side-bridged macrocycle containing the ester functional pendent arm 
(15) could be methylated (Figure 116).
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Figure 116. Proposed synthetic route to 16
The alkylation of [Ni21]2+ with 4-(bromomethyl)benzoate was attempted first as the 
starting material was available. The addition of nBuLi to the orange DMSO solution gave 
the expected blue solution; however, the addition of a DMSO solution of the alkyl bromide 
had no effect whatsoever and the second suggested route was tried. In fact, the blue colour 
persisted for approximately three months before an orange solution developed.
The nickel(II) complex of 15 was prepared by mixing the ligand with a slight excess 
of nickel(II) perchlorate in acetonitrile for two hours. The crude orange solid can be 
purified via size exclusion chromatography to remove the excess metal salt. The yields for 
the complexation are excellent (80-90%). Although attempts to grow single crystals of 
[Nil5]2+ were unsuccessful, the nickel(II) metal centre would be expected to coordinate to 
each of the four nitrogen atoms of the macrocyclic ring in a square planar geometry. This 
would have the effect of disrupting the hydrogen bonding network in the macrocycle which 
has been reported by Kotek et al. This should result in the secondary amine position 
becoming the most reactive site and it could, therefore, be deprotonated by a strong base, 
such as nBuLi.
On dissolution in dry DMSO, [Nil5]2+ gives an orange colour which on addition of 
nBuLi, changes to a blue solution as expected. Addition of excess methyl iodide to the blue
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solution results in the formation of an orange solution which was dripped into ethanol in 
order to aid precipitation. Both the ammonium hexafluorophosphate and perchlorate salts of 
[Nil6]2+ have been isolated with varying yields. [Nil6](ClO4)2 is obtained in excellent 
yield (90%) by dripping the DMSO solution into neat ethanol and filtering off the resulting 
orange precipitate. [Nil6](PFe)2 is obtained by dripping the orange solution into a saturated 
solution of ammonium hexafluorophosphate in ethanol and filtering off the orange 
precipitate. However, [Nil6](PF6)2 delivered lower yields (< 70%) in comparison to 
[Nil6](ClO4)2, but without the benefit of a purer product. Both complexes are soluble in 
acetonitrile and are identical by proton NMR spectrometry. The aromatic region of the 
spectrum reveals a 1,4-disubstituted rooftop effect and the Ctfe group of the pendent arm 
reveals two sets of doublets, indicating that they are diastereotopic as a result of the rigidity 
imparted by the addition of the nickel(II) metal ion. Although, the new N-methyl group is 
not clearly seen in the proton NMR spectrum, its presence is confirmed in the carbon NMR 
spectrum with a peak at 31.2 ppm.
6.3.3.1 Decomposition with Cyanide
The decomposition of nickel(II) macrocyclic complexes with sodium cyanide is well 
known.206' 207 These reactions have traditionally been carried out in aqueous media; 
however, poor yields (~ 20%) were recovered in the case of [Nil6]2+ due to difficulties in 
extracting 16 from either benzene or DCM. The choice of reaction solvent is dictated by the 
solubility of the starting material, [Nil6]2+, which has been found to be only really soluble 
in acetonitrile. It was envisaged that the reaction could be carried out in this solvent and 
then worked up using a soxhlet extraction apparatus. However, sodium cyanide is not 
soluble in acetonitrile and the reaction will not proceed in neat solvent. After carrying out
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the reaction in various media, the optimum conditions have been found to be heating at 
reflux for two hours in acetonitrile containing ca. 5% water, followed by purification via 
soxhlet extraction. This results in the isolation of the bis-alkylated side-bridged compound 
16 in approximately 50% yield.
The proton NMR spectrum of 16 reveals a pair of doublets in the aromatic region as 
well as the disappearance of the diastereotopic CFk doublets seen in the nickel(II) complex. 
The alkyl region is, as expected, difficult to interpret fully; however the carbon NMR 
spectrum reveals the expected number of environments (20) with the N-methyl peak being 
observed at 31.1 ppm.
6.3.4 Preparation of 26
The reduction of the macrocyclic ester compound, 16, with lithium aluminium 
hydride proceeded smoothly in dry THF. A yield of over 70% was obtained after extraction 
of the crude reactant. Once again, 17 was not mobile on silica or alumina TLC plates, 
however, the proton and carbon NMR spectra indicated a pure product.
Bromination of 17 with PBrs in pyridine results in the desired precursor, 18, in a 
decent yield of ca. 50%. The proton and carbon NMR spectra of 18 are quite difficult to 
interpret due to the weakness of the sample, even after scans of over an hour for the proton 
and over 16 hours for the carbon. However, a clean 1,4-aromatic peak was observed in the 
aromatic region. Furthermore, the mass spectrum of 18 revealed the expected molecular ion
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Having prepared the precursor to asymmetrical bis-macrocycles, 18, the next stage in 
the research was to attach the second ring. There are various strategies that could be 
employed in order to append the second macrocycle. However, due to time constraints, it 
was decided to simply react 18 directly with cyclam (Figure 117). Compound 18 was 
dissolved in a dilute solution of acetonitrile and a solution of cyclam was added dropwise in 
order to prevent any polymeric species forming. Again, the proton NMR spectrum was 
difficult to fully interpret. The mass spectrum of this bis-macrocyclic compound revealed a 
molecular ion peak indicating that the desired compound had been synthesised.
-NH HN. 
NH HN
26
Figure 117. Synthesis of asymmetrical bis-macrocycle, 26.
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6.4 Conclusions
A synthetic route to an asymmetrical bis-macrocyclic compound, 26, has been 
designed. The alkylation of the secondary amine of 15 has proven to be unexpectedly 
challenging and a number of alternative routes have been attempted. A successful strategy 
involving a nickel(II) template has been found to result in a good yield. The isolation of the 
protected macrocycle, 16, also proved difficult but optimum reaction conditions have been 
found to result in yields of approximately 50%. Reduction of the ester functionality leads to 
17, which has been fully analysed and brominated with PBra to give 18. Unfortunately, due 
to time constraints, this compound could not be characterised completely; however, its 
mass spectrum contained the expected molecular ion peak.
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Chapter 7. CONCLUSIONS
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Synthetic routes to two rigidified bis-macrocyclic ligands have been designed and 
implemented resulting in the preparation of 5 and 9 in good overall yields. In addition, 
these syntheses benefit from not requiring any lengthy purification steps. A range of 
transition metal complexes of 5 and 9 have been prepared and tested for their CXCR4 
binding potency and anti-HIV activity using a variety of assays. All of the compounds 
tested are effective CXCR4 antagonists and are highly active against HIV. For example, 
[Zn25(OAc)2]2+ and [Cu29Cl2]2+ are more potent than complexes of AMDS 100 and have 
proven to be the most active bis-macrocyclic complexes found to date.
The X-ray crystal structure of [Zn25(OAc)2]2+ reveals that the metal ion resides 
outside the macrocyclic cavity (0.74 A) and, as a result, could potentially strengthen the 
coordination interaction with aspartate residues on the CXCR4 surface. This is reflected in 
the anti-HIV assay which confirms that [Zn25(OAc)2]2+ is a more potent antagonist than the 
analogous zinc(II) AMDS 100 complex. The coordination preferences of the copper(II) 
metal ion could explain the higher activity of [Cu29Cl2]2+ compared to [Cu25Cl2]2+ . For 
example, [Cu29Cl2]2+ interacts with CXCR4 aspartate residues via an equatorial 
coordination site whereas [Cu25Cl2]2+ coordinates via a weaker axial coordination site. 
Furthermore, [Cu29Cl2]2+ is effective against an AMDS 100 resistant viral strain which 
suggests that it may have a different mode of action to AMDS 100, or at the very least there 
is some variation in the binding site. It would be of interest to further probe this finding by 
developing a resistant viral strain to [Cu29Cl2]2+ to see which regions of the HIV RNA are 
altered. 124
It is suggested that the high anti-HIV activity observed for [Zn25(OAc)2]2+ and 
[Cu29Cl2]2+ is due to a combination of the binding kinetics to aspartate residues on the
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CXCR4 surface and the stability of the interaction. For example, the metal ion in 
[Zn25(OAc)2]2+ is accessible for aspartate binding, resulting in a thermodynamically stable 
complex once bound to the CXCR4 surface. These kinetic aspects could be investigated 
further by designing an assay to determine how long the complex remains bound to the 
receptor.
It would be desirable to investigate the binding of [Zn25(OAc)2]2+ and [Cu29Cl2]f+ to 
CXCR4 further in conjunction with site directed mutagenesis of the receptor.34 It would 
also be interesting to conduct in vivo studies. Ultimately, these complexes are unlikely to be 
successful anti-HIV drugs due to the fact that they are not orally bioavailable. However, 
they could still find use in the clinic for treating other disease states. For example, 
AMDS 100 has found success as a stem cell mobiliser and many other potential uses of 
CXCR4 antagonists are currently under investigation. 82' 208> 209 Oral bioavailability, 
according to Lipinski's "Rule of five" could be increased in a number of ways.210 For 
example, by lowering the molecular weight to below 500 Daltons. This means that a mono- 
cyclam derivative such as L42 or L43 could be orally bioavailable but this would be at the 
expense of the compound's potency.
X-ray absorption spectroscopy has been used to characterise the coordination 
environments of the novel metal complexes discussed in this work and also probe their 
interactions with various counter anions. EXAFS experiments on [Cu29Cl2]2+ have shown 
that the metal coordination geometry changes on the addition of acetate. These data suggest 
that the copper(II) complexes of 9 will bind to aspartate residues on the CXCR4 surface. It 
is interesting to compare the differences between the complexes of 5 and 9. For example, 
both complexes adopt a square-based pyramidal geometry; however, the complexes of 5
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have a long range interaction with an axial counter anion, whereas the complexes of 9 have 
an equatorial counter anion which is shorter as expected. The axial position is occupied by 
a macrocyclic nitrogen atom which has a short bond length as a result of the 
configurationally restricted nature of the ethylene cross bridge.
The opening of the new Diamond Synchrotron Radiation Source promises an exciting 
future for EXAFS in the UK and could lead to the possibility of doing experiments at even 
lower concentrations than is presently possible. This offers the opportunity to conduct 
EXAFS experiments directly with the isolated (recombinant) CXCR4 receptor immobilised 
in a synthetic membrane on an appropriate surface. A method of preparing recombinant 
CXCR4 on a milligram scale has recently been reported.211
The synthesis of asymmetrical bis-macrocyclic compounds proved to be more 
challenging than was imagined when the work was started. This was due primarily to 
difficulty in the N-alkylation of the side-bridged derivative, 15. A number of methods were 
attempted in order to prepare the methylated compound, 16, which was eventually 
successfully synthesised using a nickel(II) template reaction followed by decomplexation 
with cyanide using a modification of the procedure described by Curtis207 . The nickel(II) 
template reaction could also potentially be utilised on 5 to synthesise the bis-macrocycle 27 
(Figure 118). Transition metal complexes of this compound would be expected to adopt a 
trans-IV configuration.
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Figure 118. Proposed bis-macrocyclic compound, 27; transition metal complexes 
should adopt a trans-IV configuration.
Reduction of 16 results in the alcohol derivative, 17, which has been fully 
characterised. The bromination of 17 has been achieved but requires further work to 
provide a robust procedure. A preliminary reaction of crude 10 with cyclam was attempted, 
and the resulting mass spectrum indicated that the desired compound was present.
The brominated compound, 10, is the precursor to a number of bis-macrocyclic 
ligands. The preparation of 10 allows the synthesis of a range of asymmetrical bis- 
macrocyclic compounds which could potentially be prepared by a variety of strategies. For 
example, compounds containing either a trans-II, trans-IV or cis-V configurationally 
restricted macrocycle could be prepared (Figure 119). One preliminary example, 26, with a 
trans-IV and a cyclam ring has been prepared and requires further study.
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trans-IV trans-ll trans-IV cis-V 
Figure 119. Two examples of asymmetrical bis-macrocyclic compounds.
The asymmetry of the bis-macrocyclic systems could be extended to a complex 
containing one zinc(II) ion and one copper(II) centre. One possible method would be to 
carry out the first complexation with half an equivalent of metal salt at low temperature, 
which has been successfully achieved for bis-macrocyclic cyclen compounds. 108
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Chapter 8. EXPERIMENTAL
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8.1 General Methods
8.1.1 Solvents and Reagents
All solvents and reagents were purchased from either Sigma-Aldrich Ltd., Lancaster 
Chemicals Ltd. (Alfa-Aesar) or Fisher Chemicals Ltd. and were used as supplied unless 
otherwise stated. Drying of reaction solvents was achieved according to literature 
methods.212 Organic solvent extracts were dried with magnesium or sodium sulphate and 
bulk solvent was removed via rotary evaporation under reduced pressure. Trace solvent was 
removed using an Edwards RV5 oil pump connected to a standard Schlenk line. Reactions 
involving dry solvents were carried out under an inert (nitrogen or argon) atmosphere using 
standard Schlenk line techniques.
8.1.2 Analytical Techniques
All 'H NMR and proton decoupled 13C NMR spectra were collected on a JEOL JNM- 
LA400 spectrometer (400 and 100 MHz respectively) at the University of Hull, except that 
of [Zn25(OAc)2]2+, which was carried out at the University of Edinburgh using a Bruker 
Avance 4-channel 800 MHz spectrometer with cryoprobe. Chemical shifts are referenced 
against residual solvent signals and are designated as: s, singlet; d, doublet; t, triplet; q, 
quartet; p, pentent; m, multiplet; br, broad. Deuterated solvents were purchased from either 
Cambridge Isotopes Ltd. or Goss Chemicals Ltd.
Mass spectrometry was carried out via electrospray ionisation (ESI) on a Finnigan 
LCQ spectrometer. Accurate mass spectra were collected on a Thermofisher LTQ Orbitrap 
XL spectrometer by the EPSRC National Mass Spectrometry Service at the University of
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Wales, Swansea. All calculated models for accurate mass analysis are based on the 
predominant natural isotopes of C, N, H, and O, and on 63Cu, 65Zn, 35C1 and 79Br isotopes. 
The molecular ion peak (M+) is defined as the total mass of the compound. Some of the 
metal complexes show the major peaks with the loss of one or more of the counter anions.
UV-vis spectra were obtained using an Agilent 8453 diode array spectrometer.
Single crystal X-ray diffraction data sets were collected on a Stoe IPDS-II imaging 
plate diffractometer at the University of Hull using MoKa X-rays (A, = 0.71073 A). Crystals 
were cooled to ca. 150 K during data collection, with the temperature controlled by an 
Oxford Systems Cryostream Cooler. Diffraction data were solved using direct methods or 
Patterson syntheses (ShelXS), and the refinement was by the full-matrix least squares 
against F2 (ShelXL-97) method.213 ' 214 The WinGX program was used for refinement and 
production of data tables.215 ORTEP-3 was used for structural visualisation.216 Hydrogen 
atoms were fixed in idealised positions and refined against a riding model, with C-H 
distances of 0.97 A, N-H distances of 0.91 A and Ujso 1.5 times Ueq of the carrier atom. All 
ORTEP representations show ellipsoids at the 50% probability level.216
Copper(II) and zinc(II) K-edge XAS were collected on either station 7.1 or 16.5 of 
the Daresbury Laboratory SRS (2 GeV, 100-200 mA). The experimental setup on station 
7.1 used either a sagitally focusing or flat crystal Si(lll) double crystal monochromator 
with 70% harmonic rejection in conjunction with a collimating mirror. The data from the 
solid samples were collected in transmission mode using ion chambers whilst for the 
solution samples the data were acquired using a nine-element solid state fluorescence 
detector. On station 16.5 the experimental setup was the same as 7.1 except that a flat
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crystal Si(220) monochromator was used with a 30 element detector. The spectra were 
averaged (ca. 3 for solids, ca. 10 for solutions) and calibrated (first maximum of the 
derivative of the Cu-K edge of Cu foil, 8979.0 eV, Zn-K edge of Zn foil, x eV) using 
PAXAS.217 The data were modelled using curved wave theory in EXCURV98.218 
Preliminary analysis was carried out; however, due to the complex nature of the 
macrocyclic complexes, full analysis was completed by Dr Nigel Young.
Solid samples were prepared by grinding ca. 5 mg of metal ion (i.e. 20-40 mg 
sample) and ca. 100 mg boron nitride and pressing at a pressure of 10 tonnes. The pellets 
were held in a sample holder using sellotape and cooled to ca. 80 K for data collection. 
Solution samples (ca. 20 mM on station 7.1, ca. 10 mM on station 16.5) were prepared by 
dissolving the metal complex in deionised water (1 mL) and placing in an aluminium 
solution cell with kapton windows. The solutions were carefully cooled to ca. 80 K for data 
collection. The solutions containing an excess of acetate were prepared 24 h before data 
collection and left to stand at room temperature.
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8.2 Synthesis of Organic Compounds
8.2.1 Synthesis of 1,4,8,11-tetraazacyclotetradodecane, cyclam, 1
The synthesis of cyclam was carried out according to a literature procedure.219 
1,5,8,12-tetrazadodecane (26 g, 0.15 mol) was added to a solution of nickel (II) perchlorate 
(54.7 g, 0.15 mol) in water (400 mL). An aqueous solution of glyoxal (40%, 22.5 mL, 0.15 
mol) was added and the resulting purple solution was left to stand for 4 h. The solution was 
cooled to ~ 5°C and sodium borohydride (11 g, 0.3 mol) was added slowly. The solution 
was heated to 90°C for 20 minutes and filtered whilst hot. Sodium cyanide (29 g, 0.6 mol) 
was added to the filtrate and heated at reflux for 2 h. On cooling, sodium hydroxide (15 g, 
0.38 mol) was added to the yellow-brown mixture and then concentrated in vacua to a semi 
solid. The semi solid was washed with chloroform (4 x 100 mL) and the resulting biphasic 
system was extracted from further chloroform (3 x 100 mL). The combined organic layers 
were dried (Na2SO4), filtered and concentrated in vacua. The crude material was 
recrystallised from chlorobenzene (350 mL) and washed with diethyl ether (100 mL) to 
yield a white crystalline product (11 g, 37%).
'H NMR: (CDC13) 5 1.62-1.68 (p, 4H, 5.33 Hz, N-p-C//2), 2.27 (br s, 4H, N#), 2.60 
(s, 8H, N-a-C#2), 2.66-2.68 (t, 8H, 5.33 Hz, N-a-C#2).
13C NMR: (CDC13) 8 29.35 (N-p-CH2), 49.38 (N-a-CH2), 50.80 (N-a-CH2).
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8.2.2 Synthesis of decahydro-3a,5a,8a,10a-tetraaza-pyrene, 3
The synthesis of 3 was carried out following a minor modification of a literature 
procedure. 164 Cyclam (5 g, 25 mmol) was dissolved in methanol (100 mL) and cooled to - 
10°C. A cold (0°C) aqueous solution of glyoxal (40%, 3.63 g) was added over 90 minutes. 
The clear solution was stirred at -10°C for 30 minutes and at room temperature for 3 h. The 
solvent was concentrated in vacuo and the crude solid was redissolved in diethyl ether (200 
mL). The filtrate was dried (MgSO4), filtered and evaporated in vacuo to yield a white solid 
(5.45 g, 98%).
'H NMR: (CDC13) 5 1.12-1.16 (m, 2H), 2.03-2.26 (m, 8H), 2.64-2.67 (d, 2H), 2.86- 
2.96 (m, 6H), 3.00 (s, 2H), 3.35-3.52 (m, 2H).
13C NMR: (CDC13) 5 19.53 (N-P-CH2), 44.68 (N-a-CH2), 52.41 (N-a-CH2), 54.27 
(N-a-CH2), 55.97 (N-a-CH2), 76.98 (Cammai).
MS: (ESI) m/z 222 [M]+.
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8.2.2.1 Crystal data and structural refinement for 3.2HC1O4
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.80°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
a= 90°.
p= 114.166(5)°.
y = 90°.
423.25
150(2)K
0.71073 A
Monoclinic
P21/n
a =14.4745(10) A
b = 8.9214(8) A
c= 14.6706(10) A
1728.4(2) A3
4
1.627Mg/m3
0.428 mnr 1
888
0.3 x 0.3 x 0.2 rnm3
2.57 to 34.80°.
-22<=h<=18, -14<=k<=14, -20<=1<=23
29524
7063 [R(int) = 0.0370]
94.1 %
None
Full-matrix least-squares on F^
7063 / 0/242
0.964
Rl = 0.0550, wR2 = 0.1459
Rl => 0.0844, wR2 = 0.1588
0.0041(12)
0.905 and -0.808 e.A'3
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Crystals of 3.2HC1O4 were grown following evaporation of the methanol from the 
reaction mixture in the presence of Zn(ClO4)2 .
o
Figure 120. ORTEP representation of 3.2HC1O4.
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Table 21. Bond lengths (A) and angles (°) for 3.2HC1O4.
C(1)-N(1) 1.504(2)
C(1)-C(2) 1.506(3)
C(2)-N(2) 1.458(2)
C(3)-N(2) 1.471(2)
C(3)-C(4) 1.523(2)
C(4)-C(5) 1.517(3)
C(5)-N(3) 1.510(2)
C(6)-N(3) 1.494(2)
C(6)-C(7) 1.508(3)
C(7)-N(4) 1.467(3)
C(8)-N(4) 1.468(3)
C(8)-C(9) 1.529(3)
C(9)-C(10) 1.522(3)
C(10)-N(1) 1.508(2)
C(11)-N(4) 1.424(2)
C(11)-C(12) 1.528(2)
C(11)-N(1) 1.538(2)
C(12)-N(2) 1.419(2)
C(12)-N(3) 1.538(2)
O(1)-C1(1) 1.4471(15)
0(2)-C1(1) 1.4242(18)
0(3)-CI(1) 1.4253(16)
O(4)-C1(1) 1.418(2)
0(5)-C1(2) 1.4294(17)
O(6)-C1(2) 1.4291(15)
O(7)-C1(2) 1.4342(19)
0(8)-C1(2) 1.417(2)
N(1)-C(1)-C(2) 108.51(13)
N(2)-C(2)-C(1) 109.36(15)
N(2)-C(3)-C(4) 112.31(14)
C(5)-C(4)-C(3) 109.93(17)
N(3)-C(5)-C(4) 109.97(14)
N(3)-C(6)-C(7) 108.89(14)
N(4)-C(7)-C(6) 109.08(15)
N(4)-C(8)-C(9) 113.01(17)
C(10)-C(9)-C(8) 110.38(15)
N(1)-C(10)-C(9) 109.86(15)
N(4)-C(11)-C(12) 112.75(14)
N(4)-C(11)-N(1) 112.35(13)
C(12)-C(11)-N(1) 112.10(14)
N(2)-C(12)-C(11) 112.54(13)
N(2)-C(12)-N(3) 112.35(14)
C(11)-C(12)-N(3) 112.35(12)
C(1)-N(1)-C(10) 111.99(13)
C(1)-N(1)-C(11) 111.09(12)
C(10)-N(1)-C(11) 109.05(14)
C(12)-N(2)-C(2) 114.55(13)
C(12)-N(2)-C(3) 111.95(13)
C(2)-N(2)-C(3) 114.62(15)
C(6)-N(3)-C(5) 112.77(14)
C(6)-N(3)-C(12) 110.70(15)
C(5)-N(3)-C(12) 108.55(12)
C(11)-N(4)-C(7) 113.93(16)
C(11)-N(4)-C(8) 112.02(15)
C(7)-N(4)-C(8) 114.78(15)
O(4)-C1(1)-O(2) 109.82(12)
O(4)-C1(1)-O(3) 111.78(15)
O(2)-C1(1)-O(3) 109.73(14)
0(4)-C1(1)-0(1) 109.41(13)
0(2)-C1(1)-O(1) 108.40(11)
O(3)-C1(1)-O(1) 107.61(10)
O(8)-C1(2)-O(6) 111.59(14)
O(8)-C1(2)-O(5) 108.34(13)
O(6)-C1(2)-O(5) 110.41(11)
0(8)-C1(2)-O(7) 107.97(18)
O(6)-C1(2)-O(7) 108.97(12)
O(5)-C1(2)-O(7) 109.51(13)
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8.2.2.2 Crystal data and structural refinement for 3.H[ZnCl3(OH2)]
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 35.13°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)J
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
o= 90°.
P= 99.386(6)°.
y = 90°.
Ci2 H25 C13 N4 O Zn
413.08
150(2)K
0.71073 A
Monoclinic
P21/c
a = 7.0552(5) A
b= 12.3597(11) A
c = 20.2463(14) A
1741.8(2) A3
4
1.575Mg/m3
1.874mm- 1
856
0.2 x 0.2 x 0.2 mm3
2.93 to 35.13°.
-ll<=h<=8, -19<=k<=19, -32<=1<=32
21853
7597 [R(int) = 0.0497]
98.0 %
None
Full-matrix least-squares on F^
7597 / 1 /206
1.045
Rl = 0.0383, wR2 = 0.0946
Rl = 0.0592, wR2 = 0.1048
0.0094(8)
0.684 and-1.031 e.A'3
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Crystals of S.HfZnCbCOty] were grown following evaporation of a methanolic
'#
solution of 3 in the presence of ZnCl2.6H2O.
Figure 121. ORTEP representation of 3.H[ZnCl3(OH2)].
208
Table 22. Bond lengths (A) and angles (°) for 3.H[ZnCl3(OH2)].
C(1)-N(1) 1.477(2)
C(1)-C(2) 1.504(3)
C(2)-N(2) 1.496(3)
C(3)-N(2) 1.511(2)
C(3)-C(4) 1.518(3)
C(4)-C(5) 1.527(3)
C(5)-N(3) 1.469(3)
C(6)-N(3) 1.475(3)
C(6)-C(7) 1.511(3)
C(7)-N(4) 1.462(3)
C(8)-N(4) 1.477(2)
C(8)-C(9) 1.519(3)
C(9)-C(10) 1.530(3)
C(10)-N(1) 1.484(2)
C(11)-N(1) 1.467(2)
C(11)-N(4) 1.472(2)
C(11)-C(12) 1.533(2)
C(12)-N(3) 1.426(2)
C(12)-N(2) 1.545(2)
Zn(l)-O(l) 2.0009(15)
Zn(l)-Cl(l) 2.2227(5)
Zn(l)-Cl(3) 2.2574(5)
Zn(l)-Cl(2) 2.2873(5)
N(1)-C(1)-C(2) 109.44(15)
N(2)-C(2)-C(1) 109.43(15)
N(2)-C(3)-C(4) 110.41(16)
C(3)-C(4)-C(5) 110.71(16)
N(3)-C(5)-C(4) 112.35(18)
N(3)-C(6)-C(7) 108.90(16)
N(4)-C(7)-C(6) 110.59(16)
N(4)-C(8)-C(9) 111.26(17)
C(8)-C(9)-C(10) 109.46(18)
N(1)-C(10)-C(9) 111.30(15)
N(1)-C(11)-N(4) 112.39(15)
N(1)-C(11)-C(12) 110.21(14)
N(4)-C(11)-C(12) 110.29(14)
N(3)-C(12)-C(11) 111.97(14)
N(3)-C(12)-N(2) 111.63(13)
C(11)-C(12)-N(2) 109.82(14)
C(11)-N(1)-C(1) 112.17(14)
C(11)-N(1)-C(10) 109.50(15)
C(1)-N(1)-C(10) 111.31(16)
C(2)-N(2)-C(3) 111.45(15)
C(2)-N(2)-C(12) 111.44(13)
C(3)-N(2)-C(12) 110.87(15)
C(12)-N(3)-C(5) 111.16(16)
C(12)-N(3)-C(6) 113.60(16)
C(5)-N(3)-C(6) 113.32(16)
C(7)-N(4)-C(11) 109.52(15)
C(7)-N(4)-C(8) 108.91(16)
C(11)-N(4)-C(8) 110.10(14)
O(l)-Zn(l)-Cl(l) 110.03(4)
O(l)-Zn(l)-Cl(3) 107.44(5)
Cl(l)-Zn(l)-Cl(3) 117.34(2)
0(l)-Zn(l)-Cl(2) 103.01(4)
Cl(l)-Zn(l)-Cl(2) 112.284(18)
Cl(3)-Zn(l)-Cl(2) 105.65(2)
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8.2.3 Synthesis of 3a-[methyl]-decahydro-3a,5a,8a,10a-tetraaza-pyrenium bromide, 
20
The synthesis of 20 was carried out following a minor modification of a literature 
procedure. 160 Methyl iodide (0.5 mL, 8 mmol) was added to a solution of decahydro- 
3a,5a,8a,10a-tetraaza-pyrene (1.77 g, 8 mmol) in acetone (50 mL) and the clear solution 
was stirred at room temperature for 6 h. A white precipitate was filtered off, washed with 
acetone (50 mL) and dried in vacua to yield a white powder (2.53 g, 96%).
'H NMR: (D20) 5 1.32-1.35 (m, 1H), 1.74-1.78 (m, 1H), 2.15-2.43 (m, 6H), 2.78- 
2.97 (m, 8H), 3.23 (s, N-a-CH3), 3.36-3.61 (m, 4H), 3.94-3.95 (d, 1H), 4.14-4.19 (m, 1H).
13C NMR: (D2O) 5 18.17 (N-P-CH2), 18.91 (N-p-CH2), 42.27 (N-a-CH2), 46.58 (N-a- 
CH2), 48.83 (N-a-CH2), 51.39 (N-a-CH2), 51.39 (N-a-CH2), 52.24 (N-a-CH2), 53.16 (N-a- 
CH2), 54.04 (N-a-CH2), 64.80 (N-a-CH3), 69.65 (Caminal), 83.03 (Caminal).
MS: (ESI) m/z 237 [M-I]+. HRMS: Calcd. for Ci 3H25N4+ : 237.2074; Found: 
237.2075.
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8.2.4 Crystal data and structural refinement for 3a-[methyl]-decahydro- 
3a,5a,8a,10a-tetraaza-pyrenium bromide, 20
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.79°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
364.27
150(2)K
0.71073 A
Monoclinic
P21/n
a= 11.3340(11) A a=90°.
b = 7.0850(5) A p= 103.617(7)°
c= 19.1840(18) A y = 90°.
1497.2(2) A3
4
1.616Mg/m3
2.130 mm-1
736
0.15x0.10x0.10 mm3
3.08 to 34.79°.
-18<=h<=18, -ll<=k<=8, -30<=1<=29
17011
6373 [R(int) = 0.0770]
98.2 %
Numerical
0.7979 and 0.6149
Full-matrix least-squares on F^
6373/0/164
0.956
Rl= 0.0744, wR2 = 0.1813
Rl = 0.0997, wR2 = 0.1929
0.0090(13)
13.045 and -1.746 e.A"3
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Figure 122. ORTEP representation of 20.
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Table 23. Bond lengths (A) and angles (°) for 3a-[methyl]-decahydro-3a,5a,8a,10a-
tetraaza-pyrenium bromide.
C(1)-C(2) 1.516(7)
C(1)-N(1) 1.520(6)
C(2)-C(3) 1.507(7)
C(3)-N(4) 1.473(6)
C(4)-N(4) 1.452(5)
C(4)-N(1) 1.525(6)
C(4)-C(5) 1.543(6)
C(5)-N(3) 1.456(6)
C(5)-N(2) 1.473(6)
C(6)-N(3) 1.460(6)
C(6)-C(7) 1.507(8)
C(7)-N(4) 1.475(6)
C(8)-N(3) 1.481(7)
C(8)-C(9) 1.521(9)
C(9)-C(10) 1.520(9)
C(10)-N(2) 1.485(7)
C(11)-N(2) 1.464(6)
C(11)-C(12) 1.506(7)
C(12)-N(1) 1.512(6)
C(13)-N(1) 1.502(6)
C(2)-C(1)-N(1) 112.3(4)
C(3)-C(2)-C(1) 109.6(4)
N(4)-C(3)-C(2) 109.6(4)
N(4)-C(4)-N(1) 110.0(3)
N(4)-C(4)-C(5) 111.5(4)
N(1)-C(4)-C(5) 109.3(3)
N(3)-C(5)-N(2) 111.6(4)
N(3)-C(5)-C(4) 108.2(4)
N(2)-C(5)-C(4) 112.0(3)
N(3)-C(6)-C(7) 109.1(4)
N(4)-C(7)-C(6) 110.7(4)
N(3)-C(8)-C(9) 111.6(5)
C(10)-C(9)-C(8) 109.5(5)
N(2)-C(10)-C(9) 111.1(5)
N(2)-C(11)-C(12) 110.6(4)
C(11)-C(12)-N(1) 111.7(4)
C(13)-N(1)-C(12) 110.8(3)
C(13)-N(1)-C(1) 105.1(4)
C(12)-N(1)-C(1) 110.7(4)
C(13)-N(1)-C(4) 110.3(3)
C(12)-N(1)-C(4) 109.4(3)
C(1)-N(1)-C(4) 110.5(3)
C(11)-N(2)-C(5) 111.3(4)
C(11)-N(2)-C(10) 108.4(4)
C(5)-N(2)-C(10) 109.3(4)
C(5)-N(3)-C(6) 111.8(4)
C(5)-N(3)-C(8) 109.6(4)
C(6)-N(3)-C(8) 113.3(4)
C(4)-N(4)-C(3) 112.1(4)
C(4)-N(4)-C(7) 109.5(3)
C(3)-N(4)-C(7) 108.6(4)
213
8.2.5 Synthesis of 3a-[phenylenemethylene benzoate]-decahydro-3a,5a,8a,10a- 
tetraaza-pyrenium bromide, 14
Decahydro-3a,5a,8a,10a-tetraaza-pyrene (4.93 g, 22 mmol) and 4- 
(methylbromo)benzoate (5.08 g, 22 mmol) were dissolved in dry acetonitrile (100 mL) 
under nitrogen and stirred at room temperature for 7 days. A white precipitate was collected 
by filtration, washed with acetonitrile (50 mL) followed by tetrahydrofuran (100 mL) and 
dried in vacua to yield a white powder (9.48 g, 95%).
'HNMR: (D20) 5 1.38-1.42 (d, 1H), 1.70-1.73 (d, 1H), 2.13-2.24 (m, 3H), 2.39-2.45 
(m, 2H), 2.54-2.59 (td, 1H), 2.94-3.09 (m, 7H), 3.17-3.29 (m, 3H), 3.41-3.51 (m, 2H), 3.64 
(s, 1H), 3.89 (s, 3H, O-C//3), 4.12-4.19 (td, 1H), 4.29-4.30 (d, 1H, 12.91 Hz, N+-C#2), 
5.10-5.13 (d, 1H, 12.91 Hz, N+-C#2), 7.59-7.61 (d, 2H, 8.42 Hz, Ctfaromatlc), 8.06-8.08 (d,
2H, 8.42 Hz, C//aromatic)-
13C NMR: (D2O) 8 18.13 (N-p-CH2), 18.53 (N-p-CH2), 42.11 (N-a-CH2), 46.73 (N-a- 
CH2), 48.79 (N-a-CH2), 51.50 (N-a-CH2), 52.10 (N-a-CH2), 53.10 (CH3-O), 53.46 (N-a- 
CH2), 54.12 (N-a-CH2), 60.32 (N-a-CH2), 61.94 (N-a-CH2), 69.74 (Cammal), 82.53 (Caminal), 
130.28 (CHaromat,c), 131.02 (Caromat ic), 132.02 (Caromatic), 133.69 (CH^™^) 168.63 (C=O).
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MS: (ESI) m/z 371 [M-Br]+. HRMS: Calcd. for C2iH3iN4O2 : 371.2442; Found 
371.2442.
Elemental Analysis: (%) Calcd. for C2iH3 iN4O2Br: C:55.88 H:6.92 N: 12.40; Found 
C:55.78H:7.24N: 12.27.
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8.2.6 Synthesis of 3a,3a'-[l,4-phenylenebis(methylene)]-bis(decahydro-3a,5a,8a,10a- 
tetraazapyrenium) dibromide, 4
Decahydro-3a,5a,8a,10a-tetraaza-pyrene (5.34 g, 24 mmol) and para-xylene 
dibromide (3.17 g, 12 mmol) were dissolved in dry acetonitrile (100 mL) and stirred under 
nitrogen at room temperature for 3 days. A white precipitate was collected by filtration, 
washed with acetonitrile (50 mL) followed by tetrahydrofuran (200 mL) and dried in vacua 
to yield a white powder (7.56 g, 89%).
'HNMR: (D2O) 5 1.26-1.29 (d, 2H), 1.59-1.71 (m, 2H), 2.02-2.13 (m, 6H), 2.28-2.30 
(m, 4H), 2.42-2.45 (td, 2H), 2.85-3.16 (m, 18H), 3.31-3.56 (m, 8H), 4.02-4.05 (td, 2H), 
4.17 (s, 2H) 4.97-5.01 (m, 2H) 7.50 (s, 4H, CHaTomatlc).
13C NMR: (D20) 5 17.94 (N-P-CH2), 18.35 (N-P-CH2), 41.91 (N-a-CH2), 46.52 (N-a- 
CH2), 48.65 (N-a-CH2), 51.29 (N-a-CH2), 51.88 (N-a-CH2), 53.24 (N-o-CH2), 53.90 (N-a- 
CH2), 60.04 (N-a-CH2), 61.58 (N-a-CH2), 69.49 (Caminal), 82.22 (Cammal), 128.64 (
134.04 (CHaromat,c).
MS: (ESI) m/z 274 [M-2Br]2+, 579.4 [M+OMe]+ .
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8.2.7 Synthesis of 5,5'-[l,4-phenylenebis(methylene)]-bis(l,5,8,12-tetraaza-bicyclo- 
[10.2.2]hexadecane), 5
3a,3a' -[ 1 ,4-Phenylenebis(methylene)]-bis(decahydro-3a,5a,8a, 1 Oa-tetraazapyrenium) 
dibromide (5.00 g, 7 mmol) was dissolved in methanol (100 mL) and cooled to 0°C. 
Sodium borohydride (10.72g, 282 mmol) was added slowly and the clear solution was 
stirred under nitrogen at room temperature for 4 h. The solution was concentrated in vacua 
and water (50 mL) was added. The pH was adjusted to 14 (KOH pellets) and the basic 
solution was extracted into dichloromethane (5 x 50 mL). The combined organic fractions 
were dried (MgSO4), filtered and evaporated in vacua to yield a clear oil (2.28 g, 58%).
'H NMR: (CDC13) 8 1.72 (m, 4H, NCJfc), 1.81 (s, 4H, NCJfc), 2.26 (m, 4H, NCft), 
2.56 (m, 12H, NC/fc), 2.63 (m, 8H, NC/fc), 2.70 (m, 4H, NCffe), 2.93 (m, 4H, NC/fc), 3.02 
(m, 4H, NC//2), 3.27 (m, 4H, NC#2), 3.65 (s, 4H, NC^?Ar), 7.20 (s, 4H, CHaromatic).
13C NMR: (CDC13) 5 23.52, (N-p-CH2), 26.43 (N-P-CH2), 48.17 (N-o-CH2), 48.26 
(N-a-CH2), 50.62 (N-a-CH2), 51.30 (N-o-CH2), 54.73 (N-a-CH2), 55.15 (N-a-CH2), 55.51 
(N-a-CH2), 56.24 (N-a-CH2), 57.07 (N-a-CH2), 129.36 (Can,™^), 136.40
MS: (ES): m/z: 555 [MH]+. HRMS: Calcd. for C32H59N8+ : 555.4857; Found 
555.4856.
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8.2.8 Synthesis of l,r-[l,4-phenylenebis(methylene)]bis[l,4,8,ll-tetraazacyclotetra- 
decane]/AMD3100,2
The synthesis of 2 was carried out following a minor modification of a literature 
procedure. 164 3a,3a' -[ 1,4-Phenylenebis(methylene)]-bis(decahydro-3a,5a,8a, 1 Oa-tetraaza- 
pyrenium) dibromide (320 mg, 0.45 mmol), sodium ethoxide (1.24 g, 18 mmol) and 
hydroxylamine hydrochloride (1.26 g, 18 mmol) were dissolved in dry methanol (100 mL) 
and stirred at reflux under nitrogen for 4 h and then at room temperature overnight. The 
clear solution was concentrated in vacua and a sodium hydroxide solution (10 M, 25 mL) 
was added. The crude product was extracted from dichloromethane (8 x 50 mL). The 
combined organic fractions were dried (MgSC>4), filtered and evaporated in vacua to yield a 
white powder (200 mg, 87%).
]H NMR: (D20) 5 1.83-1.88 (m, 5H), 2.04-2.21 (m, 7H), 2.76-2.80 (m, 9H), 2.92- 
2.97 (12H), 3.10-3.21 (m, 13H), 3.29-3.32 (t, 4H) 5.44 (s, 1H), 7.35 (s, 4H, CHmmaie').
218
13C NMR: (D2O) 8 21.97 (N-p-CH2), 24.80 (N-p-CH2), 44.90 (N-a-CH2), 46.75 (N-a- 
CH2), 47.58 (N-a-CH2), 49.52 (N-a-CH2), 49.66 (N-a-CH2), 51.15 (N-a-CH2), 52.78 (N-a-
CH2), 54.70 (N-a-CH2), 54.83 (N-a-CH2), 130.74 (CHaromatic), 134.60 (Caromatic). 
MS: (ESI) w/z 503 [MH]+.
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8.2.9 Synthesis of 8a,8a'-(bismethyl)-3a,3a'-[l,4-phenylenebis(methyl-ene)]bis- 
(decahydro-3a,5a,8a,10a-tetraazapyrenium) dibromide, 8
3a,3a'-[l,4-Phenylenebis(methylene)]-bis(decahydro-3a,5a,8a,10a-tetraazapyrenium) 
dibromide (2.60 g, 3.7 mmol) was suspended in dry acetonitrile (150 mL) under nitrogen 
and methyl iodide (20 mL, 320 mmol) was added dropwise. The white suspension was 
stirred at room temperature for 10 days. A second portion of methyl iodide (10 mL, 160 
mmol) was added to the now yellow suspension after 5 days. Excess methyl iodide was 
removed by flowing nitrogen through the suspension for 30 minutes. The yellow solid was 
collected by filtration, washed with diethyl ether (200 mL) and dried in vacua (3.45 g,
13C NMR: (DMSO-d6) 18.28 (N-p-CH2), 18.59 (N-P-CH2), 37.95 (N-a-CH2), 38.17 
(N-a-CH2), 38.37 (N-a-CH2), 46.58 (N-a-CH2), 46.64 (N-a-CH2), 48.45 (N-a-CH3), 51.39 
(N-a-CH2), 60.89 (N-a-CH2), 61.52 (N-a-CH2), 65.46 (N-a-CH2), 76.98 (Cammal), 77.27
)) 128.29 (Caromatic)5 134.57 (CHaromatic)-
MS: (ESI) m/z 959 [M-I]+ . HRMS: Calcd. for C34H58N8I3 : 959.1913; Found 
959.1914.
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8.2.10 Synthesis of 12,12'-(bismethyl)-5,5'-[l,4-phenylenebis(methyl-ene)]bis- 
(l,5,8,12-tetraaza-bicyclo-[6.6.2]hexadecane).7 HC1, 9
8a,8a'-(Bismethyl)-3a,3a'-[l,4-Phenylenebis(methylene)]-bis(decahydro- 
3a,5a,8a,10a-tetraazapyrenium) dibromide (3.03 g, 2.8 mmol) was dissolved in ethanol 
(150 mL) and sodium borohydride (4.25 g, 112 mmol) was added slowly. The clear 
solution was stirred at room temperature for 14 days and concentrated in vacua. Water (100 
mL) was added, the pH was adjusted to 14 (KOH pellets) and the basic solution was 
extracted with dichloromethane (5 x 100 mL). The combined organic fractions were dried 
(MgSO4), filtered and evaporated in vacua to yield a clear oil. The HC1 salt was prepared 
by bubbling HC1 gas into a methanolic solution of the ligand and concentrating the yellow 
solution in vacua to a yellow powder (1.15 g, 71%).
13C NMR: (D2O) 5 18.84 (N-P-CH2), 19.23 (N-p-CH2), 40.05 (N-o-CH3), 45.02 (N-a- 
CH2), 49.16 (N-o-CH2), 49.34 (N-a-CH2), 49.43 (N-a-CH2), 50.40 (N-o-CH2), 52.96 (N-a- 
CH2), 53.25 (N-a-CH2), 56.37 (N-a-CH2), 58.72 (N-a-CH2), 59.52 (N-o-CH2), 128.65
(Caromatic)j 133.13 (CHaromatic)-
MS: (ESI) m/z 584 [MH]+, HRMS: Calcd. for C34H63N8+ : 583.5170; Found 583.5180.
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8.2.11 Synthesis of 5-(4-phenylmethy 1 benzoate)-l,5,8,12-tetraazabicyclo[10.2.2]- 
hexadeca'ne, 15
4-(Decahydro-3a,5a,8a,10a-tetraaza-pyren-3a-ylmethyl)-benzoic acid methyl ester 
bromide (4.93 g, 1 1 mmol) was dissolved in methanol (250 mL) and cooled to 0°C. Sodium 
borohydride (7.40g, 200 mmol) was added slowly and the clear solution was stirred at room 
temperature for 3 h. The solvent was concentrated in vacuo and water (75 mL) was added. 
The pH was adjusted to 14 (KOH pellets) and the basic solution was extracted with 
dichloromethane (5 x 75 mL). The combined organic fractions were dried (MgSO,}), filtered 
and evaporated in vacuo to yield a clear oil (2.45 g, 60%).
'H NMR: (CDC13) 6 1.60-1.66 (p, 2H, 11.23 Hz, N-p-C/fc), 1.68-1.73 (p, 2H, 10.67 
Hz, N-p-C#2), 2.16-2.21 (m, 2H, N-a-C#2), 2.44-2.61 (m, 12H, N-a-C#2), 2.84-2.87 (m, 
2H, N-a-C#2), 2.92-2.97 (m, 2H, N-a-C//2), 3.13-3.20 (m, 2H, N-a-C#2), 3.61 (s, 2H, N-a- 
CH2), 3.86 (s, 3H, O-CH3), 7.28-7.30 (d, 2H, 8.14 Hz, C//aromatic), 7.91-7.30 (d, 2H, 8.14
rlZ,
13C NMR: (CDC13) 6 23.65 (N-P-CH2), 26.07 (N-p-CH2), 48.21 (N-a-CH2), 48.37 (N- 
a-CH2), 50.46 (N-a-CH2), 51.24 (N-a-CH2), 52.18 (O-CH3), 55.32 (N-a-CH2), 55.65 (N-a-
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CH2), 57.03 (N-o-CHz), 57.77 (N-a-CH2), 128.97 (Caromatic), 129.33 (CHaromatic), 129.46
(CHaromatic), 144.24 (Caromatic), 167.09 (C=0).
MS: (ESI) m/z 375 [MH]+. HRMS: Calcd. for C2iH35N402+: 375.2755; Found 
375.2758.
223
8.2.12 Synthesis of 5-(methyl)-l,5,8,12-tetraaza-bicyclo[10.2.2]hexadecane, 21 
(Method I)
HN'
The synthesis of 21 was carried out following a minor modification of a literature 
procedure. 160 3a-Methyl-decahydro-3a,5a,8a,10a-tetraaza-pyrenium bromide (2.50 g, 69 
mmol) was dissolved in methanol (150 mL) and cooled to 0°C. Sodium borohydride (5.24 
g, 1.5 mol) was added slowly and the clear solution was stirred at room temperature for 24 
h. The solvent was concentrated in vacua and water (75 mL) was added. The pH was 
adjusted to 14 (KOH pellets) and the basic solution was extracted with dichloromethane (5 
x 75 mL). The combined organic fractions were dried (MgSO4), filtered and evaporated in 
vacua to yield a clear oil (1.33 g, 81%).
'H NMR: (CDC13) 5 1.57-1.67 (m, 4H, N-P-C#2), 2.05 (s, 3H, N-a-C#3), 2.13-2.21 
(m, 2H, N-a-C//2), 2.39-2.53 (m, 10H, N-a-C/fc), 2.61-2.63 (m, 2H, N-a-C/fc), 2.77-2.80 
(m, 2H, N-a-Ctf2), 2.91-2.94 (m, 2H, N-a-C#2), 3.17-3.24 (m, 2H, N-a-C#2), 4.46 (br s,
13C NMR: (CDC13) 8 23.86 (N-0-CH2), 26.32 (N-P-CH2), 39.38 (N-a-CH3), 47.50 (N- 
a-CH2), 48.47 (N-a-CH2), 51.10 (N-a-CH2), 51.93 (N-a-CH2), 56.50 (N-a-CH2), 57.02 (N- 
a-CH2), 59.71 (N-a-CH2), 59.89 (N-a-CH2).
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MS: (ESI)w/z241[MH]+.
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8.2.13 Synthesis of 5-(Methyl)-l,5,8,12-tetraaza-bicyclo[10.2.2]hexadecane, 21 
(Method'11)
Nickel(II) 5-(methyl)-l,5,8,12-tetraaza-bicyclo[10.2.2]hexadecane perchlorate (0.69 
g, 1.39 mmol) was dissolved in a mixture of water and acetonitrile (30:5 mL). Sodium 
cyanide (0.27 g, 5.5mmol) was added to the orange solution in one portion. The orange 
solution immediately became less intense and was heated at 80°C for 24 h. The resulting 
clear solution was cooled in an ice bath, filtered to remove any nickel(II) cyanide salts and 
the acetonitrile was removed in vacua. The pH of the aqueous layer was adjusted to 14 
(KOH pellets) and extracted with dichloromethane (5 x 50 mL). The combined organic 
fractions were dried (MgSO4), filtered and concentrated in vacua to yield a yellow oil 
product (0.24 g, 72%).
'H NMR: (CDC13) 6 1.57-1.67 (m, 4H, N-p-C#2), 2.05 (s, 3H, N-a-C#3), 2.13-2.21 
(m, 2H, N-a-C/fc), 2.39-2.53 (m, 10H, N-a-C//2), 2.61-2.63 (m, 2H, N-a-C//2), 2.77-2.80 
(m, 2H, N-a-C//2), 2.91-2.94 (m, 2H, N-a-C#2), 3.17-3.24 (m, 2H, N-a-C#2), 4.46 (br s,
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13C NMR: (CDC13) 5 23.86 (N-P-CH2), 26.32 (N-p-CH2), 39.38 (N-a-CH3), 47.50 (N- 
a-CH2), 48.47 (N-a-CH2), 51.10 (N-a-CH2), 51.93 (N-a-CH2), 56.50 (N-a-CH2), 57.02 (N- 
a-CH2), 59.71 (N-a-CH2), 59.89 (N-a-CH2).
MS:(ESI)w/z241
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8.2.13.1 Crystal data and structural refinement for 5-(methyl)-l,5,8,12-tetraaza- 
bicyclo[10.2.2]hexadecane, 21
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.84°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Extinction coefficient
Largest diff. peak and hole
a= 98.47(2)°. 
P= 93.161(19)°. 
y=115.029(18)°.
276.43
150(2)K
0.71073 A
Triclinic
P-l
a = 8.838(2) A
b = 8.997(2) A
c= 11.458(3) A
809.5(4) A3
2
1.134Mg/m3
0.077 mnr 1
308
0.20x0.15x0.10 mm3
2.54 to 34.84°.
-14<=h<=l 1, -14<=k<=14, -18<=1<=18
35577
6956 [R(int) = 0.2054]
98.7 %
None
Full-matrix least-squares on F^
6956/4/186
0.724
Rl = 0.0546, wR2 = 0.0913
Rl = 0.2253, wR2 = 0.1251
0.022(3)
0.266 and -0.249 e.A'3
228
I
cc
01
Figure 123. ORTEP representation of 21.2H2O.
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Table 24. Bond lengths (A) and angles (°) for 5-(methyl)-l,5,8,12-tetraaza-
bicyclo[10.2.2]hexadecane.
N(1)-C(11) 1.455(2)
N(1)-C(1) 1.456(2)
N(1)-C(10) 1.465(3)
N(2)-C(2) 1.462(2)
N(2)-C(12) 1.465(2)
N(2)-C(3) 1.470(3)
N(3)-C(13) 1.459(2)
N(3)-C(6) 1.471(2)
N(3)-C(5) 1.477(2)
N(4)-C(8) 1.463(2)
N(4)-C(7) 1.464(2)
N(4)-H(1N) 1.0206
C(1)-C(2) 1.513(3)
C(1)-H(1A) 0.9700
C(1)-H(1B) 0.9700
C(2)-H(2A) 0.9700
C(2)-H(2B) 0.9700
C(3)-C(4) 1.549(3)
C(3)-H(3A) 0.9700
C(3)-H(3B) 0.9700
C(4)-C(5) 1.530(3)
C(4)-H(4A) 0.9700
C(4)-H(4B) 0.9700
C(5)-H(5A) 0.9700
C(5)-H(5B) 0.9700
C(6)-C(7) 1.516(3)
C(6)-H(6A) 0.9700
C(6)-H(6B) 0.9700
C(7)-H(7A) 0.9700
C(7)-H(7B) 0.9700
C(8)-C(9) 1.527(3)
C(8)-H(8A) 0.9700
C(8)-H(8B) 0.9700
0(2>H(3O) 1.075(18)
0(2)-H(4O) 1.042(17)
C(11)-N(1)-C(1) 108.13(15)
C(11)-N(1)-C(10) 114.65(15)
C(1)-N(1)-C(10) 115.21(14)
C(2)-N(2)-C(12) 113.06(15)
C(2)-N(2)-C(3) 112.62(14)
C(12)-N(2)-C(3) 112.37(15)
C(13)-N(3)-C(6) 110.03(14)
C(13)-N(3)-C(5) 110.96(15)
C(6)-N(3)-C(5) 110.96(14)
C(8)-N(4)-C(7) 114.74(14)
C(8)-N(4)-H(1N) 107.9
C(7)-N(4)-H(1N) 105.9
N(1)-C(1)-C(2) 107.79(14)
N(1)-C(1)-H(1A) 110.1
C(2)-C(1)-H(1A) 110.1
N(1)-C(1)-H(1B) 110.1
C(2)-C(1)-H(1B) 110.1
H(1A)-C(1)-H(1B) 108.5
N(2)-C(2)-C(1) 112.44(15)
N(2)-C(2)-H(2A) 109.1
C(1)-C(2)-H(2A) 109.1
N(2)-C(2)-H(2B) 109.1
C(1)-C(2)-H(2B) 109.1
H(2A)-C(2)-H(2B) 107.8
N(2)-C(3)-C(4) 120.61(16)
N(2)-C(3)-H(3A) 107.2
C(4)-C(3)-H(3A) 107.2
N(2)-C(3)-H(3B) 107.2
C(4)-C(3)-H(3B) 107.2
C(7)-C(6)-H(6A) 109.1
N(3)-C(6)-H(6B) 109.1
C(7)-C(6)-H(6B) 109.1
H(6A)-C(6)-H(6B) 107.8
N(4)-C(7)-C(6) 109.72(14)
N(4)-C(7)-H(7A) 109.7
C(6)-C(7)-H(7A) 109.7
N(4)-C(7)-H(7B) 109.7
C(6)-C(7)-H(7B) 109.7
H(7A)-C(7)-H(7B) 108.2
N(4)-C(8)-C(9) 111.58(15)
N(4)-C(8)-H(8A) 109.3
C(9)-C(8)-H(8A) 109.3
N(4)-C(8)-H(8B) 109.3
C(9)-C(8)-H(8B) 109.3
H(8A)-C(8)-H(8B) 108.0
C(8)-C(9)-C(10) 114.18(16)
C(8)-C(9)-H(9A) 108.7
C(10)-C(9)-H(9A) 108.7
C(8)-C(9)-H(9B) 108.7
C(10)-C(9)-H(9B) 108.7
H(9A)-C(9)-H(9B) 107.6
N(1)-C(10)-C(9) 111.97(15)
N(1)-C(10)-H(10A) 109.2
C(9)-C(10)-H(10A) 109.2
N(1)-C(10)-H(10B) 109.2
C(9)-C(10)-H(10B) 109.2
H(10A)-C(10)-H(10B) 107.9
N(1)-C(11)-C(12) 108.45(14)
N(1)-C(11)-H(11A) 110.0
C(12)-C(11)-H(11A) 110.0
N(1)-C(11)-H(11B) 110.0
C(12)-C(11)-H(11B) 110.0
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C(9)-C(10) 1.530(3)
C(9)-H(9A) Q.9700
C(9)-H(9B) 0.9700
C(10)-H(10A) 0.9700
C(10)-H(10B) 0.9700
C(11)-C(12) 1.505(3)
C(11)-H(11A) 0.9700
C(11)-H(11B) 0.9700
C(12)-H(12A) 0.9700
C(12)-H(12B) 0.9700
C(13)-H(13A) 0.9600
C(13)-H(13B) 0.9600
C(13)-H(13C) 0.9600
0(1)-H(1O) 1.060(15)
0(1)-H(20) 1.075(16)
H(3A)-C(3)-H(3B) 106.8
C(5)-C(4)-C(3) 119.40(16)
C(5)-C(4)-H(4A) 107.5
C(3)-C(4)-H(4A) 107.5
C(5)-C(4)-H(4B) 107.5
C(3)-C(4)-H(4B) 107.5
H(4A)-C(4)-H(4B) 107.0
N(3)-C(5)-C(4) 114.68(15)
N(3)-C(5)-H(5A) 108.6
C(4)-C(5)-H(5A) 108.6
N(3)-C(5)-H(5B) 108.6
C(4)-C(5)-H(5B) 108.6
H(5A)-C(5)-H(5B) 107.6
N(3)-C(6)-C(7) 112.45(15)
N(3)-C(6)-H(6A) 109.1
H(11A)-C(11)-H(11B) 108.4
N(2)-C(12)-C(11) 111.19(15)
N(2)-C(12)-H(12A) 109.4
C(11)-C(12)-H(12A) 109.4
N(2)-C(12)-H(12B) 109.4
C(11)-C(12)-H(12B) 109.4
H(12A)-C(12)-H(12B) 108.0
N(3)-C(13)-H(13A) 109.5
N(3)-C(13)-H(13B) 109.5
H(13A)-C(13)-H(13B) 109.5
N(3)-C(13)-H(13C) 109.5
H(13A)-C(13)-H(13C) 109.5
H(13B)-C(13)-H(13C) 109.5
H(1O)-O(1)-H(20) 106.9(17)
H(30)-0(2)-H(40) 121(2)
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8.2.14 Synthesis of 5-(phenylmethyl benzoate)-8-methyl-l,5,8,12-tetra-aza-bicyclo- 
[10.2.2]hexadecane, 16
Nickel(II)-5-(phenylmethyl-benzoate)-8-methyl-l,5,8,12-tetraaza-bicyclo[10.2.2]- 
hexadecane perchlorate (62 mg, 0.10 mmol) was dissolved in acetonitrile (15 mL) and a 
solution of sodium cyanide (24 mg, 0.49 mmol) in water (1 mL) was added. The mixture 
was heated to reflux for 2 h and a purple colour developed in the solution after a few 
minutes. The purple solution changed colour to give an orange solution which was 
concentrated in vacua to give an orange solid. The crude product was placed in a paper 
thimble and purified using a soxhlet apparatus with DCM. The remaining solid was 
dissolved in water (10 mL) and extracted into DCM (5x10 mL). The combined organic 
fractions were dried (MgSO4), filtered and evaporated in vacua to yield a yellow oil (21 
mg, 54%).
'H NMR: (CDC13) 5 1.56-1.75 (m, 4H, N-p-C/fc), 2.01-2.17 (m, 2H, N-a-C#2), 2.48- 
2.84 (m, 15H, N-a-C/fc and N-a-C/6), 2.85-2.87 (m, 2H, N-a-C/fc), 2.89-2.97 (m, 2H, N- 
<x-C#2), 2.99-3.08 (m, 2H, N-a-C#2), 3.69 (s, 2H, N-a-C#2), 3.84 (s, 3H, O-C//3), 7.44- 
7.52 (d, 2H, 8.72 Hz, C//aromatic), 7.81-7.96 (d, 2H, 8.72 Hz, C#aromatic).
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I3C NMR: (CDC13) 6 23.21 (N-P-CH2), 24.75 (N-p-CH2), 31.12 (N-a-CH3), 47.16 (N- 
a-CH2), 48.31 (N-a-CH2), 49.98 (N-a-CH2), 50.02 (N-a-CH2), 51.98 (O-CH3), 55.64 (N-a- 
CH2), 55.81 (N-a-CH2), 55.97 (N-a-CH2), 57.00 (N-a-CH2), 128.90 (Caromatic), 129.79 
), 130.41 (CHaromatic), 141.92 (Caromatlc), 167.39 (OO).
MS: (ESI) m/z 389 [MH]+. HRMS: Calcd. for C22H37N4O2+ : 389.2911 ; Found 
389.2917.
233
8.2.15 Synthesis of 5-(4-phenylmethyl methyl alcohol)-8-methyl-l,5,8,12-tetraaza- 
bicyclo[10.2.2]hexadecane, 17
Lithium aluminium hydride (156 mg, 4.11 mmol) was added to a solution of 5- 
(phenylmethyl benzoate)-8-methyl-l,5,8,12-tetraaza-bicyclo[10.2.2]hexadecane (80 mg, 
0.21 mmol) in dry THF (20 mL) under nitrogen and the mixture was stirred at room 
temperature for 48 h. Methanol (~ 5 mL) followed by water (~ 10 mL) was added dropwise 
and the solution was concentrated in vacuo. The crude solid was dissolved in water (15 mL) 
and then extracted with dichloromethane (5 x 20 mL). The pH was adjusted to 14 (NaOH 
pellets) and re-extracted with dichloromethane (5 x 20 mL). The combined organic 
fractions were dried (MgSO4), filtered and evaporated in vacuo to yield an orange oil (56 
mg, 76%).
'H NMR: (CD2C12) 6 1.56-1.60 (m, 4H, N-p-C/fc), 2.08-2.10 (m, 4H, N-a-C#2), 
2.24-2.60 (m, 12H, N-a-C/fc), 2.88-2.91 (m, 4H, N-a-C//2), 3.07-3.09 (m, 4H, N-a-C#2), 
3.49-3.50 (br s, 2H, N-a-C//2), 4.53-4.54 (s, 2H, ArC#2OH), 7.09-7.11 (d, 2H, J = 7.82 Hz, 
Chromatic), 7.16-7.19 (d, 2H, J = 7.82 Hz, C//aromat,c)
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13C NMR: (CD2C12) 5 23.88 (N-P-CH2), 26.32 (N-p-CH2), 30.07 (N-o-CH3), 48.08 
(N-a-CH2), 48.50 (N-a-CH2), 50.70 (N-a-CH2), 51.34 (N-a-CH2), 54.19 (N-a-CH2), 54.28 
(N-a-CH2), 54.34 (N-a-CH2), 54.77 (N-a-CH2), 55.44 (N-a-CH2), 56.30 (N-a-CH2), 57.18 
N-a-CH2), 64.75 N-a-CH2), 126.80 (C//aromat ,c), 129.35 (C^atic), 129.99 (CHaromatic),
141.12(Caromatic).
MS: (ESI) m/z 361 [MH]+. HRMS: Calcd. for C2 iH37N4O+: 361.2962; Found 
361.2963.
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8.2.16 Synthesis of 5-(4-phenylmethyl benzyl bromide)-8-methyl-l,5,8,12-tetraaza- 
bicyclo[10.2.2]hexadecane, 10
5-(4-Phenylmethyl methyl alcohol)-8-methyl-l,5,8,12-tetraaza-bicyclo[10.2.2]- 
hexadecane (40 mg, 0.11 mmol) was dissolved in dry pyridine (10 mL) and phosphorus 
tribromide (8 uL, 0.04 mmol) was added in one portion and the orange solution was stirred 
at room temperature for 4 days. Water (10 mL) was added and the pH adjusted to 14 
(NaOH pellets) and the basic solution was extracted with dichloromethane (5 x 10 mL). 
The combined organic extracts were dried (MgSO4), filtered and evaporated to an orange 
oil (23 mg, 49%).
]H and 13C NMR spectra were recorded but not fully characterised due to multiple 
overlapping signals in the aliphatic region. However, a pair of doublets indicating a 1,4- 
system was observed in the aromatic region.
MS: (ESI) m/z 361 [MH]+.
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8.2.17 Synthesis of 3a,3a'3a"-[l,3,5-phenylenetris(methylene)]-tris-(decahydro- 
3a,5a,8a,10a-tetraazapyrenium) tribromide, 7
Decahydro-3a,5a,8a,10a-tetraaza-pyrene (3.37 g, 15 mmol) and 1,3,5- 
tris(bromomethyl)benzene (provided by Dr Steve Archibald) (1.93 g, 5.42 mmol) were 
dissolved in dry acetonitrile (50 mL) and stirred under nitrogen at room temperature for 5 
days. A white precipitate was collected by filtration, washed with acetonitrile (50 mL) 
followed by diethyl ether (10 x 25 mL) and dried in vacua to yield a white powder (4.63 g,
!H NMR: (D2O) 5 1.40-1.43 (m, 3H), 1.75-1.78 (m, 3H), 2.16-2.20 (m, 6H), 2.29- 
2.34 (m, 2H), 2.42-2.48 (m, 7H), 2.63-2.69 (m, 3H), 2.96-3.10 (m, 24H), 3.19-3.33 (m, 
4H), 3,43-3.52 (m, 4H), 3.52-3.60 (m, 2H), 3.66-3.69 (m, 4H), 4.19-4.25 (m, 3H), 4.36- 
4.37 (m, 3H), 4.90-4.95 (m, 2H), 5.19-5.30 (m, 2H), 7.81-7.83 (br s, 3H, CHaromalic).
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13C NMR: (D2O) 5 18.16 (N-p-CH2), 18.63 (N-p-CH2), 42.10 (N-a-C#2), 46.74 (N-a- 
CH2), 51.56 (N-a-CH2), 52.05 (N-a-CH2), 53.48 (N-a-CH2), 54.03 (N-a-CH2), 54.12 (N-a- 
CH2), 60.15 (N-a-CH2), 61.18 (N-a-CH2), 69.64 (CHaminai), 82.53 (CHaminal), 128.88
(CHaromatic)j 140.36 (Caromatic)-
MS: (ESI) m/z 261 [M]3+. HRMS: Calcd. for C45H75Ni23+: 261.2074; Found 
261.2076.
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8.2.18 Synthesis of 12,12',12"-(trismethyl)-5,5',5"-[l,3,5-phenylenetris-(methylene)]- 
tris(l,5,8,12-tetraaza-bicyclo-[6.6.2]hexadecane), 6
3a,3a'3a"-[l,3,5-Phenylenetris(methylene)]-tris(decahydro-3a,5a,8a,10a- 
tetraazapyrenium) tribromide (4.63 g, 4.53 mmol) was dissolved in methanol (150 mL) and 
cooled to 0°C. Sodium borohydride (10.33 g, 272 mmol) was added slowly and the clear 
solution was stirred under nitrogen at room temperature for 4 h. The solution was 
concentrated in vacua and water (100 mL) was added. The pH was adjusted to 14 (KOH 
pellets) and the basic solution was extracted from dichloromethane (5 x 100 mL). The 
combined organic fractions were dried (MgSC>4), filtered and evaporated in vacua to yield a 
yellow solid (2.78 g, 77%).
13C NMR: (CDC13) 5 21.81 (N-P-CH2), 22.03 (N-p-CH2), 44.68 (N-a-CH2), 46.17 (N- 
P-CH2), 47.72 (N-p-CH2), 49.30 (N-P-CH2), 50.76 (N-p-CH2), 54.07 (N-p-CH2), 54.27 (N- 
P-CH2), 55.96 (N-p-CH2), 56.57 (N-P-CH2), 57.23 (N-P-CH2), 59.12 (N-P-CH2), 129.60
)? 130.-)U ((-aromatic)-
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MS: (ESI) m/z 794 [MH]+. HRMS: Calcd. for C45Hg5Ni2+ : 793.6942; Found 
793.6937.
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8.3 Synthesis of Transition Metal Complexes
8.3.1 General Complexation Procedure
The appropriate ligand (~ 200 mg) was dissolved in methanol (10 mL) and a solution 
of metal salt (1.1 molar equivalents per macrocycle) in methanol (10 mL) was added 
dropwise. The mixtures were stirred at room temperature for 3 h and then at reflux for 2 h. 
The complexes either remained in solution or precipitated out. The solutions were 
concentrated in vacua, redissolved in a minimum volume of methanol and purified by size 
exclusion chromatography (Sephadex LH20). Alternatively, the precipitates were collected 
by filtration, washed with methanol (5 x 20 mL) followed by diethyl ether (2 x 20 mL) and 
dried in vacua.
8.3.1.1 Size Exclusion Chromatography
Size exclusion chromatography allows the separation of compounds based on 
molecular weight. For example, high molecular weight metal complexes will run quickly 
whereas low molecular weight metal salts will run slowly, if at all. Sephadex (LH20) was 
soaked in methanol for at least 3 h before being used in order for it to swell to its optimum 
size.
Purification was carried out in two steps. Firstly, a small column in a Pasteur pipette 
fitted with glass wool was run with methanol eluent to remove the majority of the excess 
metal salt. Secondly, a column of approximately 15 cm (height) by 1 cm (diameter) was run 
with methanol eluent to remove trace metal salt. Individually coloured bands were collected 
and concentrated in vacua to give pure metal complex.
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8.3.2 Synthesis of [Zn25(OAc)2] (OAc)2
Ligand 5 (48.3 mg, 0.87 mmol), zinc(II) acetate (0.351 g, 1.91 mmol). The crude 
product was purified by size exclusion chromatography (Sephadex LH20). The clear oil 
was triturated with diethyl ether (2 x 20 mL) to give a white crystalline powder (76.9 mg, 
77%).
'H NMR: (800 MHz, 90% H2O / 10% D2O) 5 1.64 (d, J= 16.0 Hz, 1H, N-p-C#2), 
1.85 (d, J= 16.0 Hz, 1H, N-p-Ctf;,), 2.01 (m, 1H, N-P-C#2), 2.14 (m, 1H, N-p-C//2), 2.31 
(m, 1H, N-a-C//2), 2.39 (m, 1H, N-a-C#2), 2.55 (m, 1H, N-a-C#2), 2.58 (m, 1H, N-a- 
C//2), 2.60 (m, 1H, N-a-C//2), 2.62 (m, 1H, N-a-C//2) , 2.69 (m, 2H, N-a-C#2), 2.86 (m, 
1H, N-a-C#2), 2.92 (m, 1H, N-a-C#2), 2.98 (m, 1H, N-a-C//2), 3.04 (m, 1H, N-a-C#2), 
3.09 (m, 1H, N-a-C//2), 3.10 (m, 1H, N-a-C//2), 3.1 1 (m, 1H, N-a-C//2), 3.18 (m, 1H, N-a- 
CH2\ 3.19 (m, 1H, N-a-C#2), 3.35 (m, 1H, N-a-C//2), 3.46 (m, 1H, N-a-C#2), 3.60 (m, 
1H, N-a-C//2), 3.89 (d, J= 14.5 Hz, 1H, N-a-C^Ar), 4.04 (m, 1H, N#), 4.17 (d, J= 14.5 
Hz, 1H, N-a-C#2Ar), 7.36 (s, 4H,
13C('H) NMR: (200 MHz, 90% H2O / 10% D2O) 8 23.40 (N-p-CH2), 26.82 (N-p- 
CH2), 45.99 (N-a-CH2), 47.07 (N-a-CH2), 50.88 (N-a-CH2), 51.97 (N-a-CH2), 54.01 (N-a- 
CH2), 54.66 (N-a-CH2), 54.84 (N-a-CH2), 58.43 (N-a-CH2Ar), 59.18 (N-a-CH2), 60.55(N- 
a-CH2), 132.30 (Caromatic), 134.70
MS: (ESI) m/z: 399 [M-(OAc2)4-2H]2+ . HRMS: Calcd. for C36H62N8O4Zn22+ : 
399.1739; Found 399.1738.
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Elemental analysis: (%) Calcd. for C4oH7oNgO8Zn2.Et2O.5H2O: C 48.66, H 8.35, N 
10.32; Found C 49.00, H 8.07, N 10.07.
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8.3.2.1 Crystal data and structure refinement for [Zn25(OAc)2]2+
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.78°
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Largest diff. peak and hole
1128.53
150(2)K
0.71073 A
monoclinic
P21/n
a =12.0978(11) A o= 90°.
b = 14.6141(9) A p= 107.824(7)c
c= 16.4562(14) A y = 90°.
2769.8(4) A3
2
1.353Mg/m3
0.944 mm' 1
1181
0.15x0.20x0.25 mm3
2.60 to 34.78°.
-19<=h<=19, -19<=k<=23, -26<=1<=21
40408
11834 [R(int) = 0.0669]
98.6 %
Full-matrix least-squares on F^
11834/6/336
0.942
Rl = 0.0753, wR2 = 0.2032
Rl =0.1425, wR2 = 0.2293
1.120 and-1.641 e.A-3
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Crystals were grown via slow evaporation of a methanolic solution.
Figure 124. ORTEP representation of [Zn25(OAc)2] +. Symmetry transformations 
used to generate equivalent atoms: -x,-y+l,-z.
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Table 25. Bond lengths (A) and angles (°) for [Zn25(OAc)2] 2+.
Zn(l)-N(4) 2.091(3)
Zn(l)-N(2) 2.106(3)
Zn(l)-0(l) 2.112(3)
Zn(l)-N(l) 2.166(2)
Zn(l)-N(3) 2.228(3)
Zn(l)-O(2) 2.407(4)
N(1)-C(1) 1.483(4)
N(1)-C(12) 1.502(5)
N(1)-C(13) 1.505(4)
C(15)-C(14) 1.393(5)
C(15)-C(16) 1.395(4)
N(3)-C(5) 1.454(5)
N(3)-C(6) 1.464(5)
N(3)-C(8) 1.489(4)
C(1)-C(2) 1.502(5)
C(8)-C(9) 1.548(5)
N(2)-C(3) 1.481(5)
N(2)-C(2) 1.489(4)
O(1)-C(17) 1.250(6)
C(13)-C(14) 1.520(4)
C(5)-C(4) 1.522(6)
C(16)-C(14)#1 1.391(5)
N(4)-C(9) 1.475(5)
N(4)-C(10) 1.482(5)
N(4)-C(7) 1.490(4)
C(14)-C(16)#1 1.391(5)
C(12)-C(11) 1.521(6)
0(2)-C(17) 1.232(7)
C(3)-C(4) 1.530(6)
C(10)-C(11) 1.528(5)
C(17)-C(18) 1.507(5)
C(6)-C(7) 1.570(6)
C(1A)-C(2A) 1.568(16)
C(2A)-O(2A) 1.185(13)
C(2A)-0(1A) 1.186(14)
C(1B)-C(2B) 1.503(12)
C(2B)-O(2B) 1.193(12)
C(2B)-O(1B) 1.313(13)
N(4)-Zn(l)-N(2) 117.91(12)
N(4)-Zn(l)-O(l) 133.57(12)
N(2)-Zn(l)-O(l) 102.38(13)
N(4)-Zn(l)-N(l) 100.10(11)
N(2)-Zn(l)-N(l) 84.86(11)
O(l)-Zn(l)-N(l) 105.82(11)
N(4)-Zn(l)-N(3) 69.44(12)
N(2)-Zn(l)-N(3) 83.85(12)
O(l)-Zn(l)-N(3) 94.58(11)
N(l)-Zn(l)-N(3) 158.40(10)
N(4)-Zn(l)-0(2) 85.97(13)
N(2)-Zn(l)-O(2) 156.11(13)
O(l)-Zn(l)-O(2) 56.31(14)
N(l)-Zn(l)-0(2) 90.74(11)
N(3)-Zn(l)-O(2) 106.79(12)
C(1)-N(1)-C(12) 111.7(2)
C(1)-N(1)-C(13) 110.8(3)
C(12)-N(1)-C(13) 109.1(3)
C(l)-N(l)-Zn(l) 102.27(19)
C(12)-N(l)-Zn(l) 112.7(2)
C(13)-N(l)-Zn(l) 110.13(17)
C(14)-C(15)-C(16) 121.0(3)
C(5)-N(3)-C(6) 113.5(3)
C(5)-N(3)-C(8) 114.3(3)
C(6)-N(3)-C(8) 106.8(3)
C(5)-N(3)-Zn(l) 114.9(2)
C(6)-N(3)-Zn(l) 99.4(2)
C(8)-N(3)-Zn(l) 106.6(2)
N(1)-C(1)-C(2) 110.3(2)
N(3)-C(8)-C(9) 106.7(3)
C(3)-N(2)-C(2) 114.2(3)
C(3)-N(2)-Zn(l) 111.9(2)
C(2)-N(2)-Zn(l) 105.0(2)
C(17)-O(l)-Zn(l) 98.5(3)
N(1)-C(13)-C(14) 115.0(2)
N(3)-C(5)-C(4) 113.4(3)
C(14)#1-C(16)-C(15) 120.9(3)
C(9)-N(4)-C(10) 112.7(3)
C(9)-N(4)-C(7) 107.0(3)
C(10)-N(4)-C(7) 110.4(3)
C(9)-N(4)-Zn(l) 104.0(2)
C(10)-N(4)-Zn(l) 116.2(2)
C(7)-N(4)-Zn(l) 105.9(2)
C(16)#1-C(14)-C(15) 118.1(3)
C(16)#1-C(14)-C(13) 120.7(3)
C(15)-C(14)-C(13) 121.3(3)
N(1)-C(12)-C(11) 116.0(3)
C(17)-O(2)-Zn(l) 85.1(3)
N(2)-C(3)-C(4) 112.4(3)
N(4)-C(9)-C(8) 108.5(3)
N(4)-C(10)-C(11) 112.5(3)
N(2)-C(2)-C(1) 108.5(3)
C(12)-C(11)-C(10) 114.8(3)
0(2)-C(17)-0(1) 119.9(4)
O(2)-C(17)-C(18) 119.4(5)
O(1)-C(17)-C(18) 120.6(5)
N(3)-C(6)-C(7) 107.1(3)
N(4)-C(7)-C(6) 107.6(3)
C(5)-C(4)-C(3) 117.0(3)
0(2A)-C(2A)-O(1A) 125.2(14)
O(2A)-C(2A)-C(1A) 116.2(14)
0(1A)-C(2A)-C(1A) 117.5(15)
O(2B)-C(2B)-O(1B) 115.7(12)
0(2B)-C(2B)-C(1B) 125.4(11)
0(1B)-C(2B)-C(1B) 118.9(11)
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8.3.3 Synthesis of [Zn25Cl2](PF6)2
» 
Ligand 5 (198 mg, 0.36 mmol), anhydrous zinc(II) chloride (97 mg, 0.72 mmol). The
white product was collected by filtration (169 mg, 57%).
To a solution of [Zn25Cl2]Cl2 (50 mg, 0.06 mmol) in ethanol (20 mL) was added a 
solution of ammonium hexafluorophosphate (23 mg, 0.14 mmol) in ethanol (5 mL). After 
stirring at room temperature for 10 minutes the white precipitate was collected by filtration, 
washed with ethanol (5x10 mL) followed by diethyl ether (5x10 mL) and dried in vacua 
to yield a white solid (53 mg, 84%).
MS: (ESI) m/z 376 [(M-(PF6)2]2+, 897 [M-(PF6)]+. HRMS: Calcd. for 
C32H58N8Cl2Zn22+ : 376.1367; Found 376.1373.
8.3.4 Synthesis of [Zn25](ClO4)4
Ligand 5 (198 mg, 0.36 mmol), zinc(II) perchlorate hexahydrate (190 mg, 0.72 
mmol), 213 mg, 55%.
MS: (ESI) m/z 779 [M-2H-(C1O4)3]+. HRMS: Calcd. for Ca^seNgClO^n/: 
777.2696; Found 777.2694.
8.3.5 Synthesis of [Cu25(OAc)2](OAc)2
Ligand 5 (193 mg, 0.35 mmol), copper(II) acetate monohydrate (139 mg, 0.75 
mmol). The blue solution was concentrated in vacua and purified by size exclusion 
chromatography (Sephadex LH20). The resulting solvent was evaporated in vacua to yield 
a blue crystalline solid (265 mg, 83%).
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MS: (ESI) m/z 857 [M-(OAc)]+. HRMS: Calcd. for C32H58N8(OAc)3Cu2+: 857.3770; 
Found 857.3769.
UV-vis: (H2O) A™* 562 nm, e 478 NT cm" 1 . 
8.3.6 Synthesis of [Cu25](CIO4)4
Ligand 5 (198 mg, 0.36 mmol), copper(II) perchlorate hexahydrate (290 mg, 0.78 
mmol). A blue solution was observed immediately which developed into a purple 
precipitate after a few minutes. The purple product was collected by filtration (245 mg, 
75%).
MS: (ESI) m/z 111 [M-2H-(C1O4)3]+. HRMS: Calcd. for C32H58N8ClO4Cu2+: 
777.2700; Found 777.2707.
UV-vis: (H2O) ^ax 554 nm, e 411 M' 1 cm' 1 .
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8.3.6.1 Crystal data and structural refinement for [Cu25] (004)4
Empirical forrrfiila
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.91°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on p2
Final R indices [I>2sigma(I)]
R indices (all data)
Largest diff. peak and hole
1077.73
150(2)K
0.71073 A
Monoclinic
P21/n
a =17.257(2) A
b= 15.7102(16) A
c= 17.976(2) A
4759.6(9) A3
a= 90°.
p= 102.416(9)c
y = 90°.
1.504Mg/m3
1.189mm- 1
2232
0.2x0.1x0.1 mm3
2.59 to 34.91°.
-27<=h<=27, -24<=k<=25, -28<=1<=24
56800
20450[R(int) = 0.1015]
98.3 %
None
Full-matrix least-squares on F^
20450 / 60 / 559
0.874
Rl= 0.1422, wR2 = 0.3621
Rl = 0.3428, wR2 = 0.4444
1.550 and -0.871 e.A"3
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Crystals were grown by vapour diffusion of diethyl ether at room temperature into a 
solution of [Cu25](ClO4)4 in methanol.
Figure 125. ORTEP representation of [Cu25](ClO4)4.
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Table 26. Bond lengths (A) for [Cu25](CIO4)4.
Cu(l)-N(4)
Cu(l)-N(3)
Cu(l)-N(l)
Cu(l)-N(2)
Cu(l)-C(15)
Cu(l)-C(16)
Cu(2)-N(8)
Cu(2)-N(7)
Cu(2)-N(5)
Cu(2)-N(6)
Cu(2)-C(30)
N(1)-C(8)
N(1)-C(7)
N(1)-C(19)
N(2)-C(10)
N(2)-C(9)
N(3)-C(13)
N(3)-C(12)
N(3)-C(15)
N(4)-C(17)
N(4)-C(14)
N(4)-C(16)
N(5)-C(32)
N(5)-C(21)
1.855(11)
1.885(9)
2.002(5)
2.048(14)
2.443(18)
2.548(16)
1.849(11)
1.950(7)
1.988(5)
2.266(11)
2.500(19)
1.493(11)
1.496(9)
1.498(11)
1.32(2)
1.654(16)
1.297(18)
1.45(2)
1.61(3)
1.08(2)
1.459(16)
1.47(3)
1.451(11)
1.469(10)
N(5)-C(20)
N(6)-C(23)
N(6)-C(22)
N(7)-C(27)
N(7)-C(29)
N(7)-C(25)
N(8)-C(30)
N(8)-C(28)
N(8)-C(26)
C(1)-C(6)
C(1)-C(2)
C(1)-C(7)
C(2)-C(3)
C(3)-C(4)
C(4)-C(5)
C(4)-C(20)
C(5)-C(6)
C(8)-C(9)
C(10)-C(11)
C(11)-C(12)
C(13)-C(14)
C(15)-C(16)
C(17)-C(18)
C(18)-C(19)
1.509(8)
1.21(2)
1.472(11)
1.276(17)
1.394(19)
1.620(19)
1.148(17)
1.522(19)
1.53(2)
1.352(10)
1.376(10)
1.528(8)
1.396(8)
1.387(9)
1.397(10)
1.511(8)
1.381(9)
1.490(17)
1.71(4)
1.35(4)
1.71(2)
1.73(4)
1.51(2)
1.505(15)
C(21)-C(22)
C(23)-C(24)
C(24)-C(25)
C(26)-C(27)
C(28)-C(29)
C(30)-C(31)
C(31)-C(32)
C1(2)-O(8)
Cl(2)-0(7)
Cl(2)-0(5)
Cl(2)-0(6)
Cl(l)-0(l)
Cl(l)-0(3)
Cl(l)-0(4)
Cl(l)-0(2)
Cl(3)-0(10)
C1(3)-O(12)
Cl(3)-0(ll)
Cl(3)-0(9)
Cl(4)-0(16)
Cl(4)-0(15)
Cl(4)-0(13)
Cl(4)-0(14)
1.500(13)
1.50(3)
1.43(2)
1.73(3)
1.68(3)
1.453(16)
1.521(15)
1.250(10)
1.336(13)
1.374(10)
1.385(7)
1.274(11)
1.295(11)
1.340(10)
1.440(11)
1.293(9)
1.351(9)
1.397(11)
1.400(11)
1.288(12)
1.305(11)
1.368(12)
1.373(13)
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Table 27. Bond angles (°) for [Cu25](ClO4)4.
N(4)-Cu(l)-N(3) 81.4(6)
N(4)-Cu(l)-N(l) 99.4(4)
N(3)-Cu(l)-N(l) 154.1(5)
N(4)-Cu(l)-N(2) 160.9(5)
N(3)-Cu(l)-N(2) 97.1(6)
N(l)-Cu(l)-N(2) 90.3(4)
N(4)-Cu(l)-C(15) 74.4(8)
N(3)-Cu(l)-C(15) 41.1(8)
N(l)-Cu(l)-C(15) 113.9(8)
N(2)-Cu(l)-C(15) 116.7(8)
N(4)-Cu(l)-C(16) 34.6(10)
N(3)-Cu(l)-C(16) 61.9(7)
N(l)-Cu(l)-C(16) 104.6(4)
N(2)-Cu(l)-C(16) 156.5(10)
C(15)-Cu(l)-C(16) 40.6(10)
N(8)-Cu(2)-N(7) 79.1(6)
N(8)-Cu(2)-N(5) 104.9(5)
N(7)-Cu(2)-N(5) 160.3(3)
N(8)-Cu(2)-N(6) 162.8(4)
N(7)-Cu(2)-N(6) 97.4(4)
N(5)-Cu(2)-N(6) 84.1(3)
N(8)-Cu(2)-C(30) 25.4(5)
N(7)-Cu(2)-C(30) 104.5(5)
N(5)-Cu(2)-C(30) 81.1(3)
N(6)-Cu(2)-C(30) 152.1(4)
C(8)-N(1)-C(7) 110.9(6)
C(8)-N(1)-C(19) 110.2(7)
C(7)-N(1)-C(19) 110.7(6)
C(8)-N(l)-Cu(l) 104.6(5)
C(7)-N(l)-Cu(l) 109.5(4)
C(19)-N(l)-Cu(l) 110.8(5)
C(10)-N(2)-C(9) 111.3(14)
C(10)-N(2)-Cu(l) 122.5(15)
C(9)-N(2)-Cu(l) 102.2(7)
C(16)-N(4)-Cu(l) 99.5(15)
C(32)-N(5)-C(21) 110.5(6)
C(32)-N(5)-C(20) 111.9(6)
C(21)-N(5)-C(20) 112.0(5)
C(32)-N(5)-Cu(2) 108.3(4)
C(21)-N(5)-Cu(2) 106.5(4)
C(20)-N(5)-Cu(2) 107.4(3)
C(23)-N(6)-C(22) 126.2(16)
C(23)-N(6)-Cu(2) 99(2)
C(22)-N(6)-Cu(2) 102.4(6)
C(27)-N(7)-C(29) 119.4(18)
C(27)-N(7)-C(25) 109.7(14)
C(29)-N(7)-C(25) 101.2(12)
C(27)-N(7)-Cu(2) 106.5(8)
C(29)-N(7)-Cu(2) 102.1(9)
C(25)-N(7)-Cu(2) 1 1 8.5(8)
C(30)-N(8)-C(28) 116.3(16)
C(30)-N(8)-C(26) 120.5(17)
C(28)-N(8)-C(26) 99.2(16)
C(30)-N(8)-Cu(2) 110.9(12)
C(28)-N(8)-Cu(2) 100.1(12)
C(26)-N(8)-Cu(2) 107.4(15)
C(6)-C(1)-C(2) 118.8(6)
C(6)-C(1)-C(7) 122.3(6)
C(2)-C(1)-C(7) 118.9(7)
C(1)-C(2)-C(3) 120.4(7)
C(4)-C(3)-C(2) 120.5(6)
C(3)-C(4)-C(5) 118.2(5)
C(3)-C(4)-C(20) 120.5(6)
C(5)-C(4)-C(20) 121.3(6)
C(6)-C(5)-C(4) 119.6(7)
C(1)-C(6)-C(5) 122.4(7)
N(1)-C(7)-C(1) 114.0(5)
C(9)-C(8)-N(1) 111.2(9)
C(15)-C(16)-Cu(l) 66.5(9)
N(4)-C(17)-C(18) 123.7(17)
C(19)-C(18)-C(17) 111.4(15)
N(1)-C(19)-C(18) 110.9(8)
N(5)-C(20)-C(4) 1 14.9(5)
N(5)-C(21)-C(22) 111.4(6)
N(6)-C(22)-C(21) 108.8(8)
N(6)-C(23)-C(24) 117(3)
C(25)-C(24)-C(23) 101.6(14)
C(24)-C(25)-N(7) 103.7(17)
N(8)-C(26)-C(27) 102.1(14)
N(7)-C(27)-C(26) 104.9(15)
N(8)-C(28)-C(29) 107.0(14)
N(7)-C(29)-C(28) 101.8(11)
N(8)-C(30)-C(31) 130.2(15)
N(8)-C(30)-Cu(2) 43.7(9)
C(3 1 )-C(30)-Cu(2) 97.3(9)
C(30)-C(31)-C(32) 107.0(11)
N(5)-C(32)-C(31) 112.7(7)
O(8)-C1(2)-O(7) 119.7(16)
O(8)-C1(2)-O(5) 104.4(12)
O(7)-C1(2)-O(5) 102.7(14)
0(8)-C1(2)-0(6) 110.4(11)
0(7)-C1(2)-0(6) 108.9(8)
O(5)-C1(2)-O(6) 110.2(8)
O(1)-CI(1)-O(3) 123.9(10)
O(1)-C1(1)-O(4) 113.6(9)
0(3)-C1(1)-O(4) 115.8(9)
0(1)-C1(1)-O(2) 102.3(12)
0(3)-C1(1)-O(2) 101.4(12)
0(4)-C1(1)-O(2) 91.4(9)
0(10)-C1(3)-0(12) 124.4(8)
0(10)-C1(3)-0(11) 115.8(9)
0(12)-C1(3)-0(11) 110.8(8)
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C(13)-N(3)-C(12) 110.4(15)
C(13)-N(3)-C(15) 126(2)
C(12)-N(3)-C(15) 101.0(15)
C(13)-N(3)-Cu(l) 107.7(11)
C(12)-N(3)-Cu(l) 123.6(13)
C(15)-N(3)-Cu(l) 88.4(10)
C(17)-N(4)-C(14) 112.8(15)
C(17)-N(4)-C(16) 113(2)
C(14)-N(4)-C(16) 98.7(15)
C(17)-N(4)-Cu(l) 122.6(17)
C(14)-N(4)-Cu(l) 106.4(8)
C(8)-C(9)-N(2) 106.0(10)
N(2)-C(10)-C(11) 109.7(16)
C(12)-C(11)-C(10) 118(2)
C(11)-C(12)-N(3) 109(2)
N(3)-C(13)-C(14) 109.3(10)
N(4)-C(14)-C(13) 101.7(12)
N(3)-C(15)-C(16) 89.3(18)
N(3)-C(15)-Cu(l) 50.5(6)
C(16)-C(15)-Cu(l) 73.0(9)
N(4)-C(16)-C(15) 110.9(13)
N(4)-C(16)-Cu(l) 45.9(7)
O(10)-C1(3)-O(9) 109.2(12)
O(12)-C1(3)-O(9) 101.1(9)
O(11)-CI(3)-O(9) 87.8(9)
0(16)-C1(4)-O(15) 122.8(13)
O(16)-C1(4)-O(13) 111.4(11)
O(15)-C1(4)-0(13) 108.4(11)
O(16)-CI(4)-0(14) 105.6(12)
O(15)-C1(4)-0(14) 104.6(11)
0(13)-C1(4)-0(14) 101.6(15)
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8.3.7 Synthesis of [Cu25Cl2]Cl2
*•
Ligand 5 (198 mg, 0.36 mmol), copper(II) chloride dihydrate (140 mg, 82 mmol). A 
green precipitate was observed immediately which redissolved to give a blue solution after 
a few minutes. The blue solution was purified by size exclusion chromatography (Sephadex 
LH20). The resulting solvent was evaporated in vacua to yield a blue crystalline solid (178 
mg, 60%).
MS: (ESI) m/z 785 [M-C1]+. HRMS: Calcd. for C32H58N8Cl3Cu2+: 785.2452; Found 
785.2446.
UV-vis: (H2O) A^x 567 nm, e 453 1VT 1 cm' 1 .
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8.3.7.1 Crystal data and structural refinement for [Cu25Cl2]Cl2
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient
F(OOO)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 34.62°
Absorption correction
Refinement method
Data / restraints / parameters
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Extinction coefficient
Largest diff. peak and hole
C32 H58 C14 Cu2 N8 O2
855.74
150(2) K
0.71073 A
Monoclinic
C2
a =17.3370(19) A <x=90°.
b = 9.1621 (8) A p= 106.218(9)c
c= 13.5870(18) A y = 90°.
2072.3(4) A3
2
1.371 Mg/m3
1.322mm- 1
896
0.2x0.2x0.15 mm3
2.79 to 34.62°.
-21<=h<=27, -14<=k<=14, -21<=1<=21
14454
8175 [R(int) = 0.0498]
97.3 %
None
Full-matrix least-squares on F^
8175/1/194
0.870
Rl = 0.0797, wR2 = 0.2126
Rl= 0.1351, wR2 = 0.2438
0.40(4)
0.0046(12)
2.85 land-0.822 e.A'3
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Crystals were grown by vapour diffusion of diethyl ether at room temperature into a 
solution of [CugSC\2]C\2 in methanol.
Figure 126. ORTEP representation of [CujSCh] + showing the two alternative 
disordered ring positions. Symmetry transformations used to generate equivalent
atoms: -x, y, -z+1.
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Table 28. Bond lengths (A) and angles (°) for [Cu25Cl2]Cl2.
Cu(l)-N(2B)
Cu(l)-N(2)
Cu(l)-N(3B)
Cu(l)-N(3)
Cu(l)-N(lB)
Cu(l)-N(l)
Cu(l)-N(4B)
Cu(l)-N(4)
Cu(l)-Cl(l)
N(1)-C(1)
N(1)-C(12)
N(1)-C(13)
N(2)-C(3)
N(2)-C(2)
N(3)-C(8)
N(3)-C(6)
N(3)-C(58)
N(4)-C(10)
N(4)-C(7)
N(4)-C(9)
C(1)-C(2)
C(3)-C(4)
C(4)-C(58)
C(6)-C(7)
C(7)-C1(2A)
C(8)-C(9)
C(10)-C(11)
C(11)-C(12)
C(13)-C(14)
C(14)-C(15)
C(14)-C(16)
C(15)-C(15)#1
C(16)-C(16)#1
N(1B)-C(12B)
1.891(15)
1.999(11)
2.004(1 1)
2.088(11)
2.089(14)
2.112(9)
2.136(15)
2.139(16)
2.4131(11)
1.332(16)
1.584(18)
1.594(16)
1.41(2)
1.50(2)
1.39(3)
1.476(16)
1.569(15)
1.40(2)
1.46(2)
1.74(3)
1.76(2)
1.37(4)
1.63(3)
1.49(2)
2.21(2)
1.36(4)
1.52(2)
1.49(2)
1.56(2)
1.30(3)
1.42(2)
1.31(3)
1.51(3)
1.39(2)
N(2B)-Cu( 1 )-N(2) 1 36.9(4)
N(2B)-Cu(l)-N(3B) 98.4(6)
N(2)-Cu(l)-N(3B) 88.2(5)
N(2B)-Cu(l)-N(3) 92.3(6)
N(2)-Cu(l)-N(3) 98.0(5)
N(3B)-Cu(l)-N(3) 9.9(4)
N(2B)-Cu(l)-N(lB) 89.7(6)
N(2)-Cu(l)-N(lB) 73.3(5)
N(3B)-Cu(l)-N(lB) 159.5(5)
N(3)-Cu(l)-N(lB) 168.8(5)
N(2B)-Cu(l)-N(l) 74.0(6)
N(2)-Cu(l)-N(l) 88.1(4)
N(3B)-Cu(l)-N(l) 163.9(4)
N(3)-Cu(l)-N(l) 164.8(4)
N(lB)-Cu(l)-N(l) 16.2(3)
N(2B)-Cu(l)-N(4B) 132.4(6)
N(2)-Cu(l)-N(4B) 23.8(5)
N(3B)-Cu(l)-N(4B) 64.7(6)
N(3)-Cu(l)-N(4B) 74.6(5)
N(lB)-Cu(l)-N(4B) 96.0(6)
N(l)-Cu(l)-N(4B) 109.6(5)
N(2B)-Cu(l)-N(4) 24.5(6)
N(2)-Cu(l)-N(4) 132.3(5)
N(3B)-Cu(l)-N(4) 74.0(5)
N(3)-Cu(l)-N(4) 68.5(5)
N(lB)-Cu(l)-N(4) 111.9(6)
N(l)-Cu(l)-N(4) 97.2(5)
N(4B)-Cu(l)-N(4) 117.0(3)
N(2B)-Cu(l)-Cl(l) 112.8(5)
N(2)-Cu(l)-Cl(l) 108.9(3)
N(3B)-Cu(l)-Cl(l) 95.2(3)
N(3)-Cu(l)-Cl(l) 90.5(3)
N(lB)-Cu(l)-Cl(l) 99.0(4)
N(l)-Cu(l)-Cl(l) 100.8(2)
C(3)-C(4)-C(58)
N(3)-C(6)-C(7)
N(4)-C(7)-C(6)
N(4)-C(7)-C1(2A)
C(6)-C(7)-C1(2A)
C(9)-C(8)-N(3)
C(8)-C(9)-N(4)
N(4)-C(10)-C(11)
C(12)-C(11)-C(10)
C(11)-C(12)-N(1)
C(14)-C(13)-N(1)
C(15)-C(14)-C(16)
C(15)-C(14)-C(13)
C(16)-C(14)-C(13)
C(14)-C(15)-C(15)#1
C(14)-C(16)-C(16)#1
C(12B)-N(1B)-C(13B)
C(12B)-N(1B)-C(1B)
C(13B)-N(1B)-C(1B)
C(12B)-N(lB)-Cu(l)
C(13B)-N(lB)-Cu(l)
C(lB)-N(lB)-Cu(l)
C(2B)-N(2B)-C(3B)
C(2B)-N(2B)-Cu(l)
C(3B)-N(2B)-Cu(l)
C(58)-N(3B)-C(5B)
C(58)-N(3B)-C(6B)
C(5B)-N(3B)-C(6B)
C(58)-N(3B)-Cu(l)
C(5B)-N(3B)-Cu(l)
C(6B)-N(3B)-Cu(l)
C(9B)-N(4B)-C(7B)
C(9B)-N(4B)-C(10B)
C(7B)-N(4B)-C(10B)
119(2)
104.3(11)
110.6(14)
100.1(11)
143.7(12)
112(2)
106(2)
109.6(12)
111.4(12)
116.4(12)
108.7(11)
117.2(15)
125.6(15)
114.3(14)
122.3(12)
116.3(9)
111.8(12)
107.2(12)
103.8(11)
122.0(10)
113.2(10)
95.4(8)
117.6(13)
110.0(10)
109.2(11)
99.5(12)
111.4(11)
117.6(14)
115.4(8)
107.1(13)
106.2(8)
114.2(15)
116.5(13)
101.9(13)
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N(1B)-C(13B) 1.449(19)
N(1B)-C(1B) 1.72(2)
N(2B)-C(2B) 1.47(2)
N(2B)-C(3B) 1.61(2)
N(3B)-C(58) 1.419(15)
N(3B)-C(5B) 1.48(3)
N(3B)-C(6B) 1.510(17)
N(4B)-C(9B) 1.36(2)
N(4B)-C(7B) 1.56(2)
N(4B)-C(10B) 1.62(2)
C(1B)-C(2B) 1.29(2)
C(3B)-C(4B) 1.53(3)
C(4B)-C(5B) 1.68(3)
C(6B)-C(7B) 1.45(2)
C(9B)-C(58) 1.66(2)
C(10B)-C(11B) 1.48(3)
C(11B)-C(12B) 1.54(3)
C(13B)-C(14B) 1.47(2)
C(14B)-C(15B) 1.40(3)
C(14B)-C(16B) 1.52(2)
C(15B)-C(15B)#1 1.37(3)
C(16B)-C(16B)#1 1.39(2)
N(4B)-Cu(l)-Cl(l) 112.8(4)
N(4)-Cu(l)-Cl(l) 116.5(4)
C(1)-N(1)-C(12) 116.9(11)
C(1)-N(1)-C(13) 117.7(10)
C(12)-N(1)-C(13) 100.3(9)
C(l)-N(l)-Cu(l) 103.7(8)
C(12)-N(l)-Cu(l) 110.9(8)
C(13)-N(l)-Cu(l) 107.1(7)
C(3)-N(2)-C(2) 108.5(12)
C(3)-N(2)-Cu(l) 111.5(10)
C(2)-N(2)-Cu(l) 107.3(9)
C(8)-N(3)-C(6) 109.0(13)
C(8)-N(3)-C(58) 119.8(12)
C(6)-N(3)-C(58) 106.7(10)
C(8)-N(3)-Cu(l) 113.7(11)
C(6)-N(3)-Cu(l) 101.3(8)
C(58)-N(3)-Cu(l) 104.5(7)
C(10)-N(4)-C(7) 118.4(14)
C(10)-N(4)-C(9) 108.6(14)
C(7)-N(4)-C(9) 99.0(15)
C(10)-N(4)-Cu(l) 123.0(11)
C(7)-N(4)-Cu(l) 101.0(10)
C(9)-N(4)-Cu(l) 103.5(12)
N(1)-C(1)-C(2) 108.6(11)
N(2)-C(2)-C(1) 101.5(10)
C(4)-C(3)-N(2) 106.5(18)
C(9B)-N(4B)-Cu(l) 106.6(11)
C(7B)-N(4B)-Cu(l) 102.6(10)
C(10B)-N(4B)-Cu(l) 114.3(10)
C(2B)-C(1B)-N(1B) 113.0(14)
C(1B)-C(2B)-N(2B) 110.0(14)
C(4B)-C(3B)-N(2B) 114.5(14)
C(3B)-C(4B)-C(5B) 107.6(15)
N(3B)-C(5B)-C(4B) 113.9(19)
C(7B)-C(6B)-N(3B) 1*04.7(12)
C(6B)-C(7B)-N(4B) 104.1(14)
N(4B)-C(9B)-C(58) 105.4(12)
C(11B)-C(10B)-N(4B) 112.9(15)
C(10B)-C(11B)-C(12B) 106.8(18)
N(1B)-C(12B)-C(11B) 117.7(15)
N(1B)-C(13B)-C(14B) 123.6(13)
C(15B)-C(14B)-C(13B) 127.0(15)
C(15B)-C(14B)-C(16B) 116.6(14)
C(13B)-C(14B)-C(16B) 115.0(15)
C(15B)#1-C(15B)-C(14B) 121.6(10)
C(16B)#1-C(16B)-C(14B) 119.0(8)
N(3B)-C(58)-N(3) 12.7(7)
N(3B)-C(58)-C(4) 106.4(15)
N(3)-C(58)-C(4) 118.8(14)
N(3B)-C(58)-C(9B) 97.8(10)
N(3)-C(58)-C(9B) 109.2(10)
C(4)-C(58)-C(9B) 15.2(11)
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8.3.8 Synthesis of [Cu25Cl2](PF6)2
To a solution of [Cu25Cl2]Cl2 (50 mg, 0.06 mmol) in ethanol (10 mL) was added a 
solution of ammonium hexafluorophosphate (23 mg, 0.14 mmol) in ethanol (5 mL). After 
stirring at room temperature for 10 minutes the blue precipitate was collected by filtration, 
washed with ethanol (5x10 mL) followed by diethyl ether (5x10 mL) and dried in vacua 
to yield a pale blue solid (54.98 mg, 87%).
MS: (ESI) m/z 339 [M-2H-2C1-(PF6)2]2+. HRMS: Calcd. for C32H58N8Cu22+: 
339.1604; Found 339.1612.
UV-vis: (H2O) ^ 567 nm, s 452 NT 1 cm- 1 .
8.3.9 Synthesis of [Nil5](ClO4)2
An acetonitrile solution (50 mL) of nickel (II) perchlorate hexahydrate (15.70 g, 43 
mmol) was added dropwise to a solution of 5-(4-phenylmethyl benzoate)-!,5,8,12- 
tetraazabicyclo[10.2.2]hexadecane (14.59 g, 39 mmol) in acetonitrile (300 mL). An initial 
green solution was observed which changed to orange after a few minutes and this solution 
was heated at reflux for 2 h. The orange solution was filtered, concentrated in vacua and 
purified by size exclusion chromatography (Sephadex LH20). The resulting solvent was 
evaporated in vacua to yield an orange crystalline solid (16.76 g, 68%).
13C NMR: (CD3CN) 5 22.30 (N-0-CH2), 23.40 (N-p-CH2), 48.49 (N-a-CH2), 48.79 
(N-a-CH3), 51.03 (N-a-CH2), 51.30 (N-a-CH2), 52.37 (O-CH3), 52.85 (N-a-CH2), 52.97 
(N-a-CH2), 53.47 (N-a-CH2), 55.10 (N-a-CH2), 56.03 (N-a-CH2), 58.38 (N-a-CH2), 58.95
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(N-<X-CH2), 130.40 (CHaromatic), 130.65 (CHaromatic), 132.57 (Caromatic), 133.48 (Caromatic),
167.12(00).
MS: (ESI) m/z 531 [M-(C1O4)]+. HRMS: Calcd. for C^^WeNiCl*: 531.1515; 
Found 53 1.1 520.
8.3.10 Synthesis of [Nil6](CIO4)2
Nickel(ll) 5-(4-phenylmethyl benzoate)- 1,5,8, 1 2-tetraazabicyclo-[ 1 0.2.2]hexadecane 
perchlorate (2.00 g, 3.17 mmol) was dissolved in dry DMSO (10 mL) and stirred in vacua 
for 1 h. The orange solution was purged with argon for 10 minutes and n-butyl lithium (3.5 
mL, 1.75 eq) was added dropwise over 30 minutes. A blue colour developed which was 
stirred at room temperature for 30 minutes. Methyl iodide (0.8 mL, 12.7 mmol) was added 
dropwise and an orange solution reappeared which was stirred at room temperature for 1 h. 
The solution was stirred under vacuum again to remove hexanes and excess methyl iodide. 
The DMSO solution was added dropwise to a saturated solution of ammonium 
hexafluorophosphate in ethanol (100 mL). The orange precipitate which formed was 
filtered off and washed with ether (200 mL). The orange solid was dissolved in acetonitrile 
and evaporated in vacua to yield an orange crystalline solid (1.86 g, 91%).
13C NMR: (CD3CN) 5 22.32 (N-p-CH2), 22.48 (N-p-CH2), 31.20 (N-a-CH3), 50.92 
(N-a-CH2), 51.43 (N-a-CH2), 51.85 (N-a-CH2), 52.09 (O-CH3), 52.90 (N-a-CH2), 53.27 
(N-a-CH2), 53.76 (N-a-CH2), 53.90 (N-a-CH2), 58.25 (N-a-CH2), 58.54 (N-a-CH2), 61.27
(N-a-CH2), 62.74 (N-a-CH2), 129.65 (CHaromatic), 129.82 (CHaromatic), 132.73 (Caromatic), 
141.92 (Car0matic), 166.63 (C=0).
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MS: (ESI) m/z 223 [M-(PF6)2]2+. HRMS: Calcd. for C22H36N4Ni2+ : 223.1090; Found 
223.1088.
8.3.11 Synthesis of [Ni21](ClO4)2
A methanolic solution (10 mL) of nickel (II) perchlorate hexahydrate (1.39 g, 38 
mmol) was added dropwise to a solution of 5-(methyl)-l,5,8,12-tetraaza- 
bicyclo[10.2.2]hexadecane (0.83 g, 35 mmol) in methanol (10 mL). An initial green 
solution was observed which changed to orange after a few minutes and the solution was 
heated at reflux for 2 h. The orange solution was filtered off to remove a green precipitate. 
The resulting orange solution was evaporated in vacua to yield an orange crystalline solid 
(0.73 g, 42%).
13C NMR: (CD3CN) 5 20.38 (N-(3-CH2), 22.40 (N-p-CH2), 39.41 (N-a-CH3), 45.36 
(N-a-CH2), 50.81 (N-a-CH2), 56.38 (N-a-CH2), 56.98 (N-a-CH2), 57.02 (N-a-CH2), 60.17 
(N-a-CH2).
MS: (ESI) m/z 397 [M-C1O4]+. HRMS: Calcd. for Ci 3H28N4Ni+: 397.1147; Found 
397.1149.
8.3.12 Synthesis of [Zn22(OAc)2](OAc)2
Ligand 2 (56.9 mg, 0.11 mmol), zinc(II) acetate dihydrate (59.7mg, 0.36 mmol) The 
colourless solution was purified by size exclusion chromatography (Sephadex LH20). The 
resulting solvent was evaporated in vacua to give a white powder (65.2 mg, 61%).
MS: (ESI) m/z 687 [M-2H-(OAc)3] +.
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8.3.13 Synthesis of [Cu22](OAc)4
Ligand 2 (81.8 mg 0.16 mmol), copper(II) acetate dehydrate (65.4 mg, 0.36 mmol). 
The purple solution was purified by size exclusion chromatography (Sephadex LH20). The 
resulting solvent was evaporated in vacua to give a purple powder (81.5 mg, 58%).
MS: (ESI) m/z 685 [M-2H-(OAc)3]+. 
UV-vis: (H2O) l^™ 513 nm, s 163 M cm' 1 .
8.3.14 Synthesis of [Cu29Cl2]Cl2
Ligand 9 (200 mg, 0.34 mmol) was dissolved in dry methanol (20 mL) and a solution 
of copper(II) chloride dihydrate (130 mg, 1 mmol) in dry methanol (5 mL) was added under 
an atmosphere of nitrogen. A blue solution developed immediately with a green precipitate 
forming after a few minutes. The solution was heated at reflux for 2 h, the green precipitate 
was removed by filtration and the blue filtrate was concentrated in vacua. The crude 
product was purified by size exclusion chromatography (Sephadex LH20). The resulting 
solvent was removed in vacua to yield a green crystalline solid (88 mg, 36%).
MS: (ESI) m/z 813 [M-C1]+, HRMS: Calcd. for C34H62N8Cu2Cr: 813.2750; Found 
813.2743.
UV-vis: (H2O) A^x 622 nm, s 109 M cm" 1 .
8.3.15 Synthesis of [Cu29Ck](PF6)2
To a solution of [Cu29Cl2]Cl2 (50 mg, 0.06 mmol) in ethanol (10 mL), was added a 
solution of ammonium hexafluorophosphate (23 mg, 0.14 mmol) in ethanol (5 mL). After
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stirring at room temperature for 10 minutes a green precipitate had formed and was 
collected by filtration, washed with ethanol (5 x 10 mL) followed by diethyl ether (5 x 10 
mL) and dried in vacuo to yield a pale green solid (57 mg, 91%).
MS: (ESI) m/z 390 [M-(PF6)2]2+. 
UV-vis: (H2O) ^max 622 nm, E 109 M cm' 1 . 
8.3.16 Synthesis of [Cu29(OAc)2](OAc)2
Ligand 9 (317 mg, 0.54 mmol) was dissolved in dry methanol (20 mL) and a solution 
of copper acetate monohydrate (239 mg, 1.20 mmol) in methanol (5 mL) was added under 
an atmosphere of nitrogen. A green colour developed immediately and the solution was 
heated at reflux for 2 h. The crude product was purified by size exclusion chromatography 
(Sephadex LH20). The resulting solvent was removed in vacuo to yield a green crystalline 
solid (160 mg, 54%).
MS: (ESI) m/z 813 [M-(OAc)]+. HRMS: Calcd. for C34H62N8Cu2+: 813.2750; Found 
813.2743.
UV-vis: (H2O) A™* 661 nm, e 200 M cm'1 . 
8.3.17 Synthesis of [Zn36(OAc)3](OAc)3
Ligand (200 mg, 0.25 mmol), zinc(II) acetate monohydrate (150 mg, 0.83 mmol). 
The clear solution was concentrated in vacuo and purified by size exclusion 
chromatography (Sephadex LH20). The resulting solvent was evaporated in vacuo to yield 
a white crystalline solid (320 mg, 82%).
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MS: (ESI) m/z 1279 [M-(OAc)]+. HUMS: Calcd. for C45H8oN,2(OAc)5Zn3+ : 
1279.5480; Found 1279.5479.
8.3.18 Synthesis of [Zn36CI3](PF6)3
Ligand 6 (200 mg, 0.25 mmol), anhydrous zinc(II) chloride (113 mg, 0.84 mmol). 
The white solid product was collected by filtration, washed with methanol (2 x 20 mL) 
followed by diethyl ether (5 x 20 mL) and dried in vacua. To a solution of [Zn36Cl3](PF6)3 
in ethanol (20 mL) was added a solution of ammonium hexafluorophosphate (135 mg, 0.83 
mmol) in ethanol (5 mL). After stirring at room temperature for 10 minutes the white 
precipitate was collected by filtration, washed with ethanol (5x10 mL) followed by diethyl 
ether (5x10 mL) and dried in vacua to yield a white solid (210 mg, 69%).
MS: (ESI) m/z 1089 [M-(PF6)3 ]3+. HRMS: Calcd. for C45H8oNi 2Cl3Zn3+: 1089.3881; 
Found 1089.3878.
8.3.19 Synthesis of [Zn36](ClO4)6
Ligand 6 (200 mg, 0.25 mmol), zinc(II) perchlorate hexahydrate (310 mg, 0.84 
mmol). The white solid product was collected by filtration, washed with methanol (2 x 20 
mL) followed by diethyl ether (5 x 20 mL) and dried in vacua (310 mg, 78%).
MS: (ESI) m/z 1281 [M-(C1O4)3 ] 3+. HRMS: Calcd. for C45H8oN12(ClO4)3Zn33+: 
1281.3272; Found 1281.3270.
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8.3.20 Synthesis of [Cu36(OAc)3](OAc)3
Ligand 6 (200 mg, 0.25 mmol), copper(II) acetate monohydrate (166 mg, 0.83 
mmol). The blue solution was concentrated in vacua and purified by size exclusion 
chromatography (Sephadex LH20). The resulting solvent was evaporated in vacua to yield 
a blue crystalline solid (265 mg, 79%).
MS: (ESI) m/z 304 [M-(OAc)2]4+. HRMS: Calcd. for C45H8oN12(OAc)Cu34+: 
304.3843; Found 304.3841.
UV-vis: (H2O) ^ax 565 nm, g 473 MT 1 cm' 1 . 
8.3.21 Synthesis of [Cu36](ClO4)6
Ligand 6 (200 mg, 0.25 mmol), copper(II) perchlorate hexahydrate (310 mg, 0.84 
mmol). The purple solid product was collected by filtration, washed with methanol (2 x 20 
mL) followed by diethyl ether (5 x 20 mL) and dried in vacua (245 mg, 61%).
MS: (ESI) m/z 1076 [M-(C1O4)3 ]3+. HRMS: Calcd. for 
426.1087; Found 426.1086.
UV-vis: (H20) ^ax 551 nm, s 409 M' 1 cm-'.
8.3.22 Synthesis of [Cu36Cl3](PF6)3
Ligand 6 (200 mg, 0.25 mmol), copper(II) chloride dihydrate (142 mg, 0.83 mmol). 
The blue solution was purified by size exclusion chromatography (Sephadex LH20) and 
remaining solvent was removed in vacua to yield a blue crystalline solid (not isolated). The 
blue solid was dissolved in ethanol (10 mL) and a solution of ammonium
265
hexafluorophosphate (135 mg, 0.83 mmol) in ethanol (5 mL) was added dropwise. After 
stirring at room temperature for 10 minutes the blue precipitate was collected by filtration, 
washed with ethanol (5 x 10 mL) followed by diethyl ether (5x10 mL) and dried in vacua 
to yield a pale blue solid (120 mg, 40%).
MS: (ESI) m/z 362 [M-(PF6)3]3+. HRMS: Calcd. for C45H84N,2Cl3Cu33+:362.1299; 
Found 362.1296.
UV-vis: (H2O) ^ 569 nm, £ 457 NT 1 cm' 1 .
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